

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 2463305 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **A 61 K 39/00 (2006.01)** **C 07 K 16/28 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2016-08-29**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2016-05-11**
- (86) Europæisk ansøgning nr.: **11005097.8**
- (86) Europæisk indleveringsdag: **2007-01-11**
- (87) Den europæiske ansøgnings publiceringsdag: **2012-06-13**
- (30) Prioritet: **2006-01-12 US 759085 P** **2006-01-12 US 758426 P**
2006-05-18 US 801991 P
- (62) Stamansøgningsnr: **07716538.9**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **ALEXION PHARMACEUTICALS, INC., 352 Knotter Drive, Cheshire, CT 06410, USA**
- (72) Opfinder: **Bowdish, Kathrine S., 13773 Boquita Drive, Del Mar, CA 92014, USA**
KRETZ-ROMMEL, Anke, 4535 Kensington Drive, San Diego, CA 92116, USA
FAAS MCKNIGHT, Susan, 14 Stonewood Drive, Old Lyme, CT 06371, USA
SPRINGHORN, Jeremy P., 150 Ironwood Road, Guilford, CT 06437, USA
WU, Dayang, 755 Devonwood Drive, Cheshire, CT 06410, USA
- (74) Fuldmægtig i Danmark: **RWS Group, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9 9FG, Storbritannien**
- (54) Benævnelse: **Antistoffer mod OX-2/CD200 og anvendelser deraf**
- (56) Fremdragne publikationer:
US-A1- 2002 168 364
US-A1- 2005 129 690
US-A1- 2005 169 870
KRETZ-ROMMEL ANKE ET AL: "Immune evasion by CD200: New approaches to targeted therapies for chronic lymphocytic leukemia", JOURNAL OF IMMUNOTHERAPY, vol. 28, no. 6, November 2005 (2005-11), page 650, XP009088617, & 20TH ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL-SOCIETY-FOR-BIOLOGICAL-THERAPY-OF-CANCER; ALEXANDRIA, VA, USA; NOVEMBER 10 -13, 2005 ISSN: 1524-9557
KRETZ-ROMMEL ANKE ET AL: "The immuno-regulatory protein CD200 is overexpressed in a subset of B-Cell chronic lymphocytic leukemias and plays a role in down-regulating the TH1 immune response", JOURNAL OF IMMUNOTHERAPY, vol. 27, no. 6, November 2004 (2004-11), page S46, XP009088618, & 19TH ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL-SOCIETY-FOR-BIOLOGICAL-THERAPY-OF-CANCER; SAN FRANCISCO, CA, USA; NOVEMBER 04 -07, 2004 ISSN: 1524-9557
GORCZYNSKI R M ET AL: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 163, no. 3, 1 August 1999 (1999-08-01), pages 1654-1660,

Fortsættes ...

XP002222032, ISSN: 0022-1767

GORCZYNSKI R M: "CD200 AND ITS RECEPTORS AS TARGETS FOR IMMUNOREGULATION", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 6, no. 5, May 2005 (2005-05), pages 483-488, XP008051169, ISSN: 1472-4472

MCWHIRTER JOHN R ET AL: "Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 4, 24 January 2006 (2006-01-24), pages 1041-1046, XP002448171, ISSN: 0027-8424

KRETZ-ROMMEL ANKE ET AL: "CD200 expression on tumor cells suppresses anti-tumor immunity: New approaches to cancer immunotherapy", JOURNAL OF IMMUNOTHERAPY, vol. 29, no. 6, November 2006 (2006-11), page 666, XP009088616, & 21ST ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL-SOCIETY-FOR-BIOLOGICAL-THERAPY-OF-CANCER; LOS ANGELES, CA, USA; OCTOBER 26 -29, 2006 ISSN: 1524-9557

KRETZ-ROMMEL ANKE ET AL: "CD200 expression on tumor cells suppresses antitumor immunity: New approaches to cancer immunotherapy", JOURNAL OF IMMUNOLOGY, vol. 178, no. 9, May 2007 (2007-05), pages 5595-5605, XP002448172, ISSN: 0022-1767

DESCRIPTION

RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Nos. 60/758,426, filed January 12, 2006, 60/759,085, filed January 12, 2006, and 60/801,991, filed May 18, 2006.

TECHNICAL FIELD

[0002] The disclosure relates to OX-2/CD200 (herein referred to as CD200) antagonists and methods of depleting or eliminating cells overexpressing CD200 in a subject with cancer or autoimmune disease. The methods of therapy for the treatment of cancer provide a combination of two mechanisms. More specifically, this disclosure relates to treating cancer using a therapy that: (1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and/or (2) directly kills the cancer cells either by (a) antibody-dependent cellular cytotoxicity or complement-mediated cytotoxicity or by (b) targeting cells using a fusion molecule that includes a CD200-targeting portion. The disclosure also relates to a method of treating autoimmune disorders by a therapy that increases the antibody-dependent cellular cytotoxicity and/or complement-mediated cytotoxicity of CD200-positive immune cells.

BACKGROUND

[0003] Various mechanisms play a role in the body's response to a disease state, including cancer. For example, CD4⁺ T helper cells play a crucial role in an effective immune response against various malignancies by providing stimulatory factors to effector cells. Cytotoxic T cells are believed to be the most effective cells to eliminate cancer cells, and T helper cells prime cytotoxic T cells by secreting Th1 cytokines such as IL-2 and IFN- γ . In various malignancies, T helper cells have been shown to have an altered phenotype compared to cells found in healthy individuals. One of the prominent altered features is decreased Th1 cytokine production and a shift to the production of Th2 cytokines. (See, e.g., Kiani, et al., *Haematologica* 88:754-761 (2003); Maggio, et al., *Ann Oncol* 13 Suppl 1:52-56 (2002); Ito, et al., *Cancer* 85:2359-2367 (1999); Podhorecka, et al., *Leuk Res* 26:657-660 (2002); Tatsumi, et al., *J Exp Med* 196:619-628 (2002); Agarwal, et al., *Immunol Invest* 32:17-30 (2003); Smyth, et al., *Ann Surg Oncol* 10:455-462 (2003); Contasta, et al., *Cancer Biother Radiopharm* 18:549-557 (2003); Lauerova, et al., *Neoplasma* 49:159-166(2002).) Reversing that cytokine shift to a Th1 profile has been demonstrated to augment anti-tumor effects of T cells. (See Winter, et al., *Immunology* 108:409-419 (2003); Inagawa, et al., *Anticancer Res* 18:3957-3964 (1998).)

[0004] Mechanisms underlying the capacity of tumor cells to drive the cytokine expression of T helper cells from Th1 to Th2 include the secretion of cytokines such as IL-10 or TGF- β as well as the expression of surface molecules interacting with cells of the immune system. CD200, a molecule expressed on the surface of dendritic cells which possesses a high degree of homology to molecules of the immunoglobulin gene family, has been implicated in immune suppression (Gorczynski et al., *Transplantation* 65:1106-1114 (1998)). It has been shown, for example, that CD200-expressing cells can inhibit the stimulation of Th1 cytokine production.

[0005] Although immune cells can help attack and eliminate cancer cells, in certain instances, such as in autoimmune disorders, allergies, and the rejection of tissue or organ transplants, the immune system can be the cause of illness. In order to inhibit harmful immune reactions in such instances, immunosuppressive agents such as corticosteroids and cytokine antagonists may be administered to patients. However these general immunosuppressives can elicit undesirable side effects including toxicity and reduced resistance to infection. Thus alternative, and perhaps more specific, methods of treating autoimmunity are needed.

[0006] Several immunomodulatory therapies, including antibody therapies, have proven successful in the treatment of certain cancers and autoimmune disorders. However there is a clinical need for additional antibody therapies for the treatment of both cancer and autoimmune disorders. Furthermore, there is a related need for humanized or other chimeric human/mouse monoclonal antibodies. In well publicized studies, patients administered murine anti-TNF (tumor necrosis factor) monoclonal antibodies developed anti-murine antibody responses to the administered antibody. (Exley A. R., et al., *Lancet* 335:1275-1277 (1990)). This type of immune response to the treatment regimen, commonly referred to as the human anti-mouse antibody (HAMA) response (Mirick et al. *Q J Nucl Med Mol Imaging* 2004; 48: 251-7), decreases the effectiveness of the treatment and may even render the treatment completely ineffective. Humanized or chimeric human/mouse monoclonal antibodies have been shown

to significantly decrease the HAMA response and to increase the therapeutic effectiveness of antibody treatments. See, for example, LoBuglio et al., P.N.A.S. 86:4220-4224 (June 1989). Furthermore, antibodies in which particular functionalities are either enhanced or reduced may find useful applications in the clinic.

[0007] Kretz-Rommel et al. (Journal of Immunotherapy, November 2004, Volume 27, Issue 6 - page S46) discloses that CD200 is overexpressed in a subset of B-Cell chronic lymphocytic leukemias and plays a role in down-regulating the TH1 immune response.

[0008] US 2005/129690 A1 discloses a method of treating cancer using a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by a) complement-mediated or antibody-dependent cellular cytotoxicity or b) by targeting cells using a fusion molecule that includes a CD200-targeting portion.

[0009] US 2002/168364 A1 discloses that administering antibodies to CD200 inhibited the graft survival generally seen following pre-transplant portal-venous immunization. It also discloses that CD200 is responsible for promoting tumor metastases and inhibiting CD200 reduces tumor cell growth.

SUMMARY

[0010] This disclosure relates to agents and methods for modulating the function of CD200. Agents that modulate the function of CD200 include agents that modulate the activity and/or expression of CD200 and/or its receptor (CD200R).

[0011] According to the present invention there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of an anti-CD200 antibody, wherein the anti-CD200 antibody:

1. (i) inhibits the interaction between CD200 and CD200R; and
2. (ii) comprises a variant Fc constant region which:
 1. (a) is a variant Fc constant region wherein the CH1 and hinge region are derived from human IgG2 and the CH2 and CH3 regions are derived from human IgG4;
 2. (b) comprises one or both of: (A) a phenylalanine to alanine substitution at position 234 and (B) a leucine to alanine substitution at position 235 according to the EU index;
 3. (c) comprises a K322A mutation in the CH2 domain according to the EU index;
 - or
 4. (d) lacks a hinge region.

[0012] According to another aspect of the present invention there is provided an anti-CD200 antibody for use in treating cancer, wherein the anti-CD200 antibody:

1. (i) inhibits the interaction between CD200 and CD200R; and
2. (ii) comprises a variant Fc constant region which:
 1. (a) is a variant Fc constant region wherein the CH1 and hinge region are derived from human IgG2 and the CH2 and CH3 regions are derived from human IgG4;
 2. (b) comprises one or both of: (A) a phenylalanine to alanine substitution at position 234 and (B) a leucine to alanine substitution at position 235 according to the EU index;
 3. (c) comprises a K322A mutation in the CH2 domain according to the EU index;
 - or
 4. (d) lacks a hinge region.

[0013] Antibodies, as referred to herein, include antigen-binding fragments, Fab, Fv, scFv, Fab' and F(ab')₂, monoclonal and polyclonal antibodies, engineered antibodies (including chimeric, single chain, CDR-grafted, humanized, fully human antibodies, and artificially selected antibodies), and synthetic or semi-synthetic antibodies.

[0014] In certain aspects, the present disclosure relates to chimeric, humanized, human and de-immunized anti-CD200

antibodies and antigen-binding fragments thereof. There is described herein an antibody which comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from among SEQ ID NOS: 7, 9, 11, and 20, or fragments thereof. Included is an antibody comprising an amino acid sequence that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to an amino acid sequence provided in SEQ ID NOS: 7, 9, 11, and 20, or fragments thereof (including but not limited to fragments corresponding to the sequences without the leader sequences). The said antibody may additionally comprise a light chain comprising an amino acid sequence that is at least about 90% identical or similar to an amino acid sequence selected from among SEQ ID NOS: 24, 26, 28, and 32, or fragments thereof. Likewise, the aforementioned amino acid sequence may be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to an amino acid sequence provided in SEQ ID NOS: 24, 26, 28, and 32, including fragments thereof (including but not limited to fragments corresponding to the sequences without the leader sequences).

[0015] There is also described herein an anti-CD200 antibody comprising a heavy chain comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 7 and also comprising a light chain comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 24. Also included are anti-CD200 antibodies comprising amino acid sequences that are about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to one or more amino acid sequence provided in SEQ ID NOS: 7 and 24 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 7 and 24 without the leader sequences. Accordingly, there is described herein an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 6 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 23 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 6, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 23, including fragments thereof and complements thereto. There is also described herein anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous or similar to a nucleic acid sequence provided in SEQ ID NOS: 6 or 23, including fragments thereof and complements thereto.

[0016] There is also described herein an anti-CD200 antibody comprising a heavy chain comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 9 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 26. Also described herein are anti-CD200 antibodies comprising amino acid sequences that are about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to one or more amino acid sequence provided in SEQ ID NOS: 9 and 26 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 9 and 26 without the leader sequences. Accordingly, there is described herein an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 8 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 25 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 8, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 25, including fragments thereof and complements thereto. There is also described herein anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous or similar to a nucleic acid sequence provided in SEQ ID NOS: 8 or 25, including fragments thereof and complements thereto.

[0017] There is also described herein an anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 11 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 26. Also included are anti-CD200 antibodies comprising amino acid sequences that are about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to one or more amino acid sequence provided in SEQ ID NOS: 11 and 26 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 11 and 26 without the leader sequences. Accordingly, there is described herein an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 10 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 25 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence

provided in SEQ ID NO: 10, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 25, including fragments thereof and complements thereto. There is also described herein anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous or similar to a nucleic acid sequence provided in SEQ ID NOS: 10 or 25, including fragments thereof and complements thereto.

[0018] There is also described herein an anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 11 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 28. Also included are anti-CD200 antibodies comprising amino acid sequences that are about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to one or more amino acid sequence provided in SEQ ID NOS: 11 and 28 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 11 and 28 without the leader sequences. Accordingly, there is described herein an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 10 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 27 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 10, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 27, including fragments thereof and complements thereto. There is also described herein anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous or similar to a nucleic acid sequence provided in SEQ ID NOS: 10 or 27, including fragments thereof and complements thereto.

[0019] There is also described herein an anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 20 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 32. Also included are anti-CD200 antibodies comprising amino acid sequences that are about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to one or more amino acid sequence provided in SEQ ID NOS: 20 and 32 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 20 and 32 without the leader sequences. Accordingly, there is described herein an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 19 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 31 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 19, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous or similar to a nucleic acid sequence provided in SEQ ID NO: 31, including fragments thereof and complements thereto. Included, therefore, are anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous or similar to a nucleic acid sequence provided in SEQ ID NOS: 19 or 31, including fragments thereof and complements thereto.

[0020] Anti-CD200 antibodies according to the present invention include antibodies and antigen-binding fragments with altered or no effector function(s). Included are antibodies that comprise an altered constant or Fc region with decreased effector functions. There is also described herein antibodies with altered or no effector functions due to increased or decreased binding affinity, which may arise from changes in the variable regions. Altered effector functions include, for example, an increased or decreased ability to bind one or more Fc receptor (FcR) or effector cell, increased or decreased antigen-dependent cytotoxicity (ADCC), and/or increased or decreased complement-dependent cytotoxicity (CDC). Variant antibodies include but are not limited to antibodies in which the constant region or Fc region contains one or more amino acid insertions, deletions, and/or substitutions. The present invention provides variant antibodies comprising a constant region wherein the CH1 and hinge region are derived from human IgG2 and the CH2 and CH3 regions are derived from human IgG4. There is also described herein antibodies in which the constant or Fc region exhibits altered glycosylation. The aforementioned antibodies and antigen-binding fragments (including single-chain antibodies) may be murine, chimeric, humanized, fully human, or de-immunized; included are antibodies comprising the IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgA, IgD, or IgE frameworks. Furthermore, the said antibodies, including fragments and variants thereof, may be blocking or non-blocking antibodies or fragments thereof.

[0021] The present invention provides anti-CD200 antibodies that exhibit decreased or no effector function. Antibodies with decreased or no effector function may comprise a variant or altered Fc or constant region, such as, for example, a constant region with one or more amino acid substitutions, insertions, and/or deletions, or a constant region with one or more changes in glycosylation. A variant constant region includes, for example, a region wherein one or more amino acids are substituted with alanine, such as in the Ala-Ala mutation described herein, or wherein one or more carbohydrate groups is changed, added, or removed. An alteration in the number and/or location of carbohydrate groups may be achieved by producing the said antibody in particular cell types for which post-translational modifications would be reduced, absent, or increased. In one embodiment, effector function of anti-CD200 antibodies is eliminated by swapping the IgG1 constant domain for an IgG2/4 fusion domain. Other ways of eliminating effector function can be envisioned such as, e.g., mutation of the sites known to interact with an FcR or insertion of a peptide in the hinge region, thereby eliminating critical sites required for an FcR interaction.

[0022] There is described herein anti-CD200 antibodies with altered or no effector functions comprising anti-CD200 antibodies with one or more amino acid substitutions, insertions, and/or deletions. In certain embodiments, such a variant anti-CD200 antibody exhibits reduced or no effector function. The variant constant region (of said variant antibody) may possess at least about 70% homology with the native sequence constant or Fc region and/or with a constant or Fc region of the parent antibody or fragment thereof; the variant constant or Fc region may also possess at least about 80% homology or similarity therewith; or at least about 90% homology or similarity therewith or at least about 95% homology or similarity therewith. A variant antibody may comprise a G2/G4 construct. Accordingly, there is described herein a constant or Fc region of an anti-CD200 antibody with reduced or no effector function, wherein said constant region comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 13, 15, 18, 22, and fragments thereof. There is also described variant constant regions of an anti-CD200 antibody wherein an antibody comprises an amino acid sequence that is at least about 90% identical or similar to an amino acid sequence selected from among SEQ ID NOS: 13, 15, 18, 22, and fragments thereof. There is also described antibodies comprising an amino acid sequence that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical or similar to an amino acid sequence provided in SEQ ID NOS: 13, 15, 18, 22, and fragments thereof. Fragments include, but are not limited to, sequences without the leader sequences. Additionally, there is described a constant region of an anti-CD200 antibody with reduced or no effector function and comprising the G2/G4 construct is encoded by a nucleic acid selected from the group consisting of SEQ ID NOS: 12, 14, 16, 17, and 21, or fragments thereof and complements thereto. There is also described herein an anti-CD200 antibody with reduced or no effector function is encoded by a nucleic acid comprising a nucleic acid sequence that is at least about 80% homologous or similar to a sequence selected from SEQ ID NOS: 12, 14, 16, 17, and 21, including fragments thereof and complements thereto. There is also described herein a variant anti-CD200 antibody encoded by a nucleic acid sequence comprising a sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous or similar to a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 12, 14, 16, 17, and 21, including fragments thereof and complements thereto. The nucleic acid encoding a variant anti-CD200 antibody may comprise a nucleic acid sequence that hybridizes under stringent conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 12, 14, 16, 17, and 21, including fragments thereof and complements thereto. Included are antigen-binding fragments and both blocking and non-blocking antibodies or fragments thereof.

[0023] There is also described herein a variant anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 13 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 28. Also included is an anti-CD200 antibody comprising one or more amino acid sequence that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence provided in SEQ ID NOS: 13 and 28 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 13 and 28 without the leader sequences. Accordingly, there is described a variant anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 12 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 27 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 12, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 27, including fragments thereof and complements thereto. Included, therefore, are anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a nucleic acid sequence provided in SEQ ID NOS: 12 or 27, including fragments thereof and complements thereto.

[0024] There is also described herein a variant anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 15 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 24. Also included is an anti-CD200 antibody comprising an amino acid sequence that is about 90%,

91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to one or more amino acid sequence provided in SEQ ID NOS: 15 and 24 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 15 and 24 without the leader sequences (e.g., the fragment of SEQ ID NO: 15 beginning at amino acid 20 or 21). Accordingly, there is described a variant anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 14 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 23 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 14, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 23, including fragments thereof and complements thereto. Included, therefore, are anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a nucleic acid sequence provided in SEQ ID NOS: 14 or 23, including fragments thereof and complements thereto.

[0025] There is also described herein a variant anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 13 and also comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 28. Also included is an anti-CD200 antibody comprising one or more amino acid sequence that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence provided in SEQ ID NOS: 13 and 28 or fragments thereof. Fragments include, but are not limited to, sequences corresponding to the sequences set forth in SEQ ID NOS: 13 and 28 without the leader sequences. Accordingly, there is described a variant anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 16 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 27 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 16, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 27, including fragments thereof and complements thereto. Included, therefore, are anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a nucleic acid sequence provided in SEQ ID NOS: 16 or 27, including fragments thereof and complements thereto.

[0026] There is also described herein a variant anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 18 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 30. Also included is an anti-CD200 antibody comprising an amino acid sequence that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence provided in SEQ ID NOS: 18 and 30 or fragments thereof. Accordingly, there is described a variant anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 17 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 29 (including fragments thereof and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 17, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 29, including fragments thereof and complements thereto. Included, therefore, are anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a nucleic acid sequence provided in SEQ ID NOS: 17 or 29, including fragments thereof and complements thereto.

[0027] There is also described herein a variant anti-CD200 antibody comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 22 and also comprising an amino acid sequence that is at least about 90% identical to SEQ ID NO: 34. Also included is an anti-CD200 antibody comprising an amino acid sequence that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequences provided in SEQ ID NOS: 22 and 34 or fragments thereof. Accordingly, there is described a variant anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 21 (including fragments thereof and complements thereto) and also comprising an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NO: 33 (including fragments thereof

and complements thereto). Also included is an anti-CD200 antibody comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 21, including fragments thereof and complements thereto, and also comprising an amino acid sequence encoded by a nucleic acid sequence that is at least about 80% homologous to a nucleic acid sequence provided in SEQ ID NO: 33, including fragments thereof and complements thereto. Included, therefore, are anti-CD200 antibodies comprising an amino acid sequence encoded by a nucleic acid sequence that is about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a nucleic acid sequence provided in SEQ ID NOS: 21 and 33, including fragments thereof and complements thereto.

[0028] Anti-CD200 antibodies with altered effector function may also exhibit increased effector function. Increased effector functions include but are not limited to increased binding to one or more Fc receptors, increased ability to elicit ADCC, and/or increased ability to elicit CDC. Anti-CD200 antibodies with increased effector function may also comprise a variant Fc or constant region as described herein. The aforementioned anti-CD200 antibodies with altered effector functions may furthermore be blocking or non-blocking antibodies. For example, an anti-CD200 antibody with increased effector function may bind to CD200 but may not block the CD200:CD200R interaction. Such an antibody may be useful when targeting an effector function (e.g., ADCC or CDC) to a CD200-expressing cell. As mentioned previously, antibodies described herein, including the aforementioned anti-CD200 antibodies with altered effector function(s), include murine, chimeric, humanized, fully human and de-immunized antibodies, all in their blocking and non-blocking forms, and fragments thereof.

[0029] There is also described methods and compositions for modulating or depleting CD200-positive cells. CD200-positive cells may be modulated or depleted by administering a CD200 antagonist to a subject.

[0030] CD200-positive cells are implicated in certain types of cancers and certain autoimmune diseases. Accordingly, CD200-positive cells include but are not limited to immune cells (such as, e.g., B-cells and T-cells) and cancer cells (such as, e.g., cancer cells of ovarian, skin, lung, renal, breast, prostate, neuroblastoma, lymphoma, myeloma, leukemia, thyroid, and plasma cell cancers). Also included are cancer cells from any tissue or organ derived from neural crest cells. Thus the subject in need of a method of modulating or depleting CD200-positive cells may be a patient with cancer or autoimmune disease, or a patient who has received or is expected to receive an organ transplant.

[0031] There is described herein methods and compositions for treating autoimmune disease. Autoimmune diseases that may be treated by the methods and compositions provided herein include but are not limited to rheumatoid arthritis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type I diabetes, dermatomyositis, Sjogren's syndrome, lupus erythematosus, myasthenia gravis, Reiter's syndrome, Grave's disease, psoriasis, and autoimmune hemolytic diseases. In some embodiments, a patient with autoimmune disease is given an antagonist to CD200, and in certain embodiments, the antagonist is an anti-CD200 antibody. The anti-CD200 antibody may comprise a variant constant region as described herein. Accordingly, the anti-CD200 antibody may exhibit altered effector function(s), such as, for example, increased effector function(s). The said antibody may exhibit, for example, increased binding to one or more Fc receptors. Additionally, the said antibody may elicit increased ADCC and/or CDC. The said antibody may furthermore be either a blocking or non-blocking antibody or fragment thereof and may be either a murine, chimeric, humanized, fully human or de-immunized antibody or fragment thereof.

[0032] Cancers for which the disclosed methods may be used include but are not limited to melanoma, ovarian cancer, renal cancer, neuroblastoma, lung cancer, breast cancer, prostate cancer, lymphoma, myeloma, leukemia, and plasma cell cancers. Also included are cancers derived from neural crest cells and any cancers that express CD200. In certain embodiments, this disclosure provides a method for treating hematological malignancies, such as, for example, leukemias including chronic lymphocytic leukemia.

[0033] There is described herein a cancer therapy in accordance with this disclosure comprises (1) administering an anti-CD200 antibody or antagonist that interferes with the interaction between CD200 and its receptor to block immune suppression, thereby promoting eradication of the cancer cells; and/or (2) administering a fusion molecule that includes a CD-200 targeting portion to directly kill cancer cells. Alternatively, the antibody directly kills cancer cells through complement-mediated and/or antibody-dependent cellular cytotoxicity. The effector function of the anti-CD200 antibody may be altered. According to the present invention, the anti-CD200 antibody may contain a variant or altered constant region for which the effector function is decreased or eliminated; such an antibody may be useful for the methods described above in (1) and (2), for example.

[0034] There is described herein fusion molecules wherein an anti-CD200 antibody or antigen-binding fragment is linked to a second molecule. The said fusion molecule may comprise, for example, a small molecule, polypeptide, peptidomimetic, heteroclitic peptide, a chemotherapeutic agent, an immunomodulatory agent, a targeting moiety, or a nucleic acid construct (e.g., antisense, RNAi, or gene-targeting construct). The disclosure also includes antigen-binding fragments to CD200 wherein the fragment is

fused or otherwise linked to a polypeptide, protein domain, serum protein, albumin, PEG (polyethylene glycol), or any other molecule that will increase the half-life of the said fragment in vivo. Said antigen-binding fragments include Fab, Fv, single-chain fragments or scFv, Fab', and F(ab')₂, for example.

[0035] There is also described herein methods employing anti-CD200 antibodies to determine the CD200 expression status of a cell or tissue sample obtained from a patient. Such methods include but are not limited to immunohistochemical staining of tissue samples and flow cytometry analysis of CD200-stained cells from a patient. The patient may be a patient with cancer, for example.

[0036] In accordance with the methods and compositions described herein, the disclosure also relates to methods of treating a transplant or allograft patient. An anti-CD200 antibody or other CD200 antagonist of the present disclosure may be administered to a patient prior to a transplant or allograft procedure or after the procedure in order to decrease or eliminate CD200-positive immune cells that could reduce the patient's acceptance of the transplanted organ or tissue. An anti-CD200 antibody with increased effector function may be given to a transplant patient.

[0037] Methods are described herein for combination therapies comprising anti-CD200 therapy. For example, a patient receiving a first therapy comprising a CD200 antagonist (e.g., an anti-CD200 antibody described herein) may also be given a second therapy. The CD200 antagonist may be given simultaneously with the second therapy. Alternatively, the CD200 antagonist may be given prior to or following the second therapy. Second therapies include but are not limited to chemotherapeutic agents, radiation therapy, vaccines, antibiotics and anti-viral agents, and immunomodulatory therapies.

[0038] There is also described herein methods for monitoring the progress of a therapeutic treatment. The method involves administering a therapy (e.g. an immunomodulatory therapy, a chemotherapeutic therapy, etc.) and determining CD200 levels in a subject at least twice to determine the effectiveness of the therapy. Other methods to determine the effectiveness of a therapy include but are not limited to detection of cancer cells, total lymphocyte count, spleen, liver, and/or lymph node size, number of regulatory T cells, intracellular or serum cytokine profiles, or secretion of cytokines by T or B cells as measured by ELISPOT-an assay system that allows the detection of cytokines or other secreted molecules on a per cell basis.

[0039] According to the compositions and methods set forth herein there is also described any pharmaceutical composition comprising an anti-CD200 antibody. Included are chimeric, humanized, human and de-immunized anti-CD200 antibodies and antigen-binding fragments, including single-chain antibodies. Also included are murine, chimeric, humanized, human and de-immunized variant anti-CD200 antibodies and antigen-binding fragments with altered effector function(s) as described herein. The aforementioned antibodies and variant antibodies may either be blocking or non-blocking antibodies or antigen-binding fragments.

[0040] Patients for whom anti-CD200 therapy is useful or patients who expect to receive a therapy comprising a CD200 antagonist therapy (including, for example, an anti-CD200 antibody) may be screened for certain previously received treatments and procedures or for current medical status. For example, female patients may be pre-screened for pregnancy and agree to contraception, since CD200 plays an important role in protection against abortion. Accordingly, patients receiving said therapy may agree to practice one or more methods of contraception. The said patient may agree to use one or more methods of contraception for a designated period prior to starting the said therapy and/or for the duration of the said therapy. Female patients may receive counseling concerning the risks with respect to fetal exposure to such anti-CD200 therapy. Such patients may be expected to sign informed consent forms prior to such treatment. Physicals counseling patients regarding anti-CD200 therapy may require such patients to use contraceptive devices or formulations prior to administering the anti-CD200 therapy (see, for example, US6,908,432 and related patents). Patients may be screened to identify patients who have previously received brain surgery and/or radiation therapy to the brain; anti-CD200 therapy would not be prescribed for such patients.

BRIEF DESCRIPTION OF THE FIGURES

[0041]

Figure 1 provides the nucleic acid sequence for the primer C7mhHF (SEQ ID NO: 1) used in generating the G2/G4 construct.

Figure 2 provides the nucleic acid sequence for the Primer Rev Age Pri (SEQ ID NO: 2) used in generating the G2/G4 construct.

Figure 3 provides the nucleic acid sequence for the primer C2aB7 rev (SEQ ID NO: 3) used in generating the G2/G4 construct.

Figure 4 provides the nucleic acid sequence for the lacpri (SEQ ID NO: 4) used in generating the G2/G4 construct.

Figure 5 provides the nucleic acid sequence for LeadVH_pAX (SEQ ID NO: 5).

Figures 6A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody chC2aB7-hG1 (SEQ ID NOS: 6, 7, 23, 24, 37, and 38). Figure 6C shows SEQ ID NO: 37 (nucleic acid sequence) and SEQ ID NO: 7 (amino acid sequence). SEQ ID NO: 7 as shown in the schematic is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 6F shows SEQ ID NO: 38 (nucleic acid sequence) and SEQ ID NO: 24 (amino acid sequence).

Figures 7A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V4V1-hG1 (SEQ ID NOS: 8, 9, 25, 26, 39, and 40). Figure 7C shows SEQ ID NO: 39 (nucleic acid sequence) and SEQ ID NO: 9 (amino acid sequence). Figure 7F shows SEQ ID NO: 40 (nucleic acid sequence) and SEQ ID NO: 26 (amino acid sequence).

Figures 8A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V3V1-hG1 (SEQ ID NOS: 10, 11, 25, 26, 40, and 41). Figure 8C shows SEQ ID NO: 41 (nucleic acid sequence) and SEQ ID NO: 11 (amino acid sequence). Figure 8F shows SEQ ID NO: 41 (nucleic acid sequence) and SEQ ID NO: 26 (amino acid sequence).

Figures 9A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V3V2-hG1 (SEQ ID NOS: 10, 11, 27, 28, 41, and 42). Figure 9C shows SEQ ID NO: 41 (nucleic acid sequence) and SEQ ID NO: 11 (amino acid sequence). Figure 9F shows SEQ ID NO: 42 (nucleic acid sequence) and SEQ ID NO: 28 (amino acid sequence).

Figures 10A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V3V2-hG2G4 (SEQ ID NOS: 12, 13, 27, 28, 42, and 43). Figure 10C shows SEQ ID NO: 43 (nucleic acid sequence) and SEQ ID NO: 13 (amino acid sequence). SEQ ID NO: 13 as shown in the schematic is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 10F shows SEQ ID NO: 42 (nucleic acid sequence) and SEQ ID NO: 28 (amino acid sequence).

Figures 11A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody chC2aB7-hG2G4 (SEQ ID NOS: 14, 15, 23, 24, 44, 45, 46, and 47). Figure 11C shows SEQ ID NO: 44 (nucleic acid sequence) and SEQ ID NO: 45 (amino acid sequence). SEQ ID NO: 45 corresponds to amino acids 1-337 of SEQ ID NO: 15. As shown in the schematic, SEQ ID NO: 45 is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 11F shows SEQ ID NO: 46 (nucleic acid sequence) and SEQ ID NO: 47 (amino acid sequence).

Figures 12A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody hB7V3V2-cG2G4 (SEQ ID NOS: 13, 16, 27, 28, 48, and 49). Figure 12C shows SEQ ID NO: 48 (nucleic acid sequence) and SEQ ID NO: 13 (amino acid sequence). Figure 12F shows SEQ ID NO: 49 (nucleic acid sequence) and SEQ ID NO: 28 (amino acid sequence).

Figures 13A-D depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody chC7-hG2G4 (SEQ ID NOS: 17, 18, 29, and 30).

Figures 14A-F depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody D1B5-hG1 (SEQ ID NOS: 19, 20, 31, 32, 50, and 51). Figure 14C shows SEQ ID NO: 50 (nucleic acid sequence) and SEQ ID NO: 20 (amino acid sequence). SEQ ID NO: 20 as shown in the schematic is contiguous but is depicted with a corresponding nucleotide sequence that includes introns. Figure 14F shows SEQ ID NO: 51 (nucleic acid sequence) and SEQ ID NO: 32 (amino acid sequence).

Figures 15A-D depict the amino acid sequences and nucleotide sequences for the heavy and light chains of antibody G2G4 63L1D (SEQ ID NOS: 21, 22, 33, and 34).

Figure 16 provides the nucleic acid sequence for the forward primer for cloning CD200 cDNA (SEQ ID NO: 35).

Figure 17 provides the nucleic acid sequence for the reverse primer for cloning CD200 cDNA (SEQ ID NO: 36).

Figure 18 shows the effects of administering humanized CD200 antibodies in the RAJI-CD200/PBL model. Humanized anti-CD200 antibodies resulted in an inhibition of tumor growth.

Figure 19 demonstrates the effects of administering humanized CD200 antibodies with and without effector function in the Namalwa_CD200 animal model. Antibodies without effector function exhibited efficacy in inhibiting tumor growth.

Figure 20 is a table showing the expression level of CD200 in chronic lymphocytic leukemia (CLL) patient samples compared to normal samples.

Figure 21 depicts the relative levels of CD200 expression detected in cancer cell lines.

Figure 22 shows the expression level of CD200 antigen in human ovarian cancer samples relative to the expression level

detected in human peripheral blood lymphocytes (PBL).

Figure 23 shows the expression level of CD200 antigen in human melanoma patient samples relative to the expression level detected in PBL.

Figure 24 shows immunohistochemical staining of CD200 of melanoma patient samples.

Figure 25 demonstrates the effects of anti-CD200 antibody in cytokine production. The levels of IL-2 production in mixed cell population assays were measured in the absence and presence of CD200 antibody. The antibody used is a chimeric anti-CD200 antibody with no effector function.

Figure 26 shows the effects of administering anti-CD200 antibodies, with or without effector function, in the Namalwa/PBL model in which the tumors do not express CD200.

Figure 27 shows flow cytometric analysis of CD200 expression on activated T-cells. CD3+ cells were activated with mOKT3, harvested, washed and subjected to staining with the indicated conjugated antibodies specific for human CD25, CD200, CD5, CD4 and CD8. Cells were washed and analyzed for immunofluorescence on a FACS Caliber flow cytometer using CellQuest software.

Figure 28 demonstrates the effects of anti-CD200 antibodies on ADCC of activated T-cells. CD3+ human T cells were stimulated with 10 µg/mL immobilized (plate-coated) mOKT3 for 72 hrs. Activated T cells were then chromated for use as targets and incubated with purified autologous CD56+ (NK) cells as effector cells. Cells were cocubated for 4 hours at 37°C at 25:1 (A) or 10:1 (B) effector: target cell ratios in the presence or absence of a humanized anti-CD200 antibody capable of mediating effector function (V3V2-G1) or engineered to lack effector function (V3V2-G2G4). Data is represented as percent specific lysis. Anti-CD200 antibody increased ADCC of activated T-cells, whereas the anti-CD200 antibody with no effector function failed to induce ADCC.

Figure 29 is a table showing the expression level of CD200 on plasma cells.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

I. CD200 ANTAGONISTS

[0042] CD200 is a highly conserved type I transmembrane glycoprotein expressed on various cell types including cells of the immune system (e.g., T-cells, B-cells, and dendritic cells (Barclay et al., *TRENDS Immunol.* 2002: 23)) as well as certain cancer cells as shown herein. The protein interacts with its receptor CD200R on myeloid cells and sub-populations of T cells (Wright et al. *J. Immunol.* 2003 (171): 3034-3046 and Wright et al., *Immunity* 2000 (13):233-242); the CD200:CD200R interaction delivers an immunomodulatory signal to cells and induces immunosuppression including apoptosis-associated immune tolerance (Rosenblum et al. 2004 *Blood* (103): 2691-2698). Thus agents that interfere with the function or activity of CD200 and/or its receptor may inhibit or reverse the immunosuppressive effects of the CD200:CD200R interaction. In addition, agents that specifically bind CD200 (but that may or may not inhibit the CD200:CD200R interaction) may trigger downstream events that reverse or abolish the effects of CD200.

[0043] There is described herein CD200 antagonists. As used herein, the term antagonist includes any agent that is capable of inhibiting the activity, function and/or the expression of CD200 or its receptor. Examples include but are not limited to polypeptides, antibodies, small molecules, aptamers, spiegelmers, locked nucleic acid (LNA) inhibitors, peptide nucleic acid (PNA) inhibitors, nucleic acid constructs (e.g., gene-targeting constructs, antisense constructs, RNA interference (RNAi) constructs, etc.) and peptidomimetics. According to the present invention the antagonist is an antibody. According to the present invention the antagonist disrupts the interaction of CD200 and CD200R. The CD200 antagonists may be capable of decreasing the immunosuppressive effects of CD200 or are capable of targeting CD200-expressing cells for depletion or elimination.

[0044] CD200 antagonists may be polypeptides. Polypeptides can be constructed using different techniques which are known to those skilled in the art. Polypeptides may be obtained by chemical synthesis. The polypeptides may be antibodies constructed from a fragment or several fragments of one or more antibodies. The polypeptide may be an anti-CD200 antibody as described herein.

[0045] The CD200 antagonists described herein may be anti-CD200 antibodies. As used herein, the term "antibodies" refers to complete antibodies or antibody fragments capable of binding to CD200 or CD200R. Included are Fab, Fv, scFv, Fab' and F(ab')₂, monoclonal and polyclonal antibodies, engineered antibodies (including chimeric, single chain, CDR-grafted, humanized, fully human antibodies, and artificially selected antibodies), and synthetic or semi-synthetic antibodies produced using phage display or alternative techniques. Also included are antibodies engineered or produced in ways to contain variant or altered constant or Fc regions with either increased or decreased ability to bind one or more effector cell; such variant antibodies include but are not limited to antibodies in which the constant or Fc region contains altered glycosylation patterns. Small fragments, such as Fv and scFv, possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution. Antibodies with engineered or variant constant or Fc regions can be useful in modulating effector functions, such as, for example, ADCC and CDC. Such antibodies with engineered or variant constant or Fc regions may be useful in instances where CD200 is expressed in normal tissue, for example; variant anti-CD200 antibodies without effector function in these instances may elicit the desired therapeutic response while not damaging normal tissue. Furthermore, antibodies, variant antibodies, and fragments thereof may be blocking (i.e., the said antibodies or fragments inhibit the interaction of CD200 and CD200R) or non-blocking (i.e., the said antibodies or fragments bind to CD200 but do not block its interaction with CD200R).

[0046] There is also described anti-CD200 antibodies comprising heavy and light chains as provided herein, including heavy and light chains that are homologous or similar to the heavy and/or light chains provided herein. "Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology/similarity or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. The term "homology" describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. As used herein, "identity" means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Thus methods to determine identity are designed to give the largest match between the sequences tested (see Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 1988, Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984), BLASTP, BLASTN, FASTA (Altschul, S. F. et al., J. Molec. Biol. 215: 403-410 (1990) and Altschul et al. Nuc. Acids Res. 25: 3389-3402 (1997)) and BLAST X (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990)). A sequence which is "unrelated" or "non-homologous" shares less than 40% identity, though preferably less than 25% identity with a sequence of the present disclosure. In comparing two sequences, the absence of residues (amino acids or nucleic acids) or presence of extra residues also decreases the identity and homology/similarity.

[0047] Accordingly, the disclosure relates to antibodies as described herein without the leader sequences. Thus antibodies of the disclosure may comprise heavy and light chains (as described herein) in which the leader sequence is either absent or replaced by a different leader sequence. If host cells are used to produce antibodies of the present disclosure, appropriate leader sequences may therefore be selected according to the particular host cell used.

[0048] Antibodies may be produced by methods well known in the art. For example, monoclonal anti-CD200 antibodies may be generated using CD200 positive cells, CD200 polypeptide, or a fragment of CD200 polypeptide, as an immunogen, thus raising an immune response in animals from which antibody-producing cells and in turn monoclonal antibodies may be isolated. The sequence of such antibodies may be determined and the antibodies or variants thereof produced by recombinant techniques. Recombinant techniques may be used to produce chimeric, CDR-grafted, humanized and fully human antibodies based on the sequence of the monoclonal antibodies as well as polypeptides capable of binding to CD200.

[0049] Moreover, antibodies derived from recombinant libraries ("phage antibodies") may be selected using CD200-positive cells, or polypeptides derived therefrom, as bait to isolate the antibodies or polypeptides on the basis of target specificity. The production and isolation of non-human and chimeric anti-CD200 antibodies are well within the purview of the skilled artisan.

[0050] Recombinant DNA technology is used to improve the antibodies produced in non-human cells. Thus, chimeric antibodies

may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimized by humanizing the antibodies by CDR grafting and, optionally, framework modification. See, U.S. Patent No. 5,225,539.

[0051] Antibodies may be obtained from animal serum or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, including procedures in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

[0052] There is described herein a process for the production of an antibody disclosed herein which includes culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector. The vector includes one or more expression cassettes containing a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding the antibody protein. The antibody protein is then collected and isolated. Optionally, the expression cassette may include a promoter operably linked to polycistronic, for example bicistronic, DNA sequences encoding antibody proteins each individually operably linked to a signal peptide in the proper reading frame.

[0053] Multiplication of hybridoma cells or mammalian host cells in vitro is carried out in suitable culture media, which include the customary standard culture media (such as, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium), optionally replenished by a mammalian serum (e.g. fetal calf serum), or trace elements and growth sustaining supplements (e.g. feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like). Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art. For example, for bacteria suitable culture media include medium LE, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 x YT, or M9 Minimal Medium. For yeast, suitable culture media include medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.

[0054] In vitro production provides relatively pure antibody preparations and allows scale-up production to give large amounts of the desired antibodies. Techniques for bacterial cell, yeast, plant, or mammalian cell cultivation are known in the art and include homogeneous suspension culture (e.g. in an airlift reactor or in a continuous stirrer reactor), and immobilized or entrapped cell culture (e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges).

[0055] Large quantities of the desired antibodies can also be obtained by multiplying mammalian cells in vivo. For this purpose, hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethylpentadecane), prior to the injection. After one to three weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired antibodies are injected intraperitoneally into Balb/c mice optionally pre-treated with pristane. After one to two weeks, ascitic fluid is taken from the animals.

[0056] The foregoing, and other, techniques are discussed in, for example, Kohler and Milstein, (1975) *Nature* 256:495-497; U.S. Patent No. 4,376,110; Harlow and Lane, *Antibodies: a Laboratory Manual*, (1988) Cold Spring Harbor. Techniques for the preparation of recombinant antibody molecules are described in the above references and also in, for example WO97/08320; U.S. Patent No. 5,427,908; U.S. Patent No. 5,508,717; Smith, 1985, *Science*, Vol. 225, pp 1315-1317; Parmley and Smith, 1988, *Gene* 73, pp 305-318; De La Cruz et al., 1988, *Journal of Biological Chemistry*, 263 pp 4318-4322; U.S. Patent No. 5,403,484; U.S. Patent No. 5,223,409; WO88/06630; WO92/15679; U.S. Patent No. 5,780,279; U.S. Patent No. 5,571,698; U.S. Patent No. 6,040,136; Davis et al., 1999, *Cancer Metastasis Rev.*, 18(4):421-5; Taylor, et al., *Nucleic Acids Research* 20 (1992): 6287-6295; Tomizuka et al., *Proc. Natl. Academy of Sciences USA* 97(2) (2000): 722-727.

[0057] The cell culture supernatants are screened for the desired antibodies, preferentially by immunofluorescent staining of CD200-positive cells, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radioimmunoassay.

[0058] For isolation of the antibodies, the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with ammonium sulfate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like. If necessary and/or desired, the antibodies are purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-) affinity chromatography, e.g. affinity chromatography with one or more surface polypeptides derived from a CD200-positive cell line, or with Protein-A or -G.

[0059] There is also described herein a process for the preparation of a bacterial cell line secreting antibodies directed against CD200 in a suitable mammal. For example a rabbit is immunized with pooled samples from CD200-positive tissue or cells or CD200 polypeptide or fragments thereof. A phage display library produced from the immunized rabbit is constructed and panned for the desired antibodies in accordance with methods well known in the art.

[0060] Hybridoma cells secreting the monoclonal antibodies are also disclosed. The preferred hybridoma cells are genetically stable, secrete monoclonal antibodies described herein of the desired specificity, and can be activated from deep-frozen cultures by thawing and recloning.

[0061] There is also described herein a process for the preparation of a hybridoma cell line secreting monoclonal antibodies against CD200. In that process, a suitable mammal, for example a Balb/c mouse, is immunized with one or more polypeptides or antigenic fragments of CD200 or with one or more polypeptides or antigenic fragments derived from a CD200-positive cell, the CD200-positive cell itself, or an antigenic carrier containing a purified polypeptide as described. Antibody-producing cells of the immunized mammal are grown briefly in culture or fused with cells of a suitable myeloma cell line. The hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example, spleen cells of Balb/c mice immunized with a CD200-positive Chronic Lymphocytic Leukemia (CLL) cell line are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Ag 14. The obtained hybrid cells are then screened for secretion of the desired antibodies and positive hybridoma cells are cloned.

[0062] Preferred is a process for the preparation of a hybridoma cell line, characterized in that Balb/c mice are immunized by injecting subcutaneously and/or intraperitoneally between 10^6 and 10^7 cells of a CD200-positive cell line several times, e.g. four to six times, over several months, e.g. between two and four months. Spleen cells from the immunized mice are taken two to four days after the last injection and fused with cells of the myeloma cell line PAI in the presence of a fusion promoter, preferably polyethylene glycol. Preferably, the myeloma cells are fused with a three- to twenty-fold excess of spleen cells from the immunized mice in a solution containing about 30% to about 50% polyethylene glycol of a molecular weight around 4000. After the fusion, the cells are expanded in suitable culture media as described hereinbefore, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells.

[0063] The antibodies and fragments thereof can be "chimeric". Chimeric antibodies and antigen-binding fragments thereof comprise portions from two or more different species (e.g., mouse and human). Chimeric antibodies can be produced with mouse variable regions of desired specificity spliced into human constant domain gene segments (for example, U.S. patent No. 4,816,567). In this manner, non-human antibodies can be modified to make them more suitable for human clinical application.

[0064] The monoclonal antibodies of the present disclosure include "humanized" forms of the non-human (i.e., mouse) antibodies. Humanized or CDR-grafted mAbs are particularly useful as therapeutic agents for humans because they are not cleared from the circulation as rapidly as mouse antibodies and do not typically provoke an adverse immune reaction. Generally, a humanized antibody has one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Methods of preparing humanized antibodies are generally well known in the art. For example, humanization can be essentially performed following the method of Winter and co-workers (Jones et al., *Nature* 321:522-525 (1986); Reichmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239: 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Also see Staelens et al. 2006 *Mol Immunol* 43: 1243-1257. In particular embodiments, humanized forms of non-human (e.g., mouse) antibodies are human antibodies (recipient antibody) in which hypervariable (CDR) region residues of the recipient antibody are replaced by hypervariable region residues from a non-human species (donor antibody) such as a mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and binding capacity. In some instances, framework region residues of the human immunoglobulin are also replaced by corresponding non-human residues (so called "back mutations"). In addition, phage display libraries can be used to vary amino acids at chosen positions within the antibody sequence. The properties of a humanized antibody are also affected by the choice of the human framework. Furthermore, humanized and chimerized antibodies can be modified to comprise residues that are not found in the recipient antibody or in the donor antibody in order to further improve antibody properties, such as, for example, affinity or effector function.

[0065] Fully human antibodies are also provided in the disclosure. The term "human antibody" includes antibodies having variable and constant regions (if present) derived from human germline immunoglobulin sequences. Human antibodies can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody" does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been

grafted onto human framework sequences (i.e., humanized antibodies). Fully human or human antibodies may be derived from transgenic mice carrying human antibody genes (carrying the variable (V), diversity (D), joining (J), and constant (C) exons) or from human cells. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production (see, e.g., Jakobovits et al., PNAS; 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immuno., 7:33 (1993); and Duchosal et al. Nature 355:258 (1992). Transgenic mice strain can be engineered to contain gene sequences from unrearranged human immunoglobulin genes. The human sequences may code for both the heavy and light chains of human antibodies and would function correctly in the mice, undergoing rearrangement to provide a wide antibody repertoire similar to that in humans. The transgenic mice can be immunized with the target protein (e.g., CD200, fragments thereof, or cells expressing CD200) to create a diverse array of specific antibodies and their encoding RNA. Nucleic acids encoding the antibody chain components of such antibodies may then be cloned from the animal into a display vector. Typically, separate populations of nucleic acids encoding heavy and light chain sequences are cloned, and the separate populations then recombined on insertion into the vector, such that any given copy of the vector receives a random combination of a heavy and a light chain. The vector is designed to express antibody chains so that they can be assembled and displayed on the outer surface of a display package containing the vector. For example, antibody chains can be expressed as fusion proteins with a phage coat protein from the outer surface of the phage. Thereafter, display packages can be screened for display of antibodies binding to a target.

[0066] In addition, human antibodies can be derived from phage-display libraries (Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581-597 (1991); Vaughan et al. Nature Biotech 14:309 (1996)). Synthetic phage libraries can be created which use randomized combinations of synthetic human antibody V-regions. By selection on antigen fully human antibodies can be made in which the V-regions are very human-like in nature. See patents US 6,794,132, 6,680,209, 4,634,666, and Ostberg et al. (1983), Hybridoma 2:361-367.

[0067] For the generation of human antibodies, also see Mendez et al. Nature Genetics 15:146-156 (1997), Green and Jakobovits J. Exp. Med. 188:483-495 (1998). Human antibodies are further discussed and delineated in U.S. patents 5,939,598 and 6,673,986. Also see US patents 6,114,598, 6,075,181, and 6,162,963, all filed Jun. 5, 1995. Also see US patent 6,150,584, filed Oct. 2, 1996 and US patents 6,713,610 and 6,657,103 as well as US patent applications 10/421,011 (US 2003-0229905 A1), 10/455,013 (US 2004-0010810 A1), 10/627,250 (US 2004-0093622 A1), 10/656,623 (US 2006-0040363 A1), 10/658,521 (US 2005-0054055 A1), 10/917,703 (US 2005-0076395 A1) and 10/978,297 (US 2005-0287630 A1). See also PCT/US93/06926 filed on July 23, 1993, European Patent No., EP 0 463 151 B1, grant published Jun. 12, 1996, International Patent Application No., WO 94/02602, published Feb. 3, 1994, International Patent Application No., WO 96/34096, published Oct. 31, 1996, and WO 98/24893, published Jun. 11, 1998.

[0068] In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Pat. No. 5,545,807 to Surani et al. and U.S. Pat. Nos. 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, and 5,814,318 each to Lonberg and Kay, U.S. Pat. No. 5,591,669 to Krimpenfort and Berns, U.S. Pat. Nos. 5,612,205, 5,721,367, 5,789,215 to Berns et al., and U.S. Pat. No. 5,643,763 to Choi and Dunn, and GenPharm International. Also see U.S. patents 5,569,825, 5,877,397, 6,300,129, 5,874,299, 6,255,458, and 7,041,871. See also European Patent No. 0 546 073 B1, International Patent Application Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884. See further Taylor et al. (1992 Nuc. Acids. Res., 20: 6287), Chen et al. (1993 Int. Immunol. 5: 647), Tuailon et al. (1993 PNAS USA. 90: 3720-4), Choi et al., (1993 Nature Genetics 4: 117), Lonberg et al. (1994 Nature 368: 856-859), Taylor et al. (1994 International Immunology 6: 579-591), and Tuailon et al. (1995 J Immunol. 154: 6453-65), Fishwild et al. (1996 Nature Biotechnology 14: 845), and Tuailon et al. (2000 Eur J Immunol. 10: 2998-3005).

[0069] There is described herein de-immunized anti-CD200 antibodies or antigen-binding fragments thereof. De-immunized antibodies or antigen-binding fragments thereof may be modified so as to render the antibody or antigen-binding fragment thereof non-immunogenic, or less immunogenic, to a given species. Deimmunization can be achieved by modifying the antibody or antigen-binding fragment thereof utilizing any of a variety of techniques known to those skilled in the art (see e.g., PCT Publication Nos. WO 04/108158 and WO 00/34317). For example, an antibody or antigen-binding fragment thereof may be de-immunized by identifying potential T cell epitopes and/or B cell epitopes within the amino acid sequence of the antibody or antigen-binding fragment thereof and removing one or more the potential T cell epitopes and/or B cell epitopes from the antibody or antigen-binding fragment thereof, for example, using recombinant techniques. The modified antibody or antigen-binding fragment thereof may then optionally be produced and tested to identify antibodies or antigen-binding

fragments thereof that have retained one or more desired biological activities, such as, for example, binding affinity, but have reduced immunogenicity. Methods for identifying potential T cell epitopes and/or B cell epitopes may be carried out using techniques known in the art, such as, for example, computational methods (see e.g., PCT Publication No. WO 02/069232), *in vitro* or *in silico* techniques, and biological assays or physical methods (such as, for example, determination of the binding of peptides to MHC molecules, determination of the binding of peptide:MHC complexes to the T cell receptors from the species to receive the antibody or antigen-binding fragment thereof, testing of the protein or peptide parts thereof using transgenic animals with the MHC molecules of the species to receive the antibody or antigen-binding fragment thereof, or testing with transgenic animals reconstituted with immune system cells from the species to receive the antibody or antigen-binding fragment thereof, etc.). In various embodiments, the de-immunized anti-CD200 antibodies described herein include de-immunized antigen-binding fragments, Fab, Fv scFv, Fab' and F(ab')₂, monoclonal antibodies, murine antibodies, engineered antibodies (such as, for example, chimeric, single chain, CDR-grafted, humanized, fully human antibodies, and artificially selected antibodies), synthetic antibodies and semi-synthetic antibodies.

[0070] Recombinant DNA comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to CD200 or a CD200-positive cell line may be produced. The term DNA includes coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

[0071] Furthermore, DNA encoding a heavy chain variable domain and/or a light chain variable domain of antibodies directed to CD200 or the CD200-positive cell line can be enzymatically or chemically synthesized DNA having the authentic DNA sequence coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof. A mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted, inserted, or exchanged with one or more other amino acids. Preferably said modification(s) are outside the CDRs of the heavy chain variable domain and/or of the light chain variable domain of the antibody in humanization and expression optimization applications. The term mutant DNA also embraces silent mutants wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s). The term mutant sequence also includes a degenerate sequence. Degenerate sequences are degenerate within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerate sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly *E. coli*, to obtain an optimal expression of the heavy chain murine variable domain and/or a light chain murine variable domain.

[0072] The term mutant is intended to include a DNA mutant obtained by *in vitro* mutagenesis of the authentic DNA according to methods known in the art.

[0073] For the assembly of complete tetrameric immunoglobulin molecules and the expression of chimeric antibodies, the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.

[0074] Recombinant DNAs including an insert coding for a heavy chain murine variable domain of an antibody directed to CD200 or a CD200-positive cell line fused to a human constant domain IgG, for example $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$; in particular embodiments $\gamma 1$ or $\gamma 4$ may be used. Recombinant DNAs including an insert coding for a light chain murine variable domain of an antibody directed to the cell line disclosed herein fused to a human constant domain κ or λ , preferably κ are also provided.

[0075] There is described herein DNAs coding for a recombinant polypeptide wherein the heavy chain variable domain and the light chain variable domain are linked by way of a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA sequence encoding a peptide facilitating the purification of the antibody and/or a cleavage site and/or a peptide spacer and/or an agent. The DNA coding for an agent is intended to be a DNA coding for the agent useful in diagnostic or therapeutic applications. Thus, agent molecules which are toxins or enzymes, especially enzymes capable of catalyzing the activation of prodrugs, are particularly indicated. The DNA encoding such an agent has the sequence of a naturally occurring enzyme or toxin encoding DNA, or a mutant thereof, and can be prepared by methods well known in the art.

[0076] Accordingly, the monoclonal antibodies or antigen-binding fragments of the disclosure can be naked antibodies or antigen-binding fragments that are not conjugated to other agents, for example, a therapeutic agent or detectable label. Alternatively, the monoclonal antibody or antigen-binding fragment can be conjugated to an agent such as, for example, a cytotoxic agent, a small molecule, a hormone, an enzyme, a growth factor, a cytokine, a ribozyme, a peptidomimetic, a chemical, a

prodrug, a nucleic acid molecule including coding sequences (such as antisense, RNAi, gene-targeting constructs, etc.), or a detectable label (e.g., an NMR or X-ray contrasting agent, fluorescent molecule, etc). An anti-CD200 polypeptide or antigen-binding fragment (e.g., Fab, Fv, single-chain scFv, Fab' and F(ab')₂) may be linked to a molecule that increases the half-life of the said polypeptide or antigen-binding fragment. Molecules that may be linked to said anti-CD200 polypeptide or antigen-binding fragment include but are not limited to serum proteins including albumin, polypeptides, other proteins or protein domains, and PEG.

[0077] Several possible vector systems are available for the expression of cloned heavy chain and light chain genes in mammalian cells. One class of vectors relies upon the integration of the desired gene sequences into the host cell genome. Cells which have stably integrated DNA can be selected by simultaneously introducing drug resistance genes such as E. coli gpt (Mulligan, R. C. and Berg, P., Proc. Natl. Acad. Sci., USA, 78: 2072 (1981)) or Tn5 neo (Southern, P. J. and Berg, P., J. Mol. Appl. Genet., 1: 327 (1982)). The selectable marker gene can be either linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection (Wigler, M. et al., Cell, 16: 77 (1979)). A second class of vectors utilizes DNA elements which confer autonomously replicating capabilities to an extrachromosomal plasmid. These vectors can be derived from animal viruses, such as bovine papillomavirus (Sarver, N. et al., Proc. Natl. Acad. Sci., USA, 79: 7147 (1982)), polyoma virus (Deans, R. J. et al., Proc. Natl. Acad. Sci., USA, 81: 1292 (1984)), or SV40 virus (Lusky, M. and Botchan, M., Nature, 293: 79 (1981)).

[0078] Since an immunoglobulin cDNA is comprised only of sequences representing the mature mRNA encoding an antibody protein, additional gene expression elements regulating transcription of the gene and processing of the RNA are required for the synthesis of immunoglobulin mRNA. These elements may include splice signals, transcription promoters, including inducible promoters enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama, H. and Berg, P., Mol. Cell Biol., 3: 280 (1983); Cepko, C. L. et al., Cell, 37: 1053 (1984); and Kaufman, R. J., Proc. Natl. Acad. Sci., USA, 82: 689 (1985).

[0079] An anti-CD200 antibody may be a blocking or non-blocking antibody. As used herein, a blocking antibody is one that blocks the interaction between CD200 and CD200R. A non-blocking antibody binds and/or interacts with CD200 but does not block its interaction with CD200R. An anti-CD200 antibody is either a blocking or non-blocking murine, chimeric, humanized human or de-immunized antibody.

II. CD200 ANTAGONISTS WITH ALTERED EFFECTOR FUNCTIONS

[0080] CD200 antagonists may be altered to elicit increased or decreased effects relative to the original or parent antagonist. For example, an antagonist that binds CD200 may elicit secondary functions following binding to CD200 and, in some instances, inhibiting the CD200:CD200R interaction. For example, an antagonist may contain additional binding sites for other ligands, including receptors or extracellular proteins. Binding to these other ligands may trigger other events, such as the attraction or recruitment of other cells and the activation of various events including cell death. There is described herein CD200 antagonists that elicit altered secondary functions (or effector functions as referred to below). The CD200 antagonist with altered secondary or effector function(s) may exhibit increased, decreased, or no secondary or effector function(s), and further may or may not block the CD200:CD200R interaction. The CD200 antagonist with altered secondary or effector function(s) may be an anti-CD200 antibody.

A) EFFECTOR FUNCTIONS

[0081] The interaction of antibodies and antibody-antigen complexes with cells of the immune system affects a variety of responses, referred to herein as effector functions. Exemplary effector functions include Fc receptor binding, phagocytosis, down-regulation of cell surface receptors (e.g. B cell receptor; BCR), etc. Other effector functions include ADCC, whereby antibodies bind Fc receptors on natural killer (NK) cells or macrophages leading to cell death, and CDC, which is cell death induced via activation of the complement cascade (reviewed in Daeron, Annu. Rev. Immunol. 15:203-234 (1997); Ward and Ghetie, Therapeutic Immunol. 2:77-94 (1995); and Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991)). Such effector functions generally require the Fc region to be combined with a binding domain (e.g. an antibody variable domain) and can be assessed using various assays as herein disclosed, for example.

[0082] Several antibody effector functions, including ADCC, are mediated by Fc receptors (FcRs), which bind the Fc region of an antibody. In ADCC, NK cells or macrophages bind to the Fc region of the antibody complex and promote lysis of the target cell.

The cross-linking of FcRs on NK cells triggers perforin/granzyme-mediated cytotoxicity, whereas in macrophages this cross-linking promotes the release of mediators such as nitric oxide (NO), TNF- α , and reactive oxygen species. For CD200-positive target cells, an anti-CD200 antibody binds to the target cell and the Fc region directs effector function to the target cell. The affinity of an antibody for a particular FcR, and hence the effector activity mediated by the antibody, may be modulated by altering the amino acid sequence and/or post-translational modifications of the Fc and/or constant region of the antibody.

[0083] FcRs are defined by their specificity for immunoglobulin isotypes; Fc receptors for IgG antibodies are referred to as Fc γ R, for IgE as Fc ϵ R, for IgA as Fc α R and so on. Three subclasses of Fc γ R have been identified: Fc γ RI (CD64), Fc γ RII (CD32) and Fc γ RIII (CD16). Because each Fc γ R subclass is encoded by two or three genes, and alternative RNA splicing leads to multiple transcripts, a broad diversity in Fc γ R isoforms exists. The three genes encoding the Fc γ RI subclass (Fc γ RIA, Fc γ RIB and Fc γ RIC) are clustered in region 1q21.1 of the long arm of chromosome 1; the genes encoding Fc γ RII isoforms (Fc γ RIIA, Fc γ RIIB and Fc γ RIIC) and the two genes encoding Fc γ RIII (Fc γ RIIIA and Fc γ RIIIB) are all clustered in region 1q22. These different FcR subtypes are expressed on different cell types (reviewed in Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-492 (1991)). For example, in humans, Fc γ RIIIB is found only on neutrophils, whereas Fc γ RIIIA is found on macrophages, monocytes, natural killer (NK) cells, and a subpopulation of T-cells. Notably, Fc γ RIIIA is the only FcR present on NK cells, one of the cell types implicated in ADCC.

[0084] Fc γ RI, Fc γ RII and Fc γ RIII are immunoglobulin superfamily (IgSF) receptors; Fc γ RI has three IgSF domains in its extracellular domain, while Fc γ RII and Fc γ RIII have only two IgSF domains in their extracellular domains. Another type of Fc receptor is the neonatal Fc receptor (FcRn). FcRn is structurally similar to major histocompatibility complex (MHC) and consists of an α -chain noncovalently bound to β 2-microglobulin.

[0085] The binding site on human and murine antibodies for Fc γ R have been previously mapped to the so-called "lower hinge region" consisting of residues 233-239 (EU index numbering as in Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). Woof et al. *Molec. Immunol.* 23:319-330 (1986); Duncan et al. *Nature* 332:563 (1988); Canfield and Morrison, *J. Exp. Med.* 173:1483-1491 (1991); Chappel et al., *Proc. Natl. Acad. Sci USA* 88:9036-9040 (1991). Of residues 233-239, P238 and S239 have been cited as possibly being involved in binding.

[0086] Other previously cited areas possibly involved in binding to Fc γ R are: G316-K338 (human IgG) for human Fc γ RI (by sequence comparison only; no substitution mutants were evaluated) (Woof et al. *Molec. Immunol.* 23:319-330 (1986)); K274-R301 (human IgG1) for human Fc γ RIII (based on peptides) (Sarmay et al. *Molec. Immunol.* 21:43-51 (1984)); Y407-R416 (human IgG) for human Fc γ RIII (based on peptides) (Gergely et al. *Biochem. Soc. Trans.* 12:739-743 (1984)); as well as N297 and E318 (murine IgG2b) for murine Fc γ RII (Lund et al., *Molec. Immunol.*, 29:53-59 (1992)).

[0087] Human effector cells are leukocytes which express one or more FcRs and perform effector functions. In certain embodiments, the cells express at least Fc γ RIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils. Effector cells may be isolated from a native source thereof, e.g. from blood or PBMCs.

[0088] In CDC, the antibody-antigen complex binds complement, resulting in the activation of the complement cascade and generation of the membrane attack complex. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen; thus the activation of the complement cascade is regulated in part by the binding affinity of the immunoglobulin to C1q protein. C1q and two serine proteases, C1r and C1s, form the complex C1, the first component of the CDC pathway. C1q is a hexavalent molecule with a molecular weight of approximately 460,000 and a structure in which six collagenous "stalks" are connected to six globular head regions. Burton and Woof, *Advances in Immunol.* 51:1-84 (1992). To activate the complement cascade, it is necessary for C1q to bind to at least two molecules of IgG1, IgG2, or IgG3, but only one molecule of IgM, attached to the antigenic target (Ward and Ghetie, *Therapeutic Immunology* 2:77-94 (1995) p. 80). To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., *J. Immunol. Methods* 202:163 (1996), may be performed.

[0089] It has been proposed that various residues of the IgG molecule are involved in binding to C1q including the Glu318, Lys320 and Lys322 residues on the CH2 domain, amino acid residue 331 located on a turn in close proximity to the same beta strand, the Lys235 and Gly237 residues located in the lower hinge region, and residues 231 to 238 located in the N-terminal region of the CH2 domain (see e.g., Xu et al., *J. Immunol.* 150:152A (Abstract) (1993), WO94/29351; Tao et al., *J. Exp. Med.*, 178:661-667 (1993); Brekke et al., *Eur. J. Immunol.* 24:2542-47 (1994); Burton et al; *Nature*, 288:338-344 (1980); Duncan and Winter, *Nature* 332:738-40 (1988); U.S. Pat. No. 5,648,260, and U.S. Pat. No. 5,624,821). It has further been proposed that the ability of IgG to bind C1q and activate the complement cascade also depends on the presence, absence or modification of the

carbohydrate moiety positioned between the two CH2 domains (which is normally anchored at Asn297) (Ward and Ghetie, *Therapeutic Immunology* 2:77-94 (1995)). One or more of these residues may be modified, substituted, or removed or one or more amino acid residues may be inserted so as to enhance or decrease CDC activity of the anti-CD200 antibodies provided herein.

B) ANTI-CD200 ANTIBODIES WITH MODULATED EFFECTOR FUNCTION(S)

[0090] Effector functions involving the constant region of the target-specific antibody may be modulated by altering properties of the constant or Fc region. Altered effector functions include, for example, a modulation in one or more of the following activities: ADCC, CDC, apoptosis, binding to one or more Fc-receptors, and pro-inflammatory responses. Modulation refers to an increase, decrease, or elimination of an activity compared to the activity of a second antibody. The second antibody may be an antibody with effector function. The second antibody may be an engineered antibody or a naturally occurring antibody and may be referred to as a non-variant, native, or parent antibody. Modulation may include situations in which an activity is abolished or completely absent. Further, in some instances, a non-variant antibody may exhibit effector function activity similar or equivalent to the activity of the chC2aB7-hG1 or the hB7V3V2-hG1 antibodies disclosed herein. Likewise, a functional or non-variant constant or Fc region may possess an effector function of a native constant or Fc domain; in some instances, the constant or Fc region of chC2aB7-hG1 or hB7V3V2-hG1 may represent the non-variant domains. For present purposes, chC2aB7-hG1 and hB7V3V2-hG1 are the standards against which the activities of other antibodies are compared, with hB7V3V2-hG1 being the preferred standard.

[0091] A polypeptide variant with altered FcR binding affinity and/or ADCC activity and/or altered CDC activity is a polypeptide which has either enhanced or diminished FcR binding activity and/or ADCC activity and/or CDC activity compared to the native or parent polypeptide or to a polypeptide comprising a native sequence Fc or constant region. A polypeptide variant which displays increased binding to an FcR binds at least one FcR with greater affinity than the parent polypeptide. A polypeptide variant which displays decreased binding to an FcR binds at least one FcR with lower affinity than a parent polypeptide. Such variants which display decreased binding to an FcR may possess little or no appreciable binding to an FcR, e.g., 0-20% binding to the FcR compared to the level of binding of a native sequence immunoglobulin constant or Fc region to the FcR. Similarly a polypeptide variant which displays altered ADCC and/or CDC activity may exhibit either increased or reduced ADCC and/or CDC activity compared to the native or parent polypeptide. A polypeptide variant which displays reduced ADCC and/or CDC may exhibit reduced or no ADCC and/or CDC activity as shown herein by example. The parent or native polypeptide and its variant may be antibodies or antigen-binding fragments. The said antibody or antigen-binding fragment may bind CD200 and may or may not block the CD200:CD200R interaction.

[0092] A native sequence Fc or constant region comprises an amino acid sequence identical to the amino acid sequence of a Fc or constant chain region found in nature. A variant or altered Fc or constant region comprises an amino acid sequence which differs from that of a native sequence heavy chain region by virtue of at least one amino acid modification, insertion, or deletion, for example. The variant or altered constant region may have at least one amino acid substitution, insertion, and/or deletion, compared to a native sequence constant region or to the constant region of a parent polypeptide, e.g. from about one to about one hundred amino acid substitutions, insertions, and/or deletions in a native sequence constant region or in the constant region of the parent polypeptide.

[0093] There is described herein a variant or altered constant region possessing at least about 70% homology (similarity) or identity with a native sequence constant region and/or with a constant region of a parent polypeptide, and in some instances at least about 75% and in other instances at least about 80% homology or identity therewith, and in other instances at least about 85%, 90% or 95% homology or identity therewith. The variant or altered constant region may also contain one or more amino acid deletions or insertions. Additionally, the variant constant region may contain one or more amino acid substitutions, deletions, or insertions that results in altered post-translational modifications, including, for example, an altered glycosylation pattern.

[0094] Variant anti-CD200 antibodies as presently disclosed may be encoded by a nucleic acid sequence that encodes a polypeptide with one or more amino acid insertions, deletions, or substitutions relative to the native or parent polypeptide sequence. Furthermore, variant antibodies may be encoded by nucleic acid sequences that hybridize under stringent conditions to a nucleic acid sequence encoding a variant anti-CD200 antibody. A variety of conditions may be used to detect hybridization, and the stringency is determined primarily by the wash stage of the hybridization assay. Generally high temperatures and low salt concentrations give high stringency, while low temperatures and high salt concentrations give low stringency. Low stringency hybridization is achieved by washing in, for example, about 2.0 x SSC at 50 °C, and high stringency is achieved with about 0.2 x SSC at 50°C.

[0095] Antibodies or antigen-binding fragments thereof with altered or no effector functions may be generated by engineering or producing antibodies with variant constant, Fc, or heavy chain regions; recombinant DNA technology and/or cell culture and expression conditions may be used to produce antibodies with altered function and/or activity. For example, recombinant DNA technology may be used to engineer one or more amino acid substitutions, deletions, or insertions in regions (such as, for example, Fc or constant regions) that affect antibody function including effector functions. Alternatively, changes in post-translational modifications, such as, e.g. glycosylation patterns, may be achieved by manipulating the cell culture and expression conditions by which the antibody is produced.

[0096] There is described herein anti-CD200 antibodies with altered effector functions that comprise one or more amino acid substitutions, insertions, and/or deletions. Such a variant anti-CD200 antibody may exhibit reduced or no effector function. In particular embodiments, a variant antibody comprises a G2/G4 construct in place of the G1 domain (see Figures 10, 11, 12, 13, and 15, for example).

[0097] In addition to swapping the G1 domain with a G2/G4 construct as presented herein, anti-CD200 antibodies with reduced effector function may be produced by introducing other types of changes in the amino acid sequence of certain regions of the antibody. Such amino acid sequence changes include but are not limited to the Ala-Ala mutation described by Bluestone et al. (see WO 94/28027 and WO 98/47531; also see Xu et al. 2000 Cell Immunol 200; 16-26). Thus there is described anti-CD200 antibodies with mutations within the constant region including the Ala-Ala mutation which may be used to reduce or abolish effector function. The constant region of an anti-CD200 antibody may comprise a mutation to an alanine at position 234 or a mutation to an alanine at position 235. Additionally, the constant region may contain a double mutation: a mutation to an alanine at position 234 and a second mutation to an alanine at position 235. The anti-CD200 antibody may comprise an IgG4 framework, wherein the Ala-Ala mutation would describe a mutation(s) from phenylalanine to alanine at position 234 and/or a mutation from leucine to alanine at position 235. The anti-CD200 antibody may comprise an IgG1 framework, wherein the Ala-Ala mutation would describe a mutation(s) from leucine to alanine at position 234 and/or a mutation from leucine to alanine at position 235. An anti-CD200 antibody may alternatively or additionally carry other mutations, including the point mutation K322A in the CH2 domain (Hezareh et al. 2001 J Virol. 75: 12161-8). An antibody with said mutation(s) in the constant region may furthermore be a blocking or non-blocking antibody.

[0098] Changes within the hinge region also affect effector functions. For example, deletion of the hinge region may reduce affinity for Fc receptors and may reduce complement activation (Klein et al. 1981 PNAS USA 78: 524-528). The present disclosure therefore also relates to antibodies with alterations in the hinge region.

[0099] Anti-CD200 antibodies may be modified to either enhance or inhibit complement dependent cytotoxicity (CDC). Modulated CDC activity may be achieved by introducing one or more amino acid substitutions, insertions, or deletions in an Fc region of the antibody (see, e.g., U.S. Pat. No. 6,194,551). Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved or reduced internalization capability and/or increased or decreased complement-mediated cell killing. See Caron et al., J. Exp. Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992), WO99/51642, Duncan & Winter Nature 322: 738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO94/29351. Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).

[0100] Another potential means of modulating effector function of antibodies includes changes in glycosylation. This topic has been recently reviewed by Raju who summarized the proposed importance of the oligosaccharides found on human IgGs with their degree of effector function (Raju, TS. BioProcess International April 2003. 44-53). According to Wright and Morrison, the microheterogeneity of human IgG oligosaccharides can affect biological functions such as CDC and ADCC, binding to various Fc receptors, and binding to C1q protein (Wright A. & Morrison SL. TIBTECH 1997, 15 26-32). It is well documented that glycosylation patterns of antibodies can differ depending on the producing cell and the cell culture conditions (Raju, TS. BioProcess International April 2003. 44-53). Such differences can lead to changes in both effector function and pharmacokinetics (Israel et al. Immunology. 1996; 89(4):573-578; Newkirk et al. P. Clin. Exp. 1996; 106(2):259-64). Differences in effector function may be related to the IgGs ability to bind to the Fcγ receptors (FcγRs) on the effector cells. Shields, *et al.*, have shown that IgG, with variants in amino acid sequence that have improved binding to FcγR, can exhibit up to 100% enhanced ADCC using human effector cells (Shields et al. J Biol Chem. 2001 276(9):6591-604). While these variants include changes in amino acids not found at the binding interface, both the nature of the sugar component as well as its structural pattern may also contribute to the differences observed. In addition, the presence or absence of fucose in the oligosaccharide component of an IgG can improve binding and ADCC (Shields et al. J Biol Chem. 2002; 277(30):26733-40). An IgG that lacked a fucosylated carbohydrate linked to

Asn²⁹⁷ exhibited normal receptor binding to the Fcγ receptor. In contrast, binding to the FcγRIIA receptor was improved 50% and accompanied by enhanced ADCC, especially at lower antibody concentrations.

[0101] Work by Shinkawa, et al., demonstrated that an antibody to the human IL-5 receptor produced in a rat hybridoma showed more than 50% higher ADCC when compared to the antibody produced in Chinese hamster ovary cells (CHO) (Shinkawa et al. J Biol Chem. 2003 278(5):3466-73). Monosaccharide composition and oligosaccharide profiling showed that the rat hybridoma-produced IgG had a lower content of fucose than the CHO-produced protein. The authors concluded that the lack of fucosylation of an IgG1 has a critical role in enhancement of ADCC activity.

[0102] A different approach was taken by Umana, et al., who changed the glycosylation pattern of chCE7, a chimeric IgG1 anti-neuroblastoma antibody (Umana et al. Nat Biotechnol. 1999 Feb; 17(2): 176-80). Using tetracycline, they regulated the activity of a glycosyltransferase enzyme (GnII) which bisects oligosaccharides that have been implicated in ADCC activity. The ADCC activity of the parent antibody was barely above background level. Measurement of ADCC activity of the chCE7 produced at different tetracycline levels showed an optimal range of GnTII expression for maximal chCE7 in vitro ADCC activity. This activity correlated with the level of constant region-associated, bisected complex oligosaccharide. Newly optimized variants exhibited substantial ADCC activity. Similarly, Wright and Morrison produced antibodies in a CHO cell line deficient in glycosylation (1994 J Exp Med 180: 1087-1096) and showed that antibodies produced in this cell line were incapable of complement-mediated cytotoxicity. Thus as known alterations that affect effector function include modifications in the glycosylation pattern or a change in the number of glycosylated residues, the present disclosure relates to a CD200 antibody wherein glycosylation is altered to either enhance or decrease effector function(s) including ADCC and CDC. Altered glycosylation includes a decrease or increase in the number of glycosylated residues as well as a change in the pattern or location of glycosylated residues.

[0103] Still other approaches exist for the altering effector function of antibodies. For example, antibody-producing cells can be hypermutagenic, thereby generating antibodies with randomly altered nucleotide and polypeptide residues throughout an entire antibody molecule (see WO 2005/011735). Hypermutagenic host cells include cells deficient in DNA mismatch repair. Antibodies produced in this manner may be less antigenic and/or have beneficial pharmacokinetic properties. Additionally, such antibodies may be selected for properties such as enhanced or decreased effector function(s).

[0104] It is further understood that effector function may vary according to the binding affinity of the antibody. For example, antibodies with high affinity may be more efficient in activating the complement system compared to antibodies with relatively lower affinity (Marzocchi-Machado et al. 1999 Immunol Invest 28: 89-101). Accordingly, an antibody may be altered such that the binding affinity for its antigen is reduced (e.g., by changing the variable regions of the antibody by methods such as substitution, addition, or deletion of one or more amino acid residues). An anti-CD200 antibody with reduced binding affinity may exhibit reduced effector functions, including, for example, reduced ADCC and/or CDC.

III. METHODS OF DEPLETING OR ELIMINATING CELLS OVEREXPRESSING CD200

[0105] There is described herein methods for depleting cells that express CD200 in a subject by administering to the subject a therapy comprising a CD200 antagonist. As mentioned above, CD200 is expressed on certain immune cells; and as demonstrated in the present disclosure, CD200 is also expressed on certain malignant cells. The disparate expression of CD200 provides an avenue by which to target cancer cells (i.e., CD200-positive cells) for therapy. Likewise, CD200-positive immune cells may be targeted for depletion in methods of treating autoimmune disorders.

[0106] CD200, through its interaction with CD200R on myeloid cells, modulates immunosuppression by delivering an inhibitory signal for myeloid activity and/or migration. CD200-knockout mice, for example, demonstrate a more active immune response following immunogenic stimuli (Hoek et al. Science 2000), and CD200-expressing cells elicit immunosuppression by inducing a shift in the cytokine profile of stimulated immune cells (see data shown herein). Specifically, CD200-positive cells are capable of inducing a shift from Th1 to Th2 cytokine production in mixed cell population assays. While CD200-positive cells are capable of suppressing the immune response, CD200-positive cancer cells, accordingly, may be capable of escaping immune cell attack. However expression of CD200 on the membrane of cancer cells as well as immune cells can be exploited to target these cells in therapy. For example, an anti-CD200 antagonist can specifically target CD200-positive cells and disrupt the CD200:CD200R interaction, thereby inhibiting immune suppression, as well as target CD200-positive cells to immune effector cells. The embodiments of this disclosure, therefore, relate to methods of targeting CD200-positive cells for depletion comprising an antagonist that binds to CD200 and, in some instances, disrupts the CD200:CD200R interaction.

[0107] There is described herein methods of enhancing the immune response. Such methods include administering a therapy

comprising a CD200 antagonist, and in particular embodiments the antagonist is an anti-CD200 antibody or antigen-binding fragment as set forth herein. While not wishing to be bound by any particular mechanism(s), a blocking anti-CD200 antibody, antigen-binding fragment, polypeptide, or other antagonist may eliminate CD200-positive cells by blocking immune suppression, thereby allowing immune cells to attack and eliminate CD200-positive cells. Alternatively or in combination with the aforementioned mechanism, an anti-CD200 antibody (either blocking or non-blocking) or other antagonist may recruit effector cells or other ligands (e.g., complement component) to the CD200-positive cell to which the antibody or antagonist is bound and target the CD200-positive cell for effector-mediated cell death.

[0108] There is described herein methods of modulating ADCC and/or CDC of CD200-positive target cells by administering a murine, chimeric, humanized, or human anti-CD200 antibody to a subject in need thereof. The disclosure relates to variant anti-CD200 antibodies that elicit increased ADCC and/or CDC and to variant anti-CD200 antibodies that exhibit reduced or no ADCC and/or CDC activity.

[0109] The variant anti-CD200 antibody comprises a variant or altered Fc or constant region, wherein the variant Fc or constant region exhibits increased effector function. Such said variant region may contain one or more amino acid substitutions, insertions, or deletions. Alternatively or additionally, the variant or altered Fc or constant region may comprise altered post-translational modifications, including, for example, an altered glycosylation pattern. An altered glycosylation pattern includes an increase or decrease in the number of glycosidic bonds and/or a modification in the location (i.e., amino acid residue number) of one or more glycosidic bonds.

[0110] There is also described herein methods of depleting or eliminating CD200-positive cells comprising variant anti-CD200 antibodies that exhibit reduced or no ADCC and/or CDC activity. The variant anti-CD200 antibody may comprise a variant or altered Fc or constant region, wherein the variant Fc or constant region exhibits decreased or no effector function. Such said variant or altered Fc or constant region may contain one or more amino acid substitutions, insertions, or deletions. Alternatively or additionally, the variant Fc or constant region may comprise altered post-translational modifications, including but not limited to an altered glycosylation pattern. Examples of altered glycosylation patterns are described above.

[0111] A murine, chimeric, humanized, human or de-immunized anti-CD200 antibody may be administered to a patient is a non-blocking antibody. The non-blocking anti-CD200 antibody may be a variant antibody as described above and may consequently exhibit modulated effector function(s). For example, a variant anti-CD200 antibody may not block the CD200:CD200R interaction and may also comprise a variant constant region that elicits increased effector function, such as, e.g., increased ADCC.

A) METHODS OF TREATING PATIENTS WITH AUTOIMMUNE

DISORDERS

[0112] There is described herein treating patients with autoimmune disorders with a therapy comprising a CD200 antagonist. The antagonist may be an anti-CD200 antibody or antigen-binding fragment thereof. The anti-CD200 antibody or fragment thereof may be a variant anti-CD200 antibody that exhibits modulated effector activity. For example, the variant antibody may comprise a variant or altered constant region capable of eliciting increased or enhanced effector function, such as, for example, ADCC. Additionally, the said antibody may be a non-blocking antibody and may be a murine, chimeric, humanized, human or de-immunized anti-CD200 antibody. Thus, methods of treating patients with autoimmune disorders may comprise any of the CD200 antagonists and antibodies as set forth in the present disclosure.

[0113] Anti-CD200 antibodies or CD200 antagonists may be used for depleting any type of cell that expresses CD200 on its surface, including for example, immune cells such as T-cells, B-cells, and dendritic cells. Anti-CD200 antibodies may be useful for targeted destruction of immune cells involved in an unwanted immune response, such as, for example, immune responses associated with an autoimmune disorder, transplants, allergies, or inflammatory disorders. Exemplary autoimmune diseases and disorders that may be treated with the anti-CD200 antibodies provided herein include, for example, inflammatory responses such as inflammatory skin diseases including psoriasis and dermatitis (e. g. atopic dermatitis); dermatomyositis; systemic sclerosis and sclerosis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); respiratory distress syndrome (including adult respiratory distress syndrome; ARDS); dermatitis; meningitis; encephalitis; uveitis; colitis; glomerulonephritis; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus (e. g. Type I diabetes mellitus or insulin dependent diabetes mellitus); multiple sclerosis; Reynaud's

syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjogren's syndrome; juvenile onset diabetes; and immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia (including, but not limited to cryoglobulinemia or Coombs positive anemia); myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Bechet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia and autoimmune hemolytic diseases, Hashimoto's thyroiditis, etc.

[0114] In accordance with the methods and compositions described herein, the disclosure also relates to methods of treating a transplant or allograft patient. An anti-CD200 antibody or other CD200 antagonist of the present disclosure may be administered to a patient prior to a transplant or allograft procedure or after the procedure in order to decrease or eliminate CD200-positive immune cells that could reduce the patient's acceptance of the transplanted organ or tissue. An anti-CD200 antibody with increased effector function may be given to a transplant patient. In addition, an anti-CD200 antibody is a non-blocking antibody.

[0115] Therapies comprising CD200 antagonists or antibodies may be administered to patients in combination therapies. Accordingly, targeted killing of certain populations of immune cells for treating or preventing autoimmune disorders, enhancing or extending transplant survival, treating or preventing allergies, or treating or preventing inflammatory disorders, may be administered as part of a combination therapy. For example, a patient receiving a first therapy comprising a CD200 antagonist (e.g., an anti-CD200 antibody described herein) may also be given a second therapy. The CD200 antagonist may be given simultaneously with the second therapy. Alternatively, the CD200 antagonist may be given prior to or following the second therapy. Second therapies include but are not limited to antiinflammatory agents, immunosuppressive agents, and/or anti-infective agents.

[0116] Combination therapies of the present disclosure include, for example, a CD200 antagonist as described herein administered concurrently or sequentially in series with steroids, anti-malarials, aspirin, non-steroidal anti-inflammatory drugs, immunosuppressants, or cytotoxic drugs. Included are corticosteroids (e.g. prednisone, dexamethasone, and prednisolone), methotrexatem, methylprednisolone, macrolide immunosuppressants (e.g. sirolimus and tacrolimus), mitotic inhibitors (e.g. azathioprine, cyclophosphamide, and methotrexate), fungal metabolites that inhibit the activity of T lymphocytes (e.g. cyclosporine), mycophenolate mofetil, glatiramer acetate, and cytotoxic and DNA-damaging agents (e.g. chlorambucil). For autoimmune disorders and allograft or transplant patients, anti-CD200 therapy may be combined with antibody treatments including daclizumab, a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α -chain of the interleukin-2 receptor, as well as various other antibodies targeting immune cells or other cells. Such combination therapies may be useful in the treatment of type 1 diabetes, rheumatoid arthritis, lupus, and idiopathic thrombocytopenic purpura, and other autoimmune indications. The disclosure also relates to therapies for autoimmune disorders and for transplant patients comprising a CD200 antagonist (such as, for example, the antibodies and variants thereof described in the present disclosure) conjugated to one or more agent.

B) METHODS OF TREATING PATIENTS WITH CANCER

[0117] There is described herein a method of treating cancer in which an agent that disrupts or inhibits the interaction of CD200 with its receptor is administered to a subject. Disruption of the CD200:CD200R interaction subsequently reverses or inhibits immune suppression, thus enhancing the immune response. Possible agents for the disruption of the CD200:CD200R interaction include, for example, small molecules, chemicals, polypeptides, inorganic molecules, and organometallic compounds. The CD200:CD200R interaction may also be inhibited by reducing the expression of either the membrane protein or its receptor via antisense, RNAi, or gene therapy. Additionally, a polypeptide specific for CD200 or CD200R, such as an anti-CD200- or anti-CD200R-specific antibody or fragments thereof, may inhibit the immunosuppressive effects of the CD200:CD200R interaction.

[0118] Cancer cells that may be treated by a CD200 antagonist include any cancer cells that exhibit CD200 expression or CD200 up-regulation. Cancers for which anti-CD200 therapy may be used include, for example, ovarian, melanoma, myeloma, neuroblastoma, renal, breast, prostate, hematological malignancies (e.g., lymphomas and leukemias), and plasma cell cancer. Also included are any cancer cells derived from neural crest cells. The CD200 antagonist of the invention is an anti-CD200 antibody. Such antibodies used as anti-cancer therapeutics are capable of interfering with the interaction of CD200 and its receptors. This interference can block the immune-suppressing effect of CD200. By improving the immune response in this

manner, such antibodies can promote the eradication of cancer cells. Anti-CD200 antibodies may also target cancer cells for effector-mediated cell death.

[0119] A variant anti-CD200 antibody that exhibits modulated ADCC and/or CDC activity may be administered to a subject with CD200-positive cancer cells. For example, a variant anti-CD200 antibody used in cancer therapy may exhibit enhanced effector activity compared to the parent or native antibody. According to the present invention, the variant anti-CD200 antibody exhibits reduced effector function, including reduced ADCC, relative to the native antibody. The said antibody may be a murine, chimeric, humanized, human or de-immunized antibody. Cancers for which the variant anti-CD200 antibody may be used in treatment include but are not limited to neural crest cell cancers. Also included are plasma cell cancer, ovarian cancer, skin cancer, lung cancer, renal cancer, breast cancer, prostate cancer, neuroblastoma, lymphoma, myeloma, and leukemia.

[0120] The present antibodies can be administered as a therapeutic to cancer patients, especially, but not limited to, patients with CLL, plasma cell cancer, ovarian cancer, skin cancer, lung cancer, renal cancer, breast cancer, prostate cancer, neuroblastoma, lymphoma, myeloma, leukemia, and any cancer derived from neural crest cells. There is described herein a cancer therapy in accordance with this disclosure comprising (1) administering an anti-CD200 antibody or antagonist that interferes with the interaction between CD200 and its receptor to block immune suppression, thereby promoting eradication of the cancer cells; and/or (2) administering a fusion molecule that includes a CD-200 targeting portion to directly kill cancer cells. Alternatively, the antibody directly kills the cancer cells through complement-mediated or antibody-dependent cellular cytotoxicity. Since CD200 is also expressed on normal cells such as endothelial cells, albeit at lower levels than on cancer cells, it could also be advantageous to administer an anti-CD200 antibody with a constant region modified to reduce or eliminate ADCC or CDC to limit damage to normal cells. For example, if CD200 expression is upregulated on some activated normal cells (e.g., activated T cells), rendering such cells vulnerable to killing by an anti-CD200 antibody with effector function, it may therefore also be advantageous to use an anti-CD200 antibody lacking effector function to avoid depletion of these cells which aid in destroying cancer cells.

[0121] In a particular embodiment, effector function of anti-CD200 antibodies is eliminated by swapping the IgG1 constant domain for an IgG2/4 fusion domain. Other ways of eliminating effector function can be envisioned such as, e.g., mutation of the sites known to interact with FcR or insertion of a peptide in the hinge region, thereby eliminating critical sites required for FcR interaction. Variant anti-CD200 antibodies with reduced or no effector function also include variants as described previously herein.

[0122] The aforementioned agents for the inhibition or prevention of the CD200:CD200R interaction may be used in combination with other therapies or with other agents. Other agents include but are not limited to polypeptides, small molecules, chemicals, metals, organometallic compounds, inorganic compounds, nucleic acid molecules, oligonucleotides, aptamers, spiegelmers, antisense nucleic acids, locked nucleic acid (LNA) inhibitors, peptide nucleic acid (PNA) inhibitors, immunomodulatory agents, antigen-binding fragments, prodrugs, and peptidomimetic compounds.

[0123] There is also described herein combination treatments comprising a CD200 antagonist including the antibodies described herein and immunomodulatory compounds, vaccines or chemotherapy. Illustrative examples of suitable immunomodulatory agents that may be used in such combination therapies include agents that block negative regulation of T cells or antigen presenting cells (e.g., anti-CTLA4 antibodies, anti-PD-L1 antibodies, anti-PDL-2 antibodies, anti-PD-1 antibodies and the like) or agents that enhance positive co-stimulation of T cells (e.g., anti-CD40 antibodies or anti 4-1BB antibodies) or agents that increase NK cell number or T-cell activity (e.g., anti-CD200 antibodies alone or in combination with inhibitors such as IMiDs, thalidomide, or thalidomide analogs). Furthermore, immunomodulatory therapy could include cancer vaccines such as dendritic cells loaded with tumor cells, proteins, peptides, RNA, or DNA derived from such cells, patient derived heat-shocked proteins (hsp's) or general adjuvants stimulating the immune system at various levels such as CpG, Luivac, Biostim, Ribomynil, Imudon, Bronchovaxom or any other compound or other adjuvant activating receptors of the innate immune system (e.g., toll like receptor agonist, anti-CTLA-4 antibodies, etc.). Also, immunomodulatory therapy could include treatment with cytokines such as IL-2, GM-CSF and IFN-gamma.

[0124] Elimination of existing regulatory T cells with reagents such as anti-CD25, fludarabine, or cyclophosphamide may be achieved before starting anti-CD200 treatment. Also, therapeutic efficacy of myeloablative therapies followed by bone marrow transplantation or adoptive transfer of T cells reactive with CLL cells is enhanced by anti-CD200 therapy. Efficacy of anti-CD200 treatment may be improved by blocking immunosuppressive mechanisms with agents such as anti-PDL1 and/or 2 antibodies, anti-IL-10 antibodies, anti-IL-6 antibodies, and the like. Furthermore, it could be advantageous to eliminate plasmacytoid dendritic cells, shown to be immunosuppressive in the cancer environment. In these disclosures in which delivery of an anti-CD200 antibody is intended to augment an immune response by blocking immune suppression, for example, a variant anti-CD200 antibody lacking effector function may also be used.

[0125] The therapy that enhances immune response may be the administration of a polypeptide that binds to CD200, alone or in combination with one of the previously mentioned immunomodulatory therapies. Accordingly, a CD200 antagonist (including an anti-CD200 antibody as described herein) may be used in combination with a monoclonal antibody (e.g., rituximab, trastuzumab, alemtuzumab, cetuximab, or bevacizumab), including a conjugated monoclonal antibody (e.g., gemtuzumab ozogamicin, ibritumomab tiuxetan, or tositumomab).

[0126] Furthermore, combination of anti-CD200 therapy with chemotherapeutics could be particularly useful to reduce overall tumor burden, to limit angiogenesis, to enhance tumor accessibility, to enhance susceptibility to ADCC, to result in increased immune function by providing more tumor antigen, or to increase the expression of the T cell attractant LIGHT. When anti-CD200 therapy is administered to a subject in combination with another conventional anti-neoplastic agent, either concomitantly or sequentially, anti-CD200 therapy may be shown to enhance the therapeutic effect of either agent alone. Pharmaceutical compounds that may be used for combinatory anti-tumor therapy include, merely to illustrate: aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

[0127] These chemotherapeutic anti-tumor compounds may be categorized by their mechanism of action into groups, including, for example, the following classes of agents: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristine, vinblastine, nocodazole, epothilones and navelbine, epididodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxin, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, mechlorethamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide, triethylenethiophosphoramide and etoposide (VP16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes - dacarbazine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); immunomodulatory agents (thalidomide and analogs thereof such as lenalidomide (Revlimid, CC-5013) and CC-4047 (Actimid)), cyclophosphamide; anti-angiogenic compounds (TNP-470, genistein) and growth factor inhibitors (vascular endothelial growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers and caspase activators; and chromatin disruptors.

[0128] Pharmaceutical compounds that may be used for combinatory anti-angiogenesis therapy include: (1) inhibitors of release of "angiogenic molecules," such as bFGF (basic fibroblast growth factor); (2) neutralizers of angiogenic molecules, such as anti- β FGF antibodies; and (3) inhibitors of endothelial cell response to angiogenic stimuli, including collagenase inhibitor, basement membrane turnover inhibitors, angiostatic steroids, fungal-derived angiogenesis inhibitors, platelet factor 4, thrombospondin,

arthritis drugs such as D-penicillamine and gold thiomalate, vitamin D₃ analogs, alpha-interferon, and the like. For additional proposed inhibitors of angiogenesis, see Blood et al., *Biochim. Biophys. Acta*, 1032:89-118 (1990), Moses et al., *Science*, 248:1408-1410 (1990), Ingber et al., *Lab. Invest.*, 59:44-51 (1988), and U.S. Pat. Nos. 5,092,885, 5,112,946, 5,192,744, 5,202,352, and 6,573,256. In addition, there are a wide variety of compounds that can be used to inhibit angiogenesis, for example, peptides or agents that block the VEGF-mediated angiogenesis pathway, endostatin protein or derivatives, lysine binding fragments of angiostatin, melanin or melanin-promoting compounds, plasminogen fragments (e.g., Kringles 1-3 of plasminogen), troponin subunits, antagonists of vitronectin $\alpha_v\beta_3$, peptides derived from Saposin B, antibiotics or analogs (e.g., tetracycline, or neomycin), dienogest-containing compositions, compounds comprising a MetAP-2 inhibitory core coupled to a peptide, the compound EM-138, chalcone and its analogs, and naaladase inhibitors. See, for example, U.S. Pat. Nos. 6,395,718, 6,462,075, 6,465,431, 6,475,784, 6,482,802, 6,482,810, 6,500,431, 6,500,924, 6,518,298, 6,521,439, 6,525,019, 6,538,103, 6,544,758, 6,544,947, 6,548,477, 6,559,126, and 6,569,845.

[0129] Depending on the nature of the combinatory therapy, administration of the anti-CD200 antibody may be continued while the other therapy is being administered and/or thereafter. Administration of the antibody may be made in a single dose, or in multiple doses. In some instances, administration of the anti-CD200 antibody is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy. In some cases, the anti-CD200 antibody will be administered after other therapies, or it could be administered alternating with other therapies.

[0130] The present antibodies can be utilized to directly kill or ablate cancerous cells *in vivo*. Direct killing involves administering the antibodies (which are optionally fused to a cytotoxic drug) to a subject requiring such treatment. Since the antibodies recognize CD200 on cancer cells, any such cells to which the antibodies bind are destroyed. Where the antibodies are used alone to kill or ablate cancer cells, such killing or ablation can be effected by initiating endogenous host immune functions, such as CDC and/or ADCC. Assays for determining whether an antibody kills cells in this manner are within the purview of those skilled in the art.

[0131] The antibodies of the present disclosure may be used to deliver a variety of cytotoxic compounds. Any cytotoxic compound can be fused to the present antibodies. The fusion can be achieved chemically or genetically (e.g., via expression as a single, fused molecule). The cytotoxic compound can be a biological, such as a polypeptide, or a small molecule. As those skilled in the art will appreciate, for small molecules, chemical fusion is used, while for biological compounds, either chemical or genetic fusion can be employed.

[0132] Non-limiting examples of cytotoxic compounds include therapeutic drugs, a compound emitting radiation, molecules of plants, fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as short-range radiation emitters, including, for example, short-range, high-energy α -emitters. Enzymatically active toxins and fragments thereof are exemplified by diphtheria toxin A fragment, nonbinding active fragments of diphtheria toxin, exotoxin A (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sacrin, certain *Aleurites fordii* proteins, certain *Dianthin* proteins, *Phytolacca americana* proteins (PAP, PAPII and PAP-S), *Morodica charantia* inhibitor, curcun, crocin, *Saponaria officinalis* inhibitor, gelonin, mitogillin, restrictocin, phenomycin, and enomycin, for example. Procedures for preparing enzymatically active polypeptides of the immunotoxins are described in WO84/03508 and WO85/03508. Certain cytotoxic moieties are derived from adriamycin, chlorambucil, daunomycin, methotrexate, neocarzinostatin, and platinum, for example.

[0133] Procedures for conjugating the antibodies with the cytotoxic agents have been previously described and are within the purview of one skilled in the art.

[0134] Alternatively, the antibody can be coupled to high energy radiation emitters, for example, a radioisotope, such as ¹³¹I, a γ -emitter, which, when localized at the tumor site, results in a killing of several cell diameters. See, e.g., S. E. Order, "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", *Monoclonal Antibodies for Cancer Detection and Therapy*, R. W. Baldwin et al. (eds.), pp 303-316 (Academic Press 1985). Other suitable radioisotopes include α -emitters, such as ²¹²Bi, ²¹³Bi, and ²¹¹At, and β -emitters, such as ¹⁸⁶Re and ⁹⁰Y.

[0135] Present CD200 binding antibodies may provide the benefit of blocking immune suppression in CLL by targeting the leukemic cells directly through CD200. Specifically, stimulating the immune system can allow the eradication of CLL cells from the spleen and lymph nodes. Applicants are unaware of any successful eradication of CLL cells from these microenvironments having been achieved with agents that simply target B cells (such as alemtuzumab). In contrast, CLL reactive T cells can have better access to these organs than antibodies. In other embodiments, direct cell killing is achieved by tagging the CLL cells with anti-

CD200 Abs.

[0136] According to the compositions and methods of the present disclosure, the combination of direct cell killing and driving the immune response towards a Th1 profile provides a particularly powerful approach to cancer treatment. Thus, there is described herein a cancer treatment wherein an antibody or antibody fragment, which binds to CD200 and both a) blocks the interaction between CD200 and its receptor and b) directly kills the cancer cells expressing CD200, is administered to a cancer patient. The mechanism by which the cancer cells are killed can include, but are not limited to ADCC and/or CDC; fusion with a toxin; fusion with a radiolabel; fusion with a biological agent involved in cell killing, such as granzyme B or perforin; fusion with a cytotoxic virus; fusion with a cytokine such as TNF- α or IFN- α . A cancer treatment may also involve administering an antibody that both a) blocks the interaction between CD200 and its receptor and b) enhances cytotoxic T cell or NK cell activity against the tumor. Such enhancement of the cytotoxic T cell or NK cell activity may, for example, be combined by fusing the antibody with cytokines such as e.g. IL-2, IL-12, IL-18, IL-13, and IL-5. In addition, such enhancement may be achieved by administration of an anti-CD200 antibody in combination with inhibitors such as IMiDs, thalidomide, or thalidomide analogs.

[0137] The cancer treatment may involve administering an antibody that both (1) blocks the interaction between CD200 and its receptor and (2) attracts T cells to the tumor cells. T cell attraction can be achieved by fusing the Ab with chemokines such as MIG, IP-10, I-TAC, CCL21, CCL5 or LIGHT. Also, treatment with chemotherapeutics can result in the desired upregulation of LIGHT. The combined action of blocking immune suppression and killing directly through antibody targeting of the tumor cells is a unique approach that provides increased efficacy.

[0138] Anti-CD200 antibodies in accordance with the present disclosure can also be used as a diagnostic tool. Biopsies or cancer cell tissue samples may be tested for CD200 expression prior to treatment in order to predict the efficacy of anti-CD200 therapy, alone or in combination with other agents or methods (such as chemotherapeutic agents, radiation therapy, immunomodulatory therapy, etc.). For example, using blood obtained from patients with hematopoietic cancers, expression of CD200 can be evaluated on cancer cells by FACS analysis using anti-CD200 antibodies in combination with the appropriate cancer cell markers such as, e.g., CD38 and CD19 on CLL cells. Patients with CD200 levels at least 1.4-fold above the levels found on normal B cells can be selected for treatment with anti-CD200 antibodies. As another example, tissue samples from a patient may be stained with anti-CD200 antibody to determine the expression of CD200 in the patient's malignant and normal cells.

[0139] In another example of using the present anti-CD200 antibodies as a diagnostic or prognostic tool, biopsies from patients with malignancies are obtained and expression of CD200 is determined by FACS analysis using anti-CD200 antibodies or by immunohistochemistry using anti-CD200. If tumor cells express CD200 at levels that are at least 1.4-fold higher compared to corresponding normal tissue, cancer patients are selected for immunomodulatory therapy (including but not limited to a therapy comprising anti-CD200 therapy). For cancer derived from cells that normally do not express CD200, any detectable CD200 on cancer biopsies indicates potential usefulness of anti-CD200 therapy. Immunomodulatory therapy can be anti-CD200 therapy, but can also be any other therapy affecting the patient's immune system. Examples of suitable immunomodulatory therapies include the administration of agents that block negative regulation of T cells or antigen presenting cells (e.g., anti-CTLA4, anti-PD-L1, anti-PD-L2, anti-PD-1) or the administration of agents that enhance positive co-stimulation of T cells (e.g., anti-CD40 or anti 4-1BB). Furthermore, immunomodulatory therapy could be cancer vaccines such as heteroclitic peptides or tumor cell peptides that generate cytotoxic T cells or dendritic cells loaded with tumor cells, or the administration of agents that increase NK cell number or T-cell activity (e.g., anti-CD200 antibodies alone or in combination with inhibitors such as IMiDs, thalidomide, or thalidomide analogs), or the administration of agents that deplete regulatory T cells (e.g. anti-CD200 antibodies alone or in combination with ONTAK), or plasmacytoid dendritic cells. Combination with agents increasing T cell or dendritic cell migration is also advantageous, such as e.g. any agent blocking SPARC. Furthermore, immunomodulatory therapy could be cancer vaccines such as dendritic cells loaded with tumor cells, patient derived exosomes tumor RNA or tumor DNA, tumor protein or tumor peptides, patient derived heat-shocked proteins (hsp's), hsp's loaded with tumor antigens or general adjuvants stimulating the immune system at various levels such as CpG, Luivac, Biostim, Ribominy, Imudon, Bronchovaxom or any other compound activating receptors of the innate immune system (e.g., toll like receptors). Also, therapy could include treatment with cytokines such as IL-2, GM-CSF and IFN-gamma. Combination with agents restoring compromised activity of dendritic cells in the tumor environment such as e.g. MAP kinase inhibitors are also contemplated.

[0140] The antibodies described herein may also be utilized to detect cancerous cells in vivo. Detection in vivo is achieved by labeling the antibody, administering the labeled antibody to a subject, and then imaging the subject. Examples of labels useful for diagnostic imaging in accordance with the present disclosure are radiolabels such as ^{131}I , ^{111}In , ^{123}I , $^{99\text{m}}\text{Tc}$, ^{32}P , ^{125}I , ^3H , ^{14}C , and ^{188}Rh , fluorescent labels such as fluorescein and rhodamine, nuclear magnetic resonance active labels, positron emitting

isotopes detectable by a positron emission tomography ("PET") scanner, chemiluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short-range radiation emitters, such as isotopes detectable by short-range detector probes, such as a transrectal probe, can also be employed. The antibody can be labeled with such reagents using techniques known in the art. For example, see Wensel and Meares, *Radioimmunoimaging and Radioimmunotherapy*, Elsevier, N.Y. (1983) for techniques relating to the radiolabeling of antibodies. See also, D. Colcher et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice", *Meth. Enzymol.* 121: 802-816 (1986).

[0141] A radiolabeled antibody in accordance with this disclosure can be used for in vitro diagnostic tests. The specific activity of an antibody, binding portion thereof, probe, or ligand, depends upon the half-life, the isotopic purity of the radioactive label, and how the label is incorporated into the biological agent. In immunoassay tests, the higher the specific activity, in general, the better the sensitivity. Procedures for labeling antibodies with the radioactive isotopes are generally known in the art.

[0142] The radiolabeled antibody can be administered to a patient where it is localized to cancer cells bearing the antigen with which the antibody reacts, and is detected or "imaged" in vivo using known techniques such as radionuclear scanning using e.g., a gamma camera or emission tomography. See e.g., A. R. Bradwell et al., "Developments in Antibody Imaging", *Monoclonal Antibodies for Cancer Detection and Therapy*, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985). Alternatively, a positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can be used where the radiolabel emits positrons (e.g., ^{11}C , ^{18}F , ^{15}O , and ^{13}N).

[0143] Fluorophore and chromophore labeled biological agents can be prepared from standard moieties known in the art. Since antibodies and other proteins absorb light having wavelengths up to about 310 nm, the fluorescent moieties should be selected to have substantial absorption at wavelengths above 310 nm and preferably above 400 nm. A variety of suitable fluorescers and chromophores are described by Stryer, *Science*, 162:526 (1968) and Brand, L. et al., *Annual Review of Biochemistry*, 41:843-868 (1972). The antibodies can be labeled with fluorescent chromophore groups by conventional procedures such as those disclosed in U.S. Patent Nos. 3,940,475, 4,289,747, and 4,376,110.

[0144] Methods are also described herein for monitoring the progress and/or effectiveness of a therapeutic treatment. The method involves administering an immunomodulatory therapy and determining CD200 levels in a subject at least twice to determine the effectiveness of the therapy. For example, pre-treatment levels of CD200 can be ascertained and, after at least one administration of the therapy, levels of CD200 can again be determined. A decrease in CD200 levels is indicative of an effective treatment. Measurement of CD200 levels can be used by the practitioner as a guide for increasing dosage amount or frequency of the therapy. It should of course be understood that CD200 levels can be directly monitored or, alternatively, any marker that correlates with CD200 can be monitored. Other methods to determine the effectiveness of this therapy include but are not limited to detection of cancer cells, total lymphocyte count, lymph node size, number of regulatory T cells, cytokine profiles in the serum or intracellular, or secretion of cytokines by T or B cells as measured by ELISPOT.

C. OTHER CD200 ANTAGONISTS

[0145] The CD200 antagonists and polypeptides and/or antibodies utilized in the present disclosure are especially indicated for diagnostic and therapeutic applications as described herein. Accordingly CD200 antagonists and anti-CD200 antibodies and variants thereof may be used in therapies, including combination therapies, in the diagnosis and prognosis of disease, as well as in the monitoring of disease progression.

[0146] Bispecific antibodies are also described. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the CD200 antigen on a cell (such as, e.g., a cancer cell or immune cell), the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

[0147] Methods for making bispecific antibodies are within the purview of those skilled in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, including at least part of the hinge, CH2, and CH3 regions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of illustrative currently

known methods for generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986); WO 96/27011; Brennan et al., *Science* 229:81 (1985); Shalaby et al., *J. Exp. Med.* 175:217-225 (1992); Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992); Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993); and Gruber et al., *J. Immunol.* 152:5368 (1994); and Tutt et al., *J. Immunol.* 147:60 (1991). Bispecific antibodies also include cross-linked or heteroconjugate antibodies. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

[0148] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins may be linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers may be reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. See Gruber et al., *J. Immunol.*, 152:5368 (1994). Alternatively, the antibodies can be "linear antibodies" as described in Zapata et al. *Protein Eng.* 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V_H -C_H1- V_H -C_H1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

D. MODES OF ADMINISTRATION AND FORMULATIONS

[0149] The route of antibody administration of the antibodies of the present disclosure (whether the pure antibody, a labeled antibody, an antibody fused to a toxin, etc.) is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, subcutaneous, intraocular, intraarterial, intrathecal, inhalation or intralesional routes, or by sustained release systems. The antibody is preferably administered continuously by infusion or by bolus injection. One may administer the antibodies in a local or systemic manner.

[0150] The present antibodies may be prepared in a mixture with a pharmaceutically acceptable carrier. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. This therapeutic composition can be administered intravenously or through the nose or lung, preferably as a liquid or powder aerosol (lyophilized). The composition may also be administered parenterally or subcutaneously as desired. When administered systemically, the therapeutic composition should be sterile, substantially pyrogen-free and in a parenterally acceptable solution having due regard for pH, isotonicity, and stability. For example, a pharmaceutical preparation is substantially free of pyrogenic materials so as to be suitable for administration as a human therapeutic. These conditions are known to those skilled in the art.

[0151] Pharmaceutical compositions suitable for use include compositions wherein one or more of the present antibodies are contained in an amount effective to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount of antibody effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. Therapeutically effective dosages may be determined by using in vitro and in vivo methods.

[0152] While the above disclosure has been directed to antibodies, in some embodiments polypeptides derived from such antibodies can be utilized in accordance with the present disclosure.

EXEMPLIFICATION

MOUSE MODEL AND CD200+ CELL CONSTRUCTION

Raji/PBL Model

[0153] NOD.CB17-Prkdc^{scid} mice (Jackson Laboratory) were injected with 200µl RPMI containing 4x10⁶ RAJI cells (ATCC) s.c. along with 0, 1, 5 or 10 million PBLs. Nine or ten mice were included per group. PBLs were isolated from 250 ml whole blood on a histopaque gradient followed by red blood cell lysis using 0.9% ammonium chloride. Tumor growth was monitored three times a week by measuring length and width with a caliper. Tumor volume was calculated based on length x width x width/2.

[0154] Differences between the groups that were injected with PBLs compared to the group that received tumor cells only were analyzed by 2-tailed unpaired Student's t-test. Significant differences were observed in the groups that received 5 or 10 million PBLs, but not in the group that received 1 million PBLs from Day 32 on.

Namalwa PBL model

[0155] NOD.CB17-Prkdc^{scid} mice (Jackson Laboratory, Bar Harbor, Maine) were injected with 200µl RPMI containing 4x10⁶ Namalwa cells (ATCC) s.c. along with 0, 2 or 10 million PBLs. 9-10 mice were included per group. PBLs were isolated from 250 ml whole blood on a histopaque gradient followed by red blood cell lysis using 0.9% ammonium chloride. Tumor growth was monitored three times a week by measuring length and width with a caliper. Tumor volume was calculated based on length x width x width/2.

Creation of stable CD200-expressing cell lines

[0156] Stable CD200-expressing Raji and Namalwa cell lines were generated using the Virapower Lentiviral Expression System (Invitrogen, Carlsbad, CA). A CD200 cDNA was isolated from primary CLL cells by RT-PCR using forward primer 5'-GACAAGCTTGCAAGGATGGAGAGGCTGGTGA-3' (SEQ ID NO: 34) and reverse primer 5'-GACGGATCCGCCCTTTTCTCCTGCTTTTCTC-3' (SEQ ID NO: 35). The PCR product was cloned into the Gateway entry vector pCR8/GW/TOPO-TA and individual clones were sequenced. Clones with the correct sequence were recombined in both the sense and antisense orientations into the lentiviral vectors pLenti6/V5/DEST and pLenti6/UbC/V5/DEST using Gateway technology (Invitrogen, Carlsbad, CA). The primary difference between these two vectors is the promoter used to drive CD200 expression: pLenti6/V5/DEST contains the human CMV immediate early promoter, whereas pLenti6/UbC/V5/DEST contains the human ubiquitin C promoter.

[0157] High-titer, VSV-G pseudotyped lentiviral stocks were produced by transient cotransfection of 293-FT cells as recommended by the manufacturer. Raji or Namalwa cells were transduced by resuspending 10⁶ cells in 1ml of growth medium containing 12 µg/ml Polybrene and adding 1ml of lentiviral stock. After incubating the cells overnight at 37°C, the medium containing virus was removed and replaced with 4ml of fresh medium. Two days later, the infected cells were analyzed for CD200 expression by flow cytometry. In all experiments, ≥70% of the cells were CD200⁺, whereas CD200 was undetectable in the parental cell lines and in cells transduced with the negative control (antisense CD200) viruses.

[0158] To isolate clonal cell lines that overexpress CD200, the infected cells were selected with blasticidin for 13 days. The concentrations of blasticidin used were 6 µg/ml for Raji cells or 2 µg/ml for Namalwa cells. Stable clones were then isolated by limiting dilution of the blasticidin-resistant cells into 96-well plates. Clones were screened in 96-well format by flow cytometry using PE-conjugated Mouse Anti-Human CD200 (clone MRC OX104, Serotec) and a BD FACSCalibur equipped with a High Throughput Sampler. After screening a total of 2000 Raji and 2000 Namalwa clones, those clones with the highest CD200 expression were expanded for further characterization using conventional techniques.

EXAMPLE 1**Efficacy of humanized versions of C2aB7 in the RAJI_CD200/PBL model**

[0159] A) To evaluate whether humanized versions of C2aB7 retain their efficacy in *in vivo* tumor models, chimeric C2aB7 (see

U.S. patent application publication number 2005/0129690) and 3 humanized versions (C2aB7V4V1, C2aB7V3V1 and C2aB7V3V2) as well as the negative control antibody alxn4100 were tested in the RAJI-CD200/PBL model. RAJI cells transduced with CD200 were injected s.c. into NOD.CB17-Prkdc^{scid} mice, and the ability of PBLs to reduce tumor growth in the presence or absence of chimeric or humanized C2aB7 antibodies or control antibody alxn4100 (which does not bind tumor cells) was assessed. Antibodies at concentrations indicated below were administered initially with the tumor cells, and then twice/week i.v. The following groups were set up with 10 mice each:

Group 1: 4×10^6 RAJI_CD200 s.c.

Group 2: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL

Group 3: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +5 mg/kg C2aB7

Group 4: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +20 mg/kg C2aB7V4V1

Group 5: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +5 mg/kg C2aB7V4V1

Group 6: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +20 mg/kg C2aB7V3V1

Group 7: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +5 mg/kg C2aB7V3V1

Group 8: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +5 mg/kg C2aB7V3V2

Group 9: 4×10^6 RAJI_CD200 s.c. + 6×10^6 PBL +20 mg/kg alxn4100

[0160] Tumor length and width were measured 3 times a week, and the tumor volume was calculated by tumor length*width*width/2. Figure 18 shows that, as expected, CD200 expression on the tumor cells prevented the immune cells from reducing tumor growth. All humanized versions of C2aB7 blocked tumor growth by up to 97% at doses of 20 mg/kg. The control antibody alxn4100 did not affect tumor growth. These data demonstrate that all the humanized antibodies are highly efficacious in blocking tumor growth.

B) Immune evasion by CD200

[0161] Although the human immune system is capable of raising an immune response against many cancer types, that response is insufficient to eradicate the cancer in most patients, possibly due to immune evasion through negative regulation of the immune system by the tumor. We identified the immune-suppressive molecule CD200 to be upregulated 1.5-5.4-fold on chronic lymphocytic leukemia (CLL) cells in all patients examined (n=80). Interaction of CD200 with its receptor is known to alter cytokine profiles from Th1 to Th2 in mixed lymphocyte reactions, and to result in the induction of regulatory T cells, which are thought to hamper tumor-specific effector T cell immunity. In the present study we addressed whether CD200 expression on tumor cells plays a role in immune evasion, thereby preventing elimination of tumor cells by the immune system in a xenograft hu/SCID mouse model, and whether treatment with an antagonistic anti-CD200 antibody affects tumor growth in this model.

[0162] The human non-Hodgkin's lymphoma cell lines RAJI and Namalwa were transduced with human CD200 and were injected subcutaneously together with human peripheral blood lymphocytes (PBMNC) into NOD/SCID mice. Tumor growth in mice that received CD200 expressing tumor cells was compared to tumor growth in mice that received tumor cells not expressing CD200 over time. In subsequent experiments, mice were treated with chimeric or humanized anti-CD200 antibodies (dose range 1 mg/kg to 20 mg/kg) by intravenous injection. Treatment was either started immediately or 7 days after tumor cell injection.

[0163] PBMNCs reduced RAJI or Namalwa tumor growth by up to 75 % in the absence of CD200 expression. In contrast, growth of RAJI or Namalwa tumors expressing CD200 at levels comparable to CLL was not reduced by PBMNCs. Administration of anti-CD200 antibodies at 5 mg/kg resulted in nearly complete tumor growth inhibition (1/10 mice developed a small tumor) over the course of the study even when treatment was started 7 days after tumor cell injection.

[0164] The presence of human CD200 on tumor cells inhibits the ability of human lymphocytes to eradicate tumor cells. Treatment of CD200-expressing tumors with antagonistic anti-CD200 antibodies inhibits tumor growth, indicating the potential for

anti-CD200 therapy as a promising approach for CLL.

C) Efficacy of C2aB7G1 versus C2aB7G2/G4 constructs

[0165] To evaluate whether anti-CD200 antibodies without effector function (G2/G4 fusion constructs of C2aB7 as described below) are equally or more efficacious than the G1 constructs, G1 and G2/G4 versions as well as the humanized version of C2aB7 (alxn5200) were tested in the Raji_CD200/PBL model. Raji cells transduced with CD200 as described above were injected s.c. into NOD.CB17-Prkdc^{scid} mice, and the ability of PBLs to reduce tumor growth in the presence or absence of chimeric anti-CD200 antibodies c2aB7G1 (c2aB7), c2aB7G2/G4 or the humanized versions hC2aB7V3V1G1 (V3V1), or hC2aB7V3V2G1 (V3V2) or control antibody alxn4100 was assessed. Antibodies at concentrations indicated below were administered initially with the tumor cells and then twice/week i.v. The following groups were set up with 10 mice each:

Group 1: 4×10^6 Raji_CD200 s.c.

Group 2: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL

Group 3: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +20 mg/kg hV3V2-G1

Group 4: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +5 mg/kg alxn 5200

Group 5: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +2.5 mg/kg alxn 5200

Group 6: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +1 mg/kg alxn 5200

Group 7: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +20 mg/kg chC2aB7G2/G4

Group 8: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +5 mg/kg chC2aB7G2/G4

Group 9: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +2.5 mg/kg chC2aB7G2/G4

Group 10: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +1 mg/kg chC2aB7G2/G4

Group 11: 4×10^6 Raji_CD200 s.c. + 6×10^6 PBL +20 mg/kg alxn4100

[0166] Tumor length and width were measured three times a week, and the tumor volume was calculated by tumor length*width*width/2. Figure 19 shows that, as expected, CD200 expression on the tumor cells prevented the immune cells from reducing tumor growth. However, addition of anti-CD200 antibodies reduced the tumor volume by up to 100 %. While 20 mg/kg C2aB7G1 resulted in growth of small tumors in 6/10 mice, only 1 mouse grew tumors in the group treated with 20 mg/kg C2aB7G2/G4, suggesting that the G2/G4 version might result in better or at least equal efficacy as the G1 version. All anti-CD200 antibodies, including the humanized versions, completely blocked tumor growth at 5 mg/kg. Treatment with the control antibody did not reduce the tumor growth. These data prove that the G2/G4 version of C2aB7 is highly efficacious in blocking tumor growth of CD200 expressing tumors. These data further confirm that the humanized versions of C2aB7 are highly efficacious in blocking tumor growth in this model.

D) Generation of G2/G4 construct

[0167] Plasmids were altered in two steps, first replacing the IgG1 region from an Age I site in the human CH1 region through the stop codon to a BamH I site located after the SV40 poly A signal. C2aB7-6 and cC7 G2G4 (L-SIGN antibody) were digested with Age I and BamH I, and C2aB7-6 was treated with CIP. A 10,315 bp fragment from C2aB7-6 and a 1752 bp fragment from cC7 G2G4 were purified by electrophoresis and gel extraction. These fragments were ligated, electroporated into XL1 Blue *E. coli*, and plated on LB/carb/gluc plates. Colonies were grown in solution and DNA was isolated using Qiagen miniprep columns. The presence of the IgG2G4 Age I/BamH I fragment, as opposed to the IgG1 fragment, was determined by Pvu II digestion which results in the presence of two bands of 267 and 1152 bp as opposed to one band of 1419 bp. Clone 21 was selected for further use.

[0168] The remainder of the CH1 region from the end of the variable region to the Age I site was generated in an IgG2/G4 format by using overlap PCR. The PCR fragment containing the beginning of the CH1 region through the Age I site had previously been generated in the production of plasmid cC7 G2G4. Primers C7mhHF (TCCTCAGCCTCCACCAAGGGCC, SEQ ID NO:1) and Rev Age Pri (GGGCGCCTGAGTTCCACGAC, SEQ ID NO: 2) were used in a PCR reaction with G2G4 63L1D as template to generate a 142 bp fragment. Primers C2aB7 rev (GGCCCTTGGTGGAGGCTGAGGAACTGTGAGAGTGGTGC, SEQ ID NO: 3) and lacpri (GCTCCCGGCTCGTATGTTGTGT, SEQ ID NO: 4) were used with Fab C2aB7 as template to generate the murine heavy chain variable region (and upstream material) in a fragment of about 1250 bp. These fragments were purified by electrophoresis and gel extraction and were used in overlap PCR with the primers Rev Age Pri (GGGCGCCTGAGTTCCACGAC, SEQ ID NO: 2) and LeadVhPAX (ATATGAAATATCTGCTGCCGACCG, SEQ ID NO: 5) to generate a 558 bp fragment that was purified on a PCR purification column. This 558 bp fragment and clone 21 were digested with Xho I and Age I to generate a 458 bp fragment that was purified by electrophoresis and gel extraction. Clone 21 was also digested with Xho I and Age I, treated with CIP, and an 11.6 kb fragment was purified by electrophoresis and gel extraction. These fragments were ligated and electroporated into XL1 Blue *E. coli* and plated on LB/carb/gluc plates. Clone C2aB7G2G4.11 was seen to have the expected restriction fragments when digested with Pvu II.

[0169] The final construct C2AB7G2G4.11 was sequenced. It was discovered that the TAA stop codon of the light chain had been mutated to the sequence TCA such that an additional 6 amino acids would be added to the carboxy terminus of the light chain. It was found to have been present in the IgG1 version clone C2AB7-6 that was the parent for C2AB7G2G4.11. Antibodies containing the G2G4 construct are depicted in Figs 10, 11, 12, 13, and 15.

EXAMPLE 2

CD200 expression on cancer cells

A. Determination of CD200 Upregulation in CLL Patients

[0170] Lymphocytes from 15 CLL patients were stained with FITC-conjugated anti-CD5 (e-bioscience), APC-conjugated anti-CD19 (e-bioscience) and PE-conjugated anti-CD200 (Serotec). Lymphocytes from healthy donors were stained accordingly. CD200 expression on CD5+CD19+ cells was determined. As shown in Fig. 20, although the level of CD200 expression varied among CLL patient samples, all CLL samples showed elevated levels (1.6-4-fold range) higher CD200 expression compared to CD200 expression on normal B cells. The CLL patients showing elevated levels of CD200 expression are selected for anti-CD200 treatment in accordance with the methods described herein.

B. FACS analysis on cancer cell lines

[0171] CD200 expression was evaluated by FACS analysis using a panel of NCI60 cell lines from melanoma cancer patients, prostate cancer patients, glioblastoma patients, astrocytoma patients, neuroblastoma patients, ovarian cancer patients, lung cancer patients and renal cancer patients. C2aB7 was labeled with Zenon-Alexa488 according to the manufacturer's instructions (Invitrogen). One half million to 1 million cells were stained with 1 µg of the labeled antibody for 20 min, followed by a PBS wash. Cell staining was assessed using a FACSCalibur (Becton Dickinson). Staining of antibody-labeled cells was compared with samples that remained unlabeled and the ratio of stained/unstained was determined. In Fig. 21, a ratio greater than 1 but smaller than 2 is indicated as +/-, a ratio between 2 and 3 is +, between 3 and 10 is ++, >10 is +++. None of the cell lines tested for glioblastoma, astrocytoma, prostate or lung cancer expressed CD200, and are not listed below. Four out of 5 tested melanoma cell lines, 2/2 ovarian cancer cell lines, 2/3 renal cell lines, 2/2 neuroblastoma cell lines and 1/3 breast cancer cell lines expressed CD200 at detectable levels on the cell surface, suggesting that solid tumors might use CD200 as an immune escape mechanism as well.

C. RT-PCR on patient samples

[0172] To verify whether CD200 is upregulated not only on cell lines, but also on primary patient samples, RT-QPCR and

immunohistochemistry (IHC) were performed on primary patient samples. RNA samples from ovarian and melanoma patients were obtained from Cytomix. cDNA was prepared and samples were diluted 1:100 and 1:1000 in 10 ng/ml yeast RNA. Samples were run for QPCR with CD200 assay Hs00245978_ml as provided by ABI. For 18S normalization, 18S assay (ABI) was run with samples diluted 1:10,000. Each dilution was run in duplicate. Ovarian and melanoma patient samples, along with CLL patient samples were normalized to 18S, then fold expression relative to normal PBL was determined. Figure 22 shows CD200 expression on ovarian cancer samples. Serous/serous metastatic/papillary serous appeared to have the highest expression of CD200 at approximately 10- to 20-fold higher than normal PBL. CD200 expression was relatively low in endometrioid, mucinous, and clear cell samples, all at or below normal ovary expression levels (1 - 5 fold higher than normal PBL).

Fig. 23 shows the CD200 expression levels of several melanoma metastases samples: jejunum, small intestine, lymph node, lung, skin, and brain). Several of these samples are matched normal/tumor, indicated by the number (-1 pair or -2 pair). Other additional samples without matched normals were also run for comparison. Jejunum samples showed significantly higher CD200 expression levels than the normal organ, with the metastatic samples about 4 -7-fold higher than normal jejunum.

D. Immunohistochemistry on primary patient samples

[0173] IHC was performed on 2 frozen melanoma patient samples (LifeSpan). D1B5 and C2aB7 Fab fragments were used for staining. An IgG1 antibody was used as isotype control. Binding of the primary antibodies was detected with an antimouse secondary antibody and DAB chromagen.

[0174] As shown in Figure 24, both melanoma samples tested showed strong membrane staining with the anti-CD200 antibodies, but no staining with the isotype control. Normal skin tissue did not show CD200 staining. These data demonstrate that CD200 is not only upregulated on melanoma and ovarian cancer cell lines, but also on primary patient samples.

E. Immune evasion of melanoma and ovarian tumor cells through upregulation of the immunosuppressive molecule CD200

[0175] Immune escape is a critical feature of cancer progression. Tumors can evade the immune system by multiple mechanisms, each a significant barrier to immunotherapy. Implementing new and more effective forms of immunotherapy will require understanding of these processes as well as their similarities and differences across cancers. We previously identified the immunosuppressive molecule CD200 to be upregulated on chronic lymphocytic leukemia cells. Presence of CD200 downregulates Th1 cytokine production required for an effective cytotoxic T cell response. We demonstrated in animal models that CD200 expression by human tumor cells prevents human lymphocytes from rejecting the tumor, and treatment with an antagonistic anti-CD200 antibody inhibited tumor growth. In this study, we evaluated whether CD200 upregulation is found on other cancers, and whether CD200 expression on these cancer cells affects the immune response.

[0176] Relative CD200 message levels were quantitated by RT-QPCR in ovarian adenocarcinoma (serous/serous metastatic/papillary serous, endometrioid, mucinous, clear cell) and malignant melanoma metastatic patient samples.

[0177] Cell surface expression of CD200 was evaluated by IHC in two melanoma and three ovarian carcinoma (serous) patient frozen tissue samples in comparison with normal skin and normal ovaries. CD200 expression on the cell surface of the melanoma cancer cell lines SK-MEL-5, SK-MEL-24 and SK-MEL-28 and the ovarian cancer cell line OV-CAR-3 was assessed by FACS analysis using a PE-labeled anti-CD200 antibody. The effect of the CD200-expressing cancer cell lines on cytokine profile mixed in lymphocyte reactions were assessed by adding the cells to a culture of human monocyte-derived dendritic cells with allogeneic human T cells. Cytokine production (IL-2 and IFN- γ for Th1, IL4 and IL10 for Th2) was detected in the supernatant by ELISA.

[0178] Quantitative PCR showed CD200 expression levels in serous ovarian adenocarcinoma samples at up to 20 fold higher than normal PBL, and equal to or up to 4-fold higher than normal ovary. CD200 expression was at or below normal ovary levels in endometrioid, mucinous, and clear cell ovarian adenocarcinoma samples. In malignant melanoma metastases to the jejunum, CD200 expression levels appeared to be significantly higher than normal samples. In malignant melanoma lung metastases, 2/6 showed higher CD200 expression than normal samples.

[0179] IHC showed strong, specific, membrane-associated CD200 staining on malignant cells of both melanoma patients. The normal skin sample showed faint staining of endothelial cells. Among three ovarian cancer patients, one showed strong CD200 staining, one was moderately positive, and one showed subsets of faintly stained tumor cells. In all three cases, the stroma showed strong staining.

[0180] CD200 was highly expressed on the cell surface of the melanoma cancer cell lines SK-MEL-24 and SK-MEL-28 as well as on the ovarian cancer cell line OVCAR-3, and moderately expressed on the melanoma cell line SK-MEL-5. Addition of any of these cell lines to a mixed lymphocyte reaction downregulated the production of Th1 cytokines, while cell lines not expressing CD200 did not, demonstrating a direct correlation. Inclusion of an antagonistic anti-CD200 antibody during the culture abrogated the effect.

[0181] Melanoma and ovarian tumor cells can upregulate CD200, thereby potentially suppressing an effective immune response. Therapy with an antagonistic anti-CD200 might allow the immune system to mount an effective cytotoxic response against the tumor cells.

F. Effect of CD200-expressing, cancer cell lines on cytokine profiles in mixed lymphocyte reactions

[0182] The capability of cells overexpressing CD200 to shift the cytokine response from a TH1 response (IL-2, IFN- γ) to a Th2 response (IL-4, IL-10) was assessed in a mixed lymphocyte reaction. As a source of CD200-expressing cells, either CD200 transfected cells or cells from CD200 positive cancer cell lines were used.

[0183] Mixed lymphocyte reactions were set up in 24 well plates using 250,000 dendritic cells matured from human peripheral monocytes using IL-4, GM-CSF and IFN- γ and 1×10^6 responder cells. Responder cells were T cell enriched lymphocytes purified from peripheral blood using Ficoll. T cells were enriched by incubating the cells for 1 hour in tissue culture flasks and taking the non-adherent cell fraction. 500,000 cells from the melanoma cancer cell lines SK-MEL-1, SK-MEL-24, SK-MEL-28, the ovarian cancer cell line OVCAR3 and the non-Hodgkin's lymphoma cell line Namalwa or primary CLL cells as positive control were added to the dendritic cells in the presence or absence of 30 μ g/ml anti-CD200 antibody. Supernatants were collected after 48 and 68 hours and analyzed for the presence of cytokines

[0184] Cytokines such as IL-2, IFN- γ , and IL-10 found in the tissue culture supernatant were quantified using ELISA. Matched capture and detection antibody pairs for each cytokine were obtained from R+D Systems (Minneapolis, MN), and a standard curve for each cytokine was produced using recombinant human cytokine. Anti-cytokine capture antibody was coated on the plate in PBS at the optimum concentration. After overnight incubation, the plates were washed and blocked for 1 hour with PBS containing 1% BSA and 5% sucrose. After 3 washes with PBS containing 0.05% Tween, supernatants were added at dilutions of two-fold or ten-fold in PBS containing 1% BSA. Captured cytokines were detected with the appropriate biotinylated anti-cytokine antibody followed by the addition of alkaline phosphatase conjugated streptavidin and SigmaS substrate. Color development was assessed with an ELISA plate reader (Molecular Devices).

[0185] As shown in Figure 25A, the presence of cell lines with high CD200 expression (MEL-24, MEL-28, OVCAR-3) resulted in down-regulation of Th1 cytokines such as IL-2 and IFN- γ . In contrast, addition of MEL-1 (low CD200 expression) or Namalwa (no CD200 expression) did not affect the cytokine profile. Addition of the anti-CD200 antibody hB7VH3VL2 at 50 μ g/ml fully restored the Th1 response (Figure 25B), indicating that anti-CD200 antibody treatment of melanoma or ovarian cancer patients might be therapeutically beneficial.

EXAMPLE 3

Elimination of activated T cells by C2aB7-G1 and its derivatives

[0186] To evaluate whether anti-CD200 treatment has an effect in a cancer model using tumor cells not expressing CD200, Namalwa cells and human PBLs were injected into NOD/SCID mice, and mice were treated as outlined below. In this model, CD200 is only present on immune cells naturally expressing CD200 such as B cells and follicular T-helper cells.

Group design:

10 animals/group

[0187]

Group 1: 4×10^6 Namalwa s.c.

Group 2: 4×10^6 Namalwa s.c. + 8×10^6 PBL

Group 3: 4×10^6 Namalwa s.c. + 8×10^6 PBL +20 mg/kg hV3V2-G1

Group 4: 4×10^6 Namalwa s.c. + 8×10^6 PBL +5 mg/kg hV3V2-G1

Group 5: 4×10^6 Namalwa s.c. + 8×10^6 PBL +2.5 mg/kg hV3V2-G1

Group 6: 4×10^6 Namalwa s.c. + 4×10^6 PBL

Group 7: 4×10^6 Namalwa s.c. + 8×10^6 PBL +20 mg/kg chC2aB7-G2G4

Group 8: 4×10^6 Namalwa s.c. + 8×10^6 PBL +5 mg/kg chC2aB7-G2G4

Group 9: 4×10^6 Namalwa s.c. + 8×10^6 PBL +2.5 mg/kg chC2aB7-G2G4

Group 10: 4×10^6 Namalwa s.c. + 4×10^6 PBL + 20 mg/kg chC2aB7-G2G4

Group 11: 4×10^6 Namalwa s.c. + 8×10^6 PBL +20 mg/kg alxn4100

1/10th of the dose was included in the injection mixture. Subsequent dosing was 2x/week i.v. for 3 weeks.

[0188] Tumor length (L) and width (W) were measured 3 times/week and tumor volumes were calculated by $L \times W^2/2$. Figure 26 shows that as previously established, simultaneous injection of human PBLs with Namalwa cells inhibits tumor growth. No effect of chC2aB7-G2G4 on PBL-mediated tumor growth inhibition was observed. In contrast, administration of ALXN5200 (hB7VH3VL2-G1) blocked PBL mediated tumor growth inhibition. In the absence of CD200 on tumor cells, it appears that anti-CD200 antibody treatment with an antibody that mediates effector function such as G1 constructs, critical effector cells in the PBL population are eliminated. These data suggest that anti-CD200 cancer therapy is less effective when an antibody with effector function is being used as compared to using the antibody without effector function. However, anti-CD200 treatment using a construct with effector function could be therapeutically beneficial in situations where elimination of immune cells is desirable such as in the transplantation setting or autoimmune diseases.

EXAMPLE 4**T cell killing by hB7VH3VL2**

[0189] To evaluate whether incubation of activated T cells with anti-CD200 antibodies containing a constant region mediating effector function (e.g. G1) results in the killing of the T cells, T cells were activated and killing assays were set up as described below.

A). CD3+ T cell isolation

[0190] Human peripheral blood lymphocytes (PBLs) were obtained from normal healthy volunteers by density gradient centrifugation of heparinized whole blood using the Accuspin™ System. Fifteen ml of Histopaque-1077 (Sigma, St. Louis, MO; cat# H8889) was added to each Accuspin tube (Sigma, St. Louis, MO; cat# A2055) which was then centrifuged at 1500 rpm for 2 minutes so that the Histopaque was allowed to pass through the frit. Thirty ml of whole blood was layered over the frit and the tubes were centrifuged for 15 minutes at 2000 rpm at room temperature with no brake. The PBL interface was collected and mononuclear cells were washed twice in PBS with 2% heat-inactivated fetal bovine serum (FBS) (Atlas Biologicals, Ft. Collins, CO; cat# F-0500-D) with 1200 rpm centrifugation for 10 minutes. CD3+ T cells were isolated by passage over a HTCC-5 column (R&D Systems) according to the manufacturer's instructions. Eluted cells were washed, counted and resuspended in RPMI 1640

containing 5% heat-inactivated single donor serum, 2 mM L-glutamine, 10 mM Hepes and penicillin/streptomycin.

B. Activation with plate-bound mOKT3

[0191] Wells of 12-well plates (Falcon) were coated by overnight incubation at 4°C with 10 µg/mL mOKT3 (Orthoclone) diluted in PBS. Residual antibody was removed and the plates gently rinsed with PBS. Purified CD3+ T cells, isolated as described above, were added to the plates at a final concentration of 2×10^6 /well in RPMI 1640 containing 5% heat-inactivated single donor serum, 2 mM L-glutamine, 10 mM Hepes and penicillin/streptomycin. Cells were maintained for 72 hours at 37°C in a humidified incubator containing 5% CO₂.

C. ⁵¹Chromium labeling of mOKT3-activated CD3+target cells

[0192] At the end of the culture period, mOKT3-activated CD3+ cells were harvested, washed and resuspended at 10^7 cells/mL in RPMI 1640 without serum. Cells were chromated by the addition of 125 µCi of ⁵¹Chromium (Perkin Elmer, Billerica, MA)/ 10^6 cells for 2 hours at 37°C. Labeled cells were harvested, washed in RPMI containing 5% heat-inactivated single donor serum and resuspended at a final concentration of 2×10^5 cells/mL in the same medium.

D. Preparation of autologous NK effector cells

[0193] Human peripheral blood lymphocytes (PBLs) from the same individual were obtained as described above by density gradient centrifugation. The PBL interface was collected and mononuclear cells were washed twice in PBS with 2% heat-inactivated fetal bovine serum (FBS) (Atlas Biologicals, Ft. Collins, CO; cat# F-0500-D) with 1200 rpm centrifugation for 10 minutes. CD56+ cells were isolated by positive selection over anti-CD56-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA, Cat # 120-000-307) according to the manufacturer's instructions. Eluted cells were washed, counted and resuspended at 1.3×10^6 cells/mL in RPMI 1640 containing 5% heat-inactivated single donor serum, 2 mM L-glutamine, 10 mM Hepes and penicillin/streptomycin. Cells were incubated overnight at 37°C in a humidified incubator containing 5% CO₂ at a final concentration of 4×10^6 cells/well in 3 mL of the same medium. At the end of the culture period, the cells were harvested, washed, counted and resuspended in serum-free RPMI containing 2 mM L-glutamine, 10 mM Hepes, 2×10^{-5} M 2- mercaptoethanol and penicillin/streptomycin.

E. ADCC assay

[0194] ⁵¹Cr-labelled mOKT3-activated CD3+ target cells prepared as described above were distributed in wells of a 96-well plate at 10^4 cells/well in 50 µL. CD56+ effector cells were harvested, washed, counted and resuspended at either 2.5×10^6 cells/mL (for an effector:target cell ratio of 25:1) or 10^6 cells/mL (for an effector:target cell ratio of 10:1) and were distributed (100 µL/well) to wells containing the target cells. Ten-fold dilutions of anti-CD200 antibodies (V3V2-G1 or V3V2-G2/G4) were added to the effectors and targets at final concentrations of 10, 1, 0.1 and 0.01 µg/mL. Assay controls included the following: 1) effectors and targets in the absence of antibody (0 Ab); 2) target cells in the absence of effectors (spontaneous lysis) and 3) effectors and targets incubated with 0.2% Tween-80 (maximum release). All cell culture conditions were performed in triplicate. Cells were incubated at 37°C for 4 hours in a humidified incubator containing 5% CO₂. At the end of the culture period, the plates were centrifuged to pellet the cells and 150 µL of cell supernatant was transferred to scintillation vials and counted in a gamma scintillation counter (Wallac). The results are expressed as percent specific lysis according to the following formula:

$$\frac{(\text{Mean sample counts per minute (cpm)} - \text{mean spontaneous lysis})}{\text{mean maximum lysis} - \text{mean spontaneous lysis}} \times 100$$

(mean maximum lysis-mean spontaneous lysis)

F. Flow cytometry

[0195] One hundred µl of cell suspensions (mOKT3-activated CD3+ cells or purified CD56+ NK cells) prepared as described above were distributed to wells of a 96-well round bottom plate (Falcon, Franklin Lakes NJ; cat# 353077). Cells were incubated for 30 minutes at 4°C with the indicated combinations of the following fluorescein isothiocyanate (FITC)-, Phycoerythrin (PE)-, PerCP-Cy5.5-, or allophycocyanin (APC)-conjugated antibodies (all from Becton-Dickinson, San Jose, CA); anti-human CD25-FITC (cat# 555431); anti-human CD3-APC (cat# 555335); anti-human CD200-PE (cat # 552475); anti-human CD8-PerCP-Cy5.5 (cat# 341051); anti-human CD4-APC (cat# 555349); anti-human CD5-APC (cat# 555355) and anti-human CD56-APC (cat# 341025). Isotype controls for each labeled antibody were also included. After washing cells twice with FACS buffer (1800 rpm centrifugation for 3 minutes), cells were resuspended in 300 µl of PBS (Mediatech, Herndon, VA; cat# 21-031-CV) and analyzed by flow cytometry using a FACS Caliber machine and CellQuest Software (Becton Dickinson, San Jose, CA).

[0196] As shown in Figure 27, activated T cells show high CD200 expression on their surface. Activated T cells are efficiently killed in the presence of VH3VL2-G1 but not VH3VL2-G2G4 when NK cells are used as effector cells (Figure 28). These data demonstrate that anti-CD200 antibodies with effector function can eliminate activated T cells. Such an antibody could be of therapeutic use in the transplantation setting or for the treatment of autoimmune diseases.

[0197] In addition to regulatory T cells, plasmacytoid dendritic cells have been shown to play a negative immunoregulatory role in human cancer (Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005 Jun 15; 65(12):5020-6). Combination of a therapy eliminating plasmacytoid dendritic cells with anti-CD200 therapy could therefore be advantageous.

EXAMPLE 5

CD200 on plasma cells

[0198] Bone marrow cells from 10 multiple myeloma patients and 3 normal donors were prepared by first lysing red blood cells using ammonium chloride. Cells were resuspended in FACS buffer and labeled with the following antibody cocktails:

- Kappa-FITC/CD38-PE/CD138-PerCP-Cy5.5
- Lambda-FITC/CD38-PE/CD138-PerCP-Cy5.5
- Isotype Control-FITC/CD38-PE
- CD200-FITC/CD38-PE

[0199] Data were collected using a BD FACS Canto and analyzed using BD DiVA software. Expression of CD200 on CD38 bright cells (plasma cells) was analyzed. As shown in Fig. 29, a portion of plasma cells expresses CD200 at high intensity in normal donors. In multiple myeloma patients, the majority of plasma cells express CD200.

[0200] In the multiple myeloma setting, similar to CLL or other cancers expressing CD200, CD200 expression by the tumor cells might prevent the immune system from eradicating the tumor cells. Antagonistic anti-CD200 therapy might subsequently allow the immune system to eliminate cancer cells. Ablative anti-CD200 therapy targeting plasma cells could be therapeutically beneficial in the autoimmune or transplantation setting.

EXAMPLE 6

CD200 on viruses

[0201] CD200 is also expressed on a number of viruses such as myxoma virus M141R or human herpesvirus 8. Similar to expression of CD200 on tumor cells, CD200 on viruses might prevent the immune system from effectively clearing the virus. Treatment with an antagonistic anti-CD200 antibody could be therapeutically beneficial in an infection with a CD200 expressing virus, allowing the immune system to eradicate the virus. Alternatively, an ablative anti-CD200 antibody could be used.

[0202] It will be understood that various modifications may be made to the embodiments disclosed herein. For example, as those skilled in the art will appreciate, the specific sequences described herein can be altered slightly without necessarily adversely affecting the functionality of the polypeptide, antibody or antibody fragment used in binding OX-2/CD200. For instance, substitutions of single or multiple amino acids in the antibody sequence can frequently be made without destroying the functionality of the antibody or fragment. Thus, it should be understood that polypeptides or antibodies having a degree of identity greater than 70% to the specific antibodies described herein are within the scope of this disclosure. In particularly useful embodiments, antibodies having an identity greater than about 80% to the specific antibodies described herein are contemplated. In other useful embodiments, antibodies having an identity greater than about 90% to the specific antibodies described herein are contemplated. Therefore, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. Those skilled in the art will envision other modifications within the scope and spirit of this disclosure.

REFERENCES

[0203]

1. 1) Agarwal, et al., (2003). Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. *Immunol Invest* 32:17-30.
2. 2) Almasri, NM et al. (1992). *Am J Hemato* 140 259-263.
3. 3) Contasta, et al., (2003). Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. *Cancer Biother Radiopharm* 18:549-557.
4. 4) Gorczynski, et al., (1998). Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survival. *Transplantation* 65:1106-1114.
5. 5) Gorczynski, et al., (2001). Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. *Clin Exp Immunol* 126:220-229.
6. 6) Hainsworth, JD (2000). *Oncologist* 2000; 5(5):376-84.
7. 7) Inagawa, et al., (1998). Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. *Anticancer Res* 18:3957-3964.
8. 8) Ito, et al., (1999). Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. *Cancer* 85:2359-2367.
9. 9) Kiani, et al., (2003). Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. *Haematologica* 88:754-761.
10. 10) Lauerova, et al., (2002). Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. *Neoplasma* 49:159-166.
11. 11) Maggio, et al., (2002). Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. *Ann Oncol* 13 Suppl 1:52-56.
12. 12) Nilsson, K (1992). *Bum Cell*. 5(1):25-41.
13. 13) Podhorecka, et al., (2002). T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia-the three-color flow cytometry analysis. *Leuk Res* 26:657-660.
14. 14) Pu, QQ and Bezwoda, W (2000). *Anticancer Res*. 20(4):2569- 78.
15. 15) Smyth, et al., (2003). Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. *Ann Surg Oncol* 10:455-462.
16. 16) Tatsumi, et al., (2002). Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. *J Exp Med* 196:619-628.
17. 17) Walls A Vet al. (1989). *Int. J Cancer* 44846-853.
18. 18) Winter, et al., (2003). Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. *Immunology* 108:409-419.
19. 19) Cameron, C. M., J. W. Barrett, L. Liu, A. R. Lucas, and G. McFadden. 2005. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. *J Virol* 79:6052.
20. 20) Foster-Cuevas, M., G. J. Wright, M. J. Puklavec, M. H. Brown, and A. N. Barclay. 2004. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. *J Virol* 78:7667.
21. 21) Nicholas, J. 2003. Human herpesvirus-8-encoded signalling ligands and receptors. *J Biomed Sci* 10:475.
22. 22) Shiratori, I., M. Yamaguchi, M. Suzukawa, K. Yamamoto, L. L. Lanier, T. Saito, and H. Arase. 2005. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. *J Immunol* 175:4441.
23. 23) Voigt, S., G. R. Sandford, G. S. Hayward, and W. H. Burns. 2005. The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV Maastricht. *J Gen Virol* 86:263.

24. 24) Zhang, J., J. Wang, C. Wood, D. Xu, and L. Zhang. 2005. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J Virol 79:5640.

SEQUENCE LISTING

[0204]

<110> Alexion Pharmaceuticals, Inc.
Bowdish, Katherine
Kretz-Rommel, Anke
Faas McKnight, Susan
springhorn, Jeremy P.
Wu, Dayang

<120> ANTIBODIES TO OX-2/CD200 AND USES THEREOF

<130> P2493 EP/1

<150> US 60/758,426

<151> 2006-01-12

<150> US 60/759,085

<151> 2006-01-12

<150> US 60/801,991

<151> 2006-05-18

<160> 51

<170> FastSEQ for windows version 4.0

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer C7mhHF

<400> 1

tcctcagcct ccaccaaggg cc 22

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer Rev Age Pri

<400> 2

gggcgcctga gttccacgac 20

<210> 3

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer C2aB7 rev

<400> 3

ggcccttggt ggaggctgag gaaactgtga gagtgggtgc 39

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer lacpri

<400> 4

gtccccggct cgtatgtgt gt 22

<210> 5

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer LeadVHpAX

<400> 5

atatgaaata tctgctgccg accg 24

<210> 6

<211> 2010

<212> DNA

<213> Artificial Sequence

<220>

<223> heavy chain chC2aB7-hG1, genomic sequence hG1

<400> 6

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactccctc 60
gaggtccagc tgcacacgct tggacctgag ctggtgaagc ctggggcctc actgaagatg 120
tcctgcaagg ctcttggtta ttcatctact gactacatca tactctgggt gaagcagaac 180
catggaaaag gccctgagtg gattggacat attgatcctt actatggtag ttctaactac 240
aatctgaaat tcaagggcaa ggccacattg actgtagaca aatcttccag cacagcctac 300
atgcagctca acagtctgac atctgaggac tctgcagtct attactgtgg aagatcttaag 360
agggactact ttgactactg ggccaaggc accactctca cagtttctc agcctccacc 420
aaggggccat cggctctccc cctggcaccc tcctccaaga gcacctctgg cggcacagcg 480
gccctgggct gcctgggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca 540
ggcgctctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcttc aggaactctac 600
tccctcagca gcgtgggtgac cgtgcccccc agcagcttgg gcacccagac ctacatctgc 660
aacgtgaatt acaagcccag caacaccaag gtggacaaga gagtgggtga gaggccagca 720
cagggaagga ggggtgtctg tggaagccag gctcagcgct cctgccttga cgcctcccg 780
ctatgcagtc ccagtcagg gcagcaaggc agggcccgtc tgcctcttca cccggaggcc 840
tctgcccgcc ccactcatg tcagggaag ggtcttcttg cttttctccc aggcctctgg 900
caggcacagg ctagggtgcc ctaagccagg ccctgcacac aaagggcgag gtgctgggct 960
cagacctgcc aagagccata tccgggagga ccctgcccc gacctaagc caccctaaag 1020
gccaaactct ccactccctc agctcggaca ccttctctcc tcccagattc cagtaactcc 1080
caatctcttc tctgcagag ccaaatcttg tgacaaaact cacacatgcc caccgtgccc 1140
aggtaaagcca gccagggcct cggcctccag ctcaaggcgg gacaggtgcc ctagagtgc 1200
ctgcatccag ggacaggccc cagccgggtg ctgacacgtc caccctcatc tcttctcag 1260
cacctgaact cctggggggg cggtcagctc tcctcttccc cccaaaaccc aaggacaccc 1320
tcattgatct ccggaccctc gaggtcacat gcgtggtggg ggaagtgcac cacgaagacc 1380
ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc 1440
cgcgggagga gcagtacaac agcacgtacc gtgtgggtcag cgtcctcacc gtcctgcacc 1500
aggactggct gaattggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc 1560
ccatcgagaa aaccatctcc aaagccaaag gtgggaccgg tgggggtcga gggccacatg 1620
gacagaggcc ggctcggccc accctctgcc ctgagagtga ccgctgtacc aacctctgtc 1680
cctacaggcc agccccgaga accacaggtg tacacctgac ccccatcccg ggaggagatg 1740
accaagaacc aggtcagcct gacctgcctg gtcaaaaggc tctatcccag cgacatcgcc 1800
gtggagtggg agagcaatgg gcagccggag aacaaactaca agaccacgcc tcccgtgctg 1860
gactccgacg gctccttctt cctctatagc aagctcaccg tggacaagag caggtggcag 1920
caggggaaag tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1980
aagagcctct ccctgtcccc gggtaaatga 2010

```

<210> 7

<211> 467

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain chC2aB7-hG1

<400> 7

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

```

      1           5           10           15
Val His Ser Leu Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val
Lys Pro Gly Ala Ser Leu Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser
Phe Thr Asp Tyr Ile Ile Leu Trp Val Lys Gln Asn His Gly Lys Ser
Leu Glu Trp Ile Gly His Ile Asp Pro Tyr Tyr Gly Ser Ser Asn Tyr
Asn Leu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
Ser Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
Val Tyr Tyr Cys Gly Arg Ser Lys Arg Asp Tyr Phe Asp Tyr Trp Gly
Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys
465

```

<210> 8

<211> 1401

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7V4V1-hG1 Heavy chain (cDNA hG1)

```

<400> 8
atgggatgga gctggatctt tctctttctc ctgtcagtaa ctgcagggtg gttctctgag 60
gtccagctgg tggagtccgg acctgaggtg aagaagcctg gggcttcagt gaaggtgtcc 120
tgcaaggctt ctgggttattc attcactgac tacatcatac tctggatcag gcagcatagc 180
ggaaaggggc ttgagtggat tggacatatt gatccttact atggtagtcc taactacaat 240
ctgaaattca agggcagggt cacaatcact gcagacaaat ctaccaggac aacctacatg 300
gagctcacca tctctgacatc tgaggacact gcagtctatt actgtggaag atctaagagg 360
gactactttg actactgggg ccaaggcacc actctcacag ttctctcagc ctccaccaag 420
ggcccatcgg tcttcccgcct agcaccctcc tccaagagca cctctggggg cacagcggcc 480
ctgggctgcc tgggtcaaggc ctacttcccc gaaccggtga cgggtgtcgtg gaactcaggc 540
gccctgacca gcggcgtgca cacttccccg gctgtcctac agtcctcagg actctactcc 600
ctcagcagcg tgggtgacctg gccctccagc agcttgggca cccagacctc catctgcaac 660
gtgaattaca agcccagcaa caccagaggt gacaagagag ttgagcccaa atcttgtgac 720
aaaactcaca catgcccacc gtgcccagca cctgaactcc tgggggggacc gtcagtcttc 780
ctcttcccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc 840
gtggtgggtg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 900
gtggagggtg ataattgcaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt 960
gtggtcagcg tctctaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc 1020
aaggctctca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg 1080
cagcccccag aaccacaggt gtacaccctg ccccatcccc gggaggagat gaccaagaac 1140
caggctcagc tgacctgctt ggtcaaaagg ttctatccca gcgacatcgc cgtggagtgg 1200
gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1260
ggctctctct tctctacag caagctcacc gtggacaaga gcagggtgga gcagggggac 1320
gtcttctcat gctcctgtag gcatgaggct ctgcacaacc actacacgca gaagagcctc 1380
tccctgtctc cgggtaaatg a 1401

```

<210> 9

<211> 466

<212> PRT

<213> Artificial Sequence

<220>

<223> hB7V4V1-hG1 Heavy chain

<400> 9

```

Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Val Thr Ala Gly
1      5      10      15
Val Phe Ser Glu Val Gln Leu Val Glu Ser Gly Pro Glu Val Lys Lys
20      25      30
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe
35      40      45
Thr Asp Tyr Ile Ile Leu Trp Ile Arg Gln His Ser Gly Lys Gly Leu
50      55      60
Glu Trp Ile Gly His Ile Asp Pro Tyr Tyr Gly Ser Ser Asn Tyr Asn
65      70      75
Leu Lys Phe Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Arg
85      90      95
Thr Thr Tyr Met Glu Leu Thr Ser Leu Thr Ser Glu Asp Thr Ala Val
100      105      110
Tyr Tyr Cys Gly Arg Ser Lys Arg Asp Tyr Phe Asp Tyr Trp Gly Gln
115      120      125
Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
130      135      140
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
145      150      155
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
160      165      170
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
175      180      185
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
190      195      200
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
205      210      215
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
220      225      230
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
235      240      245

```

```

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
250      255      260
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
265      270      275
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
280      285      290
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
295      300      305
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
310      315      320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325      330      335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340      345      350
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355      360      365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370      375      380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385      390      395
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
400      405      410
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
415      420      425
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
430      435      440
Gly Lys
445      450      455
465

```

<210> 10

<211> 1401

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7V3V1-hG1 Heavy chain (cDNA hG1)

<400> 10

```

atgggatgga gccggatctt tctcttcctc ctgtcaataa ttgcagggtt ccattgccag 60
gtccagctgc aacagctctg atctgagctg aagaagcctg gggcttcagt gaagatctcc 120
tgcaaggctt ctgggtattc attcactgac tacatcatac tctgggtgag gcagaaccct 180
ggaaagggcc ttgagtggat tggacatatt gatccttact atggtagtct taactacaat 240
ctgaaattca agggcagagt gacaatcacc gccgaccagt ctaccaccac agcctacatg 300
gagctctcca gtctgagatc tgaggacact gcagtctatt actgtggaag atctaagagg 360
gactactttg actactgggg ccaaggcacc actctcacag ttctctcagc ctccaccaag 420
ggcccatcgg tcttcccgtc agcaccctcc tccaagagca cctctggggg cacagcggcc 480
ctgggtgccc tgggcaagga ctacttcccc gaaccgggta cgggtgctgt gaactcaggc 540
gccctgacca gcggcgtgca caccctcccc gctgtcctac agtctctcag actctactcc 600
ctcagcagcg tggtagcctg gccctccagc agcttgggca ccagaccta catctgcaac 660
gtgaatcaca agcccagcaa caccaagggt gacaagagag ttgagcccaa atcttgtgac 720
aaaactcaca catgcccacc gtgcccgaca cctgaactcc tgggggggacc gtcagtcttc 780
ctcttcccc caaaacccaa ggacaccctc atgatctccc ggaccctga ggtcacatgc 840
gtggtgtgtg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 900
gtggaggtgc ataagccaa gacaaagccg cgggaggagc agtacaacag cactaccgt 960
gtggtcagcg tcttcacgt cctgaccag gactggctga atggcaagga gtacaagtgc 1020
aaggctctca acaaagccct cccagcccc atcgagaaaa ccattctcaa agccaaagg 1080
cagccccgag aaccacaggt gtacaccctg ccccatccc gggaggagat gaccaagaac 1140
caggctagcc tgacctgctt ggtcaaaagg ttctatccca gcgacatcgc cgtggagtgg 1200
gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1260
ggctctctct tctctcag caagctcacc gtggacaaga gcagggtggc gcaggggaac 1320
gtcttctcat gctcgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 1380
tccctgtctc cgggtaaatg a                                     1401

```

<210> 11

<211> 466

<212> PRT

<213> Artificial Sequence

<220>

<223> hB7V3V1-hG1 Heavy chain

<400> 11

```

Met Gly Trp Ser Arg Ile Phe Leu Phe Leu Leu Ser Ile Ile Ala Gly
1 10 15
Val His Cys Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Lys Lys
20 25 30
Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe
35 40 45
Thr Asp Tyr Ile Ile Leu Trp Val Arg Gln Asn Pro Gly Lys Gly Leu
50 55 60
Glu Trp Ile Gly His Ile Asp Pro Tyr Tyr Gly Ser Ser Asn Tyr Asn
65 70 75 80
Leu Lys Phe Lys Gly Arg Val Thr Ile Thr Ala Asp Gln Ser Thr Thr
85 90 95
Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Gly Arg Ser Lys Arg Asp Tyr Phe Asp Tyr Trp Gly Gln
115 120 125
Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
130 135 140
Phe Pro Leu Ala Pro Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
145 150 155 160
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
165 170 175
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
180 185 190
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
195 200 205
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
210 215 220
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
225 230 235 240
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
245 250 255
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
260 265 270
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
275 280 285
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
290 295 300
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
305 310 315 320
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
325 330 335
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
340 345 350
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
355 360 365
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
370 375 380
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
385 390 395 400
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
405 410 415
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
420 425 430
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
435 440 445
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
450 455 460
Gly Lys
465

```

<210> 12

<211> 2002

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7V3V2-hG2G4 Heavy chain (genomic sequence hG2G4)

<400> 12

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacagggtg ccactccctc 60
gagggtccagc tgcacacgctc tggacctgag ctggtgaagc ctggggcttc actgaagatg 120
tcctgcaagg cttctgggtta ttcatctact gactacatca tactctgggt gaagcagaac 180
catggaaaga gcccttgagtg gattggacat attgatccct actatggtag ttctaactac 240
aatctgaaat tcaagggcaa ggccacattg actgtagaca aatcttccag cacagcctac 300
atgcagctca acagctctgac atctgaggac tctgcagctc attactgtgg aagatctaa 360
agggactact ttgactactg gggccaaggc accactctca cagtttcttc agcctccacc 420
aaggggccat ccgtcttccc cctggcgccc tgctccagga gcacctccga gagcacagcc 480
gccctgggct ccctgggtcaa ggactacttc cccgaaccgg tgacgggtgc gtggaactca 540
ggcgccctga ccagcggcgt gcacaccttc ccggtgtgct tacagtcttc aggactctac 600
tcctcagca cgtggtgac cgtgcccttc agcaacttcg gcaccagac ctacacctgc 660
aacgtagatc acaagcccag caacaccaag gtggacaaga cagttggtga gaggccagct 720
cagggaggga ggggtgtctg tggaaaggc gctcagccct cctgcccgtg cgcaccccg 780
ctgtgcagcc ccagcccagg gcagcaaggc aggccctatc tgtctctca cccggaggcc 840
tctgccgcc ccactcatgc tcagggagag ggtcttcttg ctttttccac caggctccag 900
gcaggcacag cctaccccag gcccttcaca cacaggggca ggtgcttggc 960
tcagacctgc caaagccat atccgggagg accctgcccc tgacctaaag cgaccccaaa 1020
ggccaaactg tccactccct cagctcggac accttcttc ctcccagatc cgagtaactc 1080
ccaatcttct ctctgcagag cgcaaatgtt gtgtcgagtg cccaccgtgc ccagtaagc 1140
cagcccaggc ctcgcccttc agctcaaggc gggacaggtg ccttagagta gcctgcattc 1200
agggacaggc cccagctggg tgctgacacg tccacctca tcttctctc agcaccacct 1260
gtggcaggac cctcttcccc ccaaaaccca aggacacct catgatctc 1320
cggacccttg aggtcacgtg cgtggtggtg gacgtgagcc aggaagacc caggttccag 1380
ttcaactggg acgtggatgg cgtggaggtg cataatgcc agacaaagcc gcgggaggag 1440
cagttcaaca gcagctaccg tgtggtcagc gtctcaccg tcctgcacca ggactggctg 1500
aacggcaagg agtacaagtg caaggctctc aacaaaggcc tcccgctctc catcgagaaa 1560
accatctcca aagccaaagg tgggacccac ggggtgcgag ggccacatgg acagaggtca 1620
gctcgcccca cctctgccc tgggagtgac cgtgtgcc aacctgttc ctacagggca 1680
gcccgagag ccacagggtg acacctgccc cccatcccag gaggagatga ccaagaacca 1740
ggtcagcctg acctgcctgg tcaaaaggct ctaccccagc gacatcgccg tggagtggga 1800
gagcaatggg cagcgggaga acaactacaa gaccacgcct cccgtgctgg actccgacgg 1860
ctccttcttc ctctacagca ggctaaccgt ggacaagagc aggtggcagg aggggaatgt 1920
cttctcatgc tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc 1980
cctgtctctg ggttaaatgat ga 2002

```

<210> 13

<211> 462

<212> PRT

<213> Artificial Sequence

<220>

<223> hB7V3V2-hG2G4 Heavy chain

<400> 13

```

Met Gly Trp Ser Arg Ile Phe Leu Phe Leu Leu Ser Ile Ile Ala Gly
 1          5          10          15
Val His Cys Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Lys Lys
 20          25          30
Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe
 35          40          45
Thr Asp Tyr Ile Ile Leu Trp Val Arg Gln Asn Pro Gly Lys Gly Leu
 50          55          60
Glu Trp Ile Gly His Ile Asp Pro Tyr Tyr Gly Ser Ser Asn Tyr Asn
 65          70          75          80
Leu Lys Phe Lys Gly Arg Val Thr Ile Thr Ala Asp Gln Ser Thr Thr
 85          90          95
Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
100          105          110
Tyr Tyr Cys Gly Arg Ser Lys Arg Asp Tyr Phe Asp Tyr Trp Gly Gln
115          120          125

```

Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 130 135 140
 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
 145 150 155 160
 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 165 170 175
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 180 185 190
 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 195 200 205
 Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys
 210 215 220
 Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val
 225 230 235 240
 Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe
 245 250 255
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
 260 265 270
 Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val
 275 280 285
 Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
 290 295 300
 Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
 305 310 315 320
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
 325 330 335
 Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser
 340 345 350
 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
 355 360 365
 Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
 370 375 380
 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
 385 390 395 400
 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Val Leu Asp Ser Asp
 405 410 415
 Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp
 420 425 430
 Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 435 440 445
 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
 450 455 460

<210> 14

<211> 1999

<212> DNA

<213> Artificial Sequence

<220>

<223> chC2aB7-hG2G4 Heavy chain (genomic sequence hG2G4)

<400> 14

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacagggtt ccactccctc 60
 gaggtccagc tgcaacagtc tggacctgag ctggtgaagc ctggggcttc actgaagatg 120
 tccgtcaagg ctcttggtta ttcatctact gactacatca tactctgggt gaagcagaac 180
 catggaaga gcccttgagt gattggacat attgatcctt actatggtag ttctaactac 240
 aatctgaaat tcaagggcaa ggccacattg actgtagaca aatcttccag cacagcctac 300
 atgcagctca acagtctgac atctgaggac tctgcagtct attactgtgg aagatcttaag 360
 agggactact ttgactactg gggtccaagg accactctca cagtttcttc agcctccacc 420
 aaggggccat ccgtcttccc cctggcgccc tgcctcagga gcacctccga gagcacagcc 480
 gccctgggct gccttggtcaa ggactacttc cccgaaccgg tgacgggtgc gtggaactca 540
 ggcgcccaga ccagcgcgct gcacaccttc ccgctgtgcc tacagtcttc aggaactctac 600
 tccctcagca gcgtgggtgac cgtgcccttc agcaacttcg gcacccagac ctacacctgc 660
 aacgtagatc acaagcccag caacaccaag gtggacaaga cagttggtga gaggccagct 720
 cagggaagga ggggtgtctg tggaaagccag gctcagccct cctgcctgga cgcaccccg 780
 ctgtgcagcc ccagcccagg gcagcaaggc agggccctac tgtctctca cccggaggcc 840
 tctgccgcc ccactcatgc tcagggagag ggtcttctg cttttccac caggctccag 900

gcaggcacag gctgggtgcc cctaccccag gcccttcaca cacaggggca ggtgcttggc 960
 tcagacctgc caaaagccat atccgggagg accctgcccc tgacctaaag cgaccccaaa 1020
 ggccaaactg tccactccct cagctcggac accttctctc ctcccagatc cgagtaactc 1080
 ccaattctct ctctgcagag cgcaaatggt gtgtcgagtg ccacacgtgc ccaggtaagc 1140
 cagcccaggc ctgcgctctc agctcaaggc gggacagggt ccctagagta gcctgcatcc 1200
 agggacaggc cccagctggg tctgacacg tccacctcca tcttctctc agcaccacct 1260
 gtggcaggac cgtcagctct cctcttcccc ccaaaaccca aggacacct catgatctcc 1320
 cggaccctcg aggtcacgtg cgtggtggtg gacgtgagcc aggaagaccc cgaggtccag 1380
 ttcaactggt acgtggatgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 1440
 cagttcaaca gcacgtaccg tgtggtcagc gtctcaccg tctgaccca ggaactgctg 1500
 aacggcaagg agtacaaagt caaggtctcc aacaaaggcc tccgctctc catcgagaaa 1560
 accatctcca aagccaaagg tgggaccac gggtgctgag ggccacatgg acagaggtca 1620
 gctcggccca cctctgccc tgggagtgac cgtgtgtcca acctctgtcc ctacagggca 1680
 gccccgagag ccacaggtgt acacctgccc cccatcccag gaggagatga ccaagaacca 1740
 ggtcagctcg acctgctggt tcaaaagcct ctaccccagc gacatcgccg tggagtgaga 1800
 gagcaatggg cagccggaga acaactacaa gaccacgcct cccgtgctgg actccagcgg 1860
 ctctctcttc ctctacagca ggctaaccgt ggacaagagc aggtggcagg aggggaatgt 1920
 ctctcatgac tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc 1980
 cctgtctctg ggtaaatga 1999

<210> 15

<211> 463

<212> PRT

<213> Artificial Sequence

<220>

<223> chC2aB7-hG2G4 Heavy chain

<400> 15

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 1      5      10      15
Val His Ser Leu Glu Val Gln Leu Gln Ser Gly Pro Glu Leu Val
 20      25      30
Lys Pro Gly Ala Ser Leu Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser
 35      40      45
Phe Thr Asp Tyr Ile Ile Leu Trp Val Lys Gln Asn His Gly Lys Ser
 50      55      60
Leu Glu Trp Ile Gly His Ile Asp Pro Tyr Tyr Gly Ser Ser Asn Tyr
 65      70      75
Asn Leu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
 80      85      90
Ser Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
 95      100      105
Val Tyr Tyr Cys Gly Arg Ser Lys Arg Asp Tyr Phe Asp Tyr Trp Gly
 110      115      120
Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 125      130      135
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
 140      145      150
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 155      160      165
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 170      175      180
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 185      190      195
Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
 200      205      210
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
 215      220      225
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
 230      235      240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
 245      250      255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
 260      265      270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
 275      280      285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
 290      295      300

```

```

305      310      315
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
 315      320      325
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
 330      335      340
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
 345      350      355
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
 360      365      370
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
 375      380      385
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
 390      395      400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
 405      410      415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
 420      425      430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
 435      440      445
450      455      460

```

<210> 16

<211> 1391

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7V3V2-cG2G4 Heavy chain (cDNA G2G4)

<400> 16

```

atgggatgga gccggatctt tctcttcctc ctgtcaataa ttgcagggtg ccattgccag 60
gtccagctgc aacagctctg atctgagctg aagaagcctg gggcttcagt gaagatctcc 120
tgcaaggctt ctgggttatt attcaactgac tacatcatac tctgggtgag gcagaacctt 180
ggaaagggcc ttgagtggtat tggacatatt gatccttact atggtagttc taactacaat 240
ctgaaattca agggcagagt gacaatcacc gccgaccagt ctaccaccac agcctacatg 300
gagctctcca gtctgagatc tgaggacact gcagttctatt actgtggaag atctaagagg 360
gactactttg actactgggg ccaaggcacc actctcacag ttctctcagc ctccaccaag 420
ggcccatccg tcttccctcc ggccgctctg tccaggagca cctccgagag cacagccgcc 480
ctgggctgccc tgggtcaagg aacttctccc gaaccggtga cgggtgctgt gaactcaggc 540
gccctgacca gcggcggtgca cacttctccc gctgtcttac agtctctagg actctactcc 600
ctcagcagcg tgggtgacct gccctccagc aacttcggga cccagacctc cacttgcaac 660
gtagatcaca agcccagcaa caccaggtg gacaagacag ttgagcgcaa atgttgtgtc 720
gagtgcccac cgtgccacgc accacctgtg gcaggaccgt cagtcttctt ctcccccca 780
aaacccaagg acacctctat gatctctccg acccttgagg tcacgtgcgt ggtggtggac 840
gtgagccagg aagaccccca ggtccagttc aactggtagc tggatggcgt ggaggtgcat 900
aatgcccaaga caaagccgcg ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960
ctcaccgtcc tgcaccagga ctggctgaac ggcaaggagt acaagtgcga ggtctccaac 1020
aaaggctctc cgtctctcat cgagaaaacc atctccaaag ccaaagggca gcccgagag 1080
ccacaggtgt acacctgcc ccatccccc gagggagatg ccaagaacca ggtcagcctg 1140
acctgctctg tcaaagcctt ctaccccagc gacatcgccg tggagtggga gagcaatggg 1200
cagcgggaga caaactacaa gaccacgctt cccgtgctgg actccgacgg ctcttctctc 1260
ctctacagca ggctaaccgt ggacaagagc aggtggcagg aggggaatgt ctctctatgc 1320
tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc cctgtctctg 1380
ggtaaatgat g 1391

```

<210> 17

<211> 2005

<212> DNA

<213> Artificial Sequence

<220>

<223> ChC7-hG2G4 Heavy chain (genomic sequence hG2G4)

<400> 17

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacagggtg ccactccctc 60
gaggtccaac tgcagcagtc tggacctgag ctggagaagc ctggcgcttc agtgaagata 120
tcctgcaagg ctcttggtta ctattcact ggctacaaca tgaactgggt gaagcagagc 180
agtggaaaga gccctgagtg gattggaaat ttgatcctt actatggtg tattacctac 240

```

```

aaccagaagt tcaaggccaa ggccacattg actgtagaca aatctccag cacagcctac 300
atgcagctca agagcctgac atctgaggac tctgcagctc attactgtgc aagaacggct 360
acggctctct atactatgga ctactgggtt caaggaacct cagtaccgtt ctctccagcc 420
tccaccaagg gccctccgtt ctctcccttg gcgctctgct ccaggagcac ctccgagagc 480
acagccgccc tgggctgctt ggtcaaggac tacttccccg aaccgggtgac ggtgtcgtgt 540
aactcaggcg ccttgaccag cggcgtgacac accttccccg ctgtcttaca gtcctcagga 600
ctctactccc tcagcagcgt ggtgaccgtg ccttccagca acttcggcac ccagacctac 660
acctgcaacg tagatcaca gccacgcaac accaagggtg acaagacagt tggtagaggg 720
ccagctcagg gaggaggggt gtctgtctga agccaggctc agccctctct cctggagcga 780
cccggctgtg gcagcccccag cccagggcag caaggcaggc cccatctgtc tctcaccgg 840
gaggcctctg cccgcccac tcagtctcag ggaaggggtc ttctggcttt ttccaccagg 900
ctccaggcag gcacaggctg ggtgccccta cccaggccct ttcacacaca ggggcagggt 960
cttggtctag acctgccaaa agccatattc gggaggacct tgcctctgac ctaagccgag 1020
ccc aaaaggcc aactgtcca ctccctcagc tccgacacct tctctctctc cagatccgag 1080
taactcccaa tcttctctct gcagagcgca aatgttgtgt cgaagtgcctc cgtgcccag 1140
gtaagccagc ccaggcctcg ccttccagct caaggcggga caggtgacct agagttagct 1200
gcattccagg acaggcccca gctgggtgct gacacgtcca cctccatctc ttctcagca 1260
ccactgttgg caggaccgtc agtcttctct ttcccccaa aaccacaagg caccctcatg 1320
atctcccggg cccctgaggt cacgtgctgt gttgtggacg tgagccaagg agaccccgag 1380
gtccagtcca actgtgacct ggaatggcgt gaggtgcata atgccaagac aaagcccgcg 1440
gaggagcagt tcaacagcac gtaccgtgtg gtcagcgtcc tcaccgtctt gcaccaggac 1500
tggctgaacg gcaaggagta caagtgcagg gtctccaaca aaggcctccc gtcttccatc 1560
gagaaaacca tctccaaagc caaagggtgg acccacgggg tgcgagggcc acatggacag 1620
aggtcagctc ggccacacct ctgcccctgg agtgaccgct gtgccaacct ctgtccctac 1680
agggcagccc cgagagccac aggtgtacac cctgccccta tccaggagg agatgaccaa 1740
gaaccaggtc agcctgacct gctgtgtcaa aggtctctac cccagcgaca tgcgctgga 1800
gtgggagagc aatgggcagc cggagaacaa ctacaagacc acgctctccg tgcctggact 1860
cgacggctct ttcttctctt acagcaggct aaccgtggac aagagcaggt ggcaggaggg 1920
gaatgtcttc tcatgtctcg tgatgcata ggctctgac aaccactaca cacagaagag 1980
cctctccctg tctctgggta aatga 2005

```

<210> 18

<211> 468

<212> PRT

<213> Artificial sequence

<220>

<223> ChC7-hG2G4 Heavy chain (genomic sequence hG2G4)

<400> 18

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
Val His Ser Leu Glu Val Gln Leu Gln Ser Gly Pro Glu Leu Glu
20 25 30
Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser
35 40 45
Phe Thr Gly Tyr Asn Met Asn Trp Val Lys Gln Ser Ser Gly Lys Ser
50 55 60
Leu Glu Trp Ile Gly Asn Phe Asp Pro Tyr Tyr Gly Val Ile Thr Tyr
65 70 75 80
Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
85 90 95
Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110
Val Tyr Tyr Cys Ala Arg Thr Ala Thr Ala Leu Tyr Thr Met Asp Tyr
115 120 125
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly
130 135 140
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
145 150 155 160
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
165 170 175
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
180 185 190
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Val Val
195 200 205
Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val
210 215 220

```

```

Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys
225 230 235 240
Cys Cys Val Glu Cys Pro Pro Cys Pro Gly Lys Pro Ala Pro Pro Val
245 250 255
Ala Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu
260 265 270
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
275 280 285
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
290 295 300
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
305 310 315 320
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
325 330 335
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
340 345 350
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
355 360 365
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
370 375 380
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
385 390 395 400
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
405 410 415
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
420 425 430
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
435 440 445
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
450 455 460
Ser Leu Gly Lys
465

```

<210> 19

<211> 2025

<212> DNA

<213> Artificial Sequence

<220>

<223> D1B5-hG1 Heavy chain (genomic sequence hG1 constant region)

<400> 19

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacagggtg ccactccctc 60
gagggtccaac tgcagcagcc tggggcagag cttgtgaggt caggggccc c agtcaagttg 120
tcctgcaaag ctcttggtct caacattaaa gactactata tacactgggt gaagcagagg 180
cctgaacagg gcctggagtg gattggatgg attgatcctg agattggtgc tactaaatat 240
gtcccgaagt tccagggcaa ggccactatg actacagaca catcttccaa cacagcctac 300
ctgcagctca gcagcctgac atctgaggac actgccgtct attactgtaa tgcctcttat 360
ggtaactacg accgttacta tgctatggac tactggggtc aaggaaacct agtcaccgtc 420
tcctcagcct ccaccaagg cccatcggtc ttccccctgg caccctccct caagagcacc 480
tctggcggca cagcggccct gggctgcctg gtcaaggact acttccccga accggtagcg 540
gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttccccgc tgtcttacag 600
tcctcaggac tctactcctt cagcagcgtg gtgaccgtgc cctccagcag cttgggcacc 660
cagacctaca tctgcaactg gaatcacaag ccagcaaca ccaagggtga caagagagtt 720
ggtgagaggg cagcacagg agggagggtg tctgttgaa gccaggctca gcgtctctgc 780
ctggacgcac tgggctatg cagtcccagt ccagggcagc aaggcaggcc cgtctgtcct 840
cttcaccctg aggcctctgc ccgcccact catgtcagg gagagggtct tctggctttt 900
tcccaggct ctggcaggc acaggctagg tgcccctaac ccaggccctg cacacaaagg 960
ggcagggtgt gggctcagac ctgccaagag ccatatccgg gaggaccctg cccctgacct 1020
aagcccaccc caaaggccaa acttcccact cctcagctc ggacaccttc tctctccca 1080
gattccagta actcccaatc ttctctctgc agagccaaa tcttgtgaca aaactcacac 1140
atgccacacg tgcccaggtc agccagccca ggctcgccc tccagctcaa ggcgggacag 1200
gtgcccctga gtgacctgca tccagggaca ggcaccagcc ggggtgtgac acgtccacct 1260
ccatctcttc ctcagcactt gaactcctgg ggggaccgtc agtcttcttc ttcccccaa 1320
aaccacaagg caccctcatg atctcccga cccctgaggt cacatgcgtg gtggtggacg 1380
tgagccacga agaccctgag gtcaagttca actggtactg ggacggcgtg gaggtgcata 1440

```

```

atgccaaagac aaagccgcgg gaggagcagt acaacagcac gaccgtgtg gtcagcgtcc 1500
tcaccgtctc gcaccaggac tggctgaatg gcaaggagta caagtgcagg gtctccaaca 1560
aagccctccc agcccccatt gagaaaaacca tctccaaagc caaagggtggg acccggtggg 1620
tgcgagggcc acatggacag agggcggctc gggccaccct ctgcccctgag agtgaccgct 1680
gtaccaactc ctgtccctac agggcagccc cgagaaccac aggtgtacac cctgccccca 1740
tcccgggagg agatgaccaa gaaccaggtc agcctgacct gcctgggtcaa aggccttctat 1800
cccagcgaca tcgcccgtgg gtgggagagc aatgggcagc cgagaacaa ctacaagacc 1860
acgcctcccg tgctggactc cgacggctcc ttcttctct atagcaagct caccgtggac 1920
aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac 1980
aaccactaca cgagaagag cctctccctg tccccgggta aatga 2025

```

<210> 20

<211> 472

<212> PRT

<213> Artificial sequence

<220>

<223> D1B5-hG1 Heavy chain

<400> 20

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1      5      10      15
Val His Ser Leu Glu Val Gln Leu Gln Pro Gly Ala Glu Leu Val
20     25     30
Arg Ser Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn
35     40     45
Ile Lys Asp Tyr Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly
50     55     60
Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Ile Gly Ala Thr Lys Tyr
65     70     75
Val Pro Lys Phe Gln Gly Lys Ala Thr Met Thr Thr Asp Thr Ser Ser
85     90     95
Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala
100    105    110
Val Tyr Tyr Cys Asn Ala Leu Tyr Gly Asn Tyr Asp Arg Tyr Tyr Ala
115    120    125
Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser
130    135    140
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
145    150    155
Ser Gly Gly Thr Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
165    170    175
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
180    185    190
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
195    200    205
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
210    215    220
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val
225    230    235
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
245    250    255
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
260    265    270
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
275    280    285
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
290    295    300
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
305    310    315
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
325    330    335
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
340    345    350
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
355    360    365
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
370    375    380

```

```

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
385    390    395
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
405    410    415
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
420    425    430
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
435    440    445
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
450    455    460
Ser Leu Ser Leu Ser Pro Gly Lys
465    470

```

<210> 21

<211> 2026

<212> DNA

<213> Artificial Sequence

<220>

<223> G2G4 63L1D Heavy chain (genomic sequence hG2G4)

<400> 21

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcccag 60
atgcagctgg tgcagctcgg ggctgagggt aagaagcctg ggctctcggg gaaggctctc 120
tgcaaggcct ctggaggcac cttcagcaac tatgctacca gttgggtgcg acaggccctc 180
ggacaagggtc ttgagtggct gggagggtatc atccccgtct tcgggtactgc aaactacgca 240
cagaagtctc agggcagagt caccattacc gcggacgagt ccacgagcac agcctacatg 300
gagttgaata gcttgacatt tgacgacacg gccgtctatt actgtgcgag agggggtggg 360
ggatggggag gccggaacta ctactactac tactacatgg acgtctgggg caaagggaacc 420
actgtcaccg tctctcagc ctcaccaag ggccatccg tcttccccct gccgcccctg 480
tccaggagca cctcagag cccagccgct ctgggtgctg tgggtcaagg ctacttcccc 540
gaaccggtga cgggtgctg gaactcagg gccctgacca gcggcggtga cacttccccg 600
gctgtctctac agtctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc 660
aacttcggca cccagaccta cactgcaac gtagatcaca agccacgcaa caccagggtg 720
gacaagacag ttggtgagag gccagctcag ggaggggagg tgtctgctgg aagccaggct 780
cagccctcct gccctggagc accccggctg tgcaagccca gccaggggca gcaaggcagg 840
ccccatctgt cctctcacc ggaggcctct gcccgccca ctcatgtca gggagagggt 900
cttctggctt tttccaccag gctccaggca ggcaaggtt ggggtgccct accccaggcc 960
cttcacacac aggggcaggt gcttggctca gacctgcaa aagccatctc cgggaggacc 1020
ctgcccctga cctaaagcga ccccaaaggc caaactgtcc actccctcag ctgggacacc 1080
ttctctcttc ccagatccga gtaactccca atcttctctc tgcagagcgc aaatgttgtg 1140
tcgagtgcct accgtgcca ggttaagccag cccaggcctc gccctccagc tcaaggcggg 1200
acaggtgccc tagagtacc tgcattcagg gacaggcccc agctgggtgc tgacacgtcc 1260
acctccatct ctctctcag accactgtg gcaggaccgt cagtcttctc cttcccccca 1320
aaacccaagg acaccctcat gatctcccg accctgagg tcagtgctgt ggtggtggac 1380
gtgagccagg aagaccccga ggtccagttc aactggtacg tggatggctg ggaggtgcat 1440
aatgccaaag caaagccgag ggaggagcag ttcaacagca cgtaccgtgt ggtcagctgc 1500
ctcacctgct tgcaccagga ctggctgaac ggcaaggagt acaagtgcga ggtctccaac 1560
aaaggcctcc cgtctctcat cgagaaaacc atctccaaag ccaagggtgg gacccacggg 1620
gtgagggggc cacatggaca gaggtcagct cggccaccc tctgcccctg gagtaccgc 1680
tgtgccaacc tctgtcccta cagggcagcc ccgagagcca cagggtgtaca cctgcccccc 1740
atccaggag gagatgacca agaaccaggt cagcctgacc tgcctgttca aaggcttcta 1800
ccccagcgac atcgccgtgg agtgggagag caatgggag cgggagaaca actacaagac 1860
cagcctccc gtgtggact ccgacggctc cttcttctc tacagcagc taaccgtgga 1920
caagagcagg tggcaggagg ggaatgtctt ctcatgtccc gtgatgcatg aggcctctga 1980
caaccatac acacagaaga gcctctccct gtctctgggt aaatga 2026

```

<210> 22

<211> 472

<212> PRT

<213> Artificial Sequence

<220>

<223> G2G4 63L1D Heavy chain

<400> 22

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

```

1      5      10      15
Val His Ser Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20      25      30
Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe
35      40      45
Ser Asn Tyr Ala Thr Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50      55      60
Glu Trp Leu Gly Gly Ile Ile Pro Val Phe Gly Thr Ala Asn Tyr Ala
65      70      75      80
Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser
85      90      95
Thr Ala Tyr Met Glu Leu Asn Ser Leu Thr Phe Asp Asp Thr Ala Val
100      105      110
Tyr Tyr Cys Ala Arg Gly Gly Gly Gly Trp Gly Gly Arg Asn Tyr Tyr
115      120      125
Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val
130      135      140
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
145      150      155      160
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
165      170      175
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
180      185      190
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
195      200      205
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr
210      215      220
Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val
225      230      235      240
Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro
245      250      255
Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
260      265      270
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
275      280      285
Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val
290      295      300
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
305      310      315      320
Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
325      330      335
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly
340      345      350
Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
355      360      365
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Met Thr
370      375      380
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
385      390      395      400
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
405      410      415
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
420      425      430
Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe
435      440      445
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
450      455      460
Ser Leu Ser Leu Ser Leu Gly Lys
465      470

```

<210> 23

<211> 705

<212> DNA

<213> Artificial Sequence

<220>

<223> Light Chain chC2aB7-hG1, human Ck

<400> 23

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactctaga 60
gacatccaga tgacacagtc tccatcttcc atgtatgcat ctctaggaga gagagtca 120
atcacttgca aggcgagtcg ggacattaat agctatttaa gctgggtcca gcagaaacca 180
gggaaatctc ctaagaccct gatctatcgt gcaaacagat tggtagatgg ggttccatca 240
aggttcagtg gcagtggatc tgggcaagat tattctctca ccacagcagc cctggagtat 300
gaagatatgg gaatttatta ttgtctacag tatgatgagt ttccgtacac gttcggaggg 360
gggaccaagc tggaaataaa acggactgtg gctgcacccat ctgtcttcat cttcccgcga 420
tctgatgagc agttgaaatc tggaaactgcc tctgttggtg gcctgctgaa taacttctat 480
cccagagagg ccaaagtaca gtggaagggt gataacgccc tccaatcgga taactcccag 540
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600
ctgagcaaa gactactaga gaaacacaaa gtctacgcct gcgaagtcac ccacagggc 660
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gtttaa 705

```

<210> 24

<211> 234

<212> PRT

<213> Artificial Sequence

<220>

<223> Light Chain chC2aB7-hG1, human Ck

<400> 24

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1      5      10      15
Val His Ser Arg Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Met Tyr
20      25      30
Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp
35      40      45
Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro
50      55      60
Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser
65      70      75      80
Arg Phe Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser
85      90      95
Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp
100     105     110
Glu Phe Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
115     120     125
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
130     135     140
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145     150     155     160
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
165     170     175
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
180     185     190
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195     200     205
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
210     215     220
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225     230

```

<210> 25

<211> 711

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7V4V1-hG1 light chain

<400> 25

```

atggacatga gggctctctgc tcagctcctgc gggctcctgc tgctctggct ctcaggagcc 60
agatgtgaca tccagatgac acagctctcca tcttccctgt ctgcatctat aggagacaga 120
gtcactatca cttgcaaggc gagtcaggac attaatagct atttaagctg gtaccagcag 180

```

```

aaaccaggga aagctcctaa gtccctgac tctcgtgcaa acagattggg agatgggggt 240
ccatcaaggt tcagtggcag tggatctggg acagattata ctctcaccat cagcagcctg 300
cagcctgaag atttcgcagt ttattatgt ctacagtatg atgagtttcc gtacacgttc 360
ggagggggga ccaagctgga aataaaacgt acgggtggctg caccatctgt cttcatcttc 420
ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 480
ttctatccca gagaggccaa agtacagtgg aaggtggata acgcccctcca atcgggtaac 540
tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc 600
ctgacgctga gcaaaagcaga ctacgagaaa cacaaggtct acgcctgcga agtcacccat 660
cagggcctga gctcgcccgt cacaagagac ttcaacaggg gagagtgtta g 711

```

<210> 26

<211> 236

<212> PRT

<213> Artificial Sequence

<220>

<223> hB7V4V1-hGI Light chain (human ck)

<400> 26

```

Met Asp Met Arg Val Ser Ala Gln Leu Leu Gly Leu Leu Leu Trp
1      5      10      15
Leu Ser Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
20     25     30
Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser
35     40     45
Gln Asp Ile Asn Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys
50     55     60
Ala Pro Lys Ser Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val
65     70     75     80
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr
85     90     95
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln
100    105    110
Tyr Asp Glu Phe Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile
115    120    125
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
130    135    140
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
145    150    155    160
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
165    170    175
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
180    185    190
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
195    200    205
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
210    215    220
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225    230    235

```

<210> 27

<211> 711

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7v3v2-hG1 Light chain

<400> 27

```

atggacatga gggctctgct tcagctcctg gggctcctgc tgctctggct ctcagggggcc 60
agggtgtgaca tccagatgac acagtcctcca tcttccctgt ctgcatctat aggagacaga 120
gtcactatca cttgcaaggc gagtcaggac attaatagct atttaagctg gttccagcag 180
aaaccagggg aagctcctaa gctgctgac tatcgtgcaa acagattggt agatgggggt 240
ccatcaaggt tcagtggcag tggattctggg acagattata ctctcccat cagcagcctg 300
cagcctgaag atttcgcagt ttattattgt ctacagtatg atgagtttcc gtacacgttc 360
ggagggggga ccaagctgga aataaaacgt acggtggctg caccatctgt cttcatcttc 420
ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 480

```

```

ttctatccca gagaggccaa agtacagtgg aaggtggata acgccctcca atcgggtaac 540
tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc 600
ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga agtcacccat 660
cagggcctga gctcgccctg cacaagagc ttcaacaggg gagagtgtta g 711

```

<210> 28

<211> 236

<212> PRT

<213> Artificial Sequence

<220>

<223> hB7v3v2-hG1 Light chain (human ck)

<400> 28

```

Met Asp Met Arg Val Ser Ala Gln Leu Leu Gly Leu Leu Leu Trp
1      5      10      15
Leu Ser Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
20     25     30
Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser
35     40     45
Gln Asp Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys
50     55     60
Ala Pro Lys Leu Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val
65     70     75     80
Pro Ser Arg Phe Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr
85     90     95
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln
100    105    110
Tyr Asp Glu Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
115    120    125
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
130    135    140
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
145    150    155    160
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
165    170    175
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Lys Asp
180    185    190
Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
195    200    205
Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
210    215    220
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225    230    235

```

<210> 29

<211> 708

<212> DNA

<213> Artificial Sequence

<220>

<223> Chc7-hG2G4 Light chain

<400> 29

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactctaga 60
gaaattgtgc tcacccagtc tccagcaatc atgtctgcat ctccagggga aaaggtcacc 120
atgacctgca gggccagctc aagtgttaagt tccagttact tgcactggta ccagcagaag 180
tcagggtgcct ccccaaaact ctggatttat agcacatcca acttggcttc tggagtccct 240
gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagtgtggag 300
gctgaagatg ctgccactta ttactgccag cagtacagtg gttaccact cactttcggc 360
tcggggacaa agttggaagt aaaacggact gtggctgcac catctgtctt catcttccc 420
ccatccgatg agcagttgaa atctggaact gccctgttg tgtgctgct gaataacttc 480
tatccagag aggccaaagt acagtggag gtggataacg cccccaatc gggtaacttc 540
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccttg 600
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt caccatcag 660
ggcctgagct cgcccgctac aaagagcttc aacaggggag agtggttaa 708

```

<210> 30

<211> 235

<212> PRT

<213> Artificial Sequence

<220>

<223> ChC7-hG2G4 Light chain (human ck)

<400> 30

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1      5      10      15
Val His Ser Arg Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser
20      25      30
Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser
35      40      45
Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser
50      55      60
Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro
65      70      75      80
Ala Arg Phe Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85      90      95
Ser Ser Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr
100      105      110
Ser Gly Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
115      120      125
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
130      135      140
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
145      150      155      160
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
165      170      175
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
180      185      190
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
195      200      205
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
210      215      220
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225      230      235

```

<210> 31

<211> 705

<212> DNA

<213> Artificial Sequence

<220>

<223> D1B5-hG1 Light chain

<400> 31

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactctaga 60
gacattgtga tgacccagtc tcaaaaattc atgtccacat cagtaggaga cagggtcagc 120
atcacctgca aggccagtcg gaatgttcgt actgctgtag cctgggtatca acagaaacca 180
gggcagtctc ctaaagcact gatttacttg gcatccaacc ggcacactgg agtccttgat 240
cgcttcacag gcagtggatc tgggacagat ttactctca ccattagcaa tgtgcaatct 300
gaagacctgg cagattatct ctgtctgcaa cattggaatt atctcttcac gttcggtyct 360
gggaccaagc tggagctgaa acggactgtg gctgcacat ctgtcttcac ctccccgcca 420
tctgatgagc agttgaaatc tggaaactgc tctgttgtgt gcctgttgaa taacttctat 480
cccagagagg ccaaagtaca gtggaagggt gataacgccc tccaatcggg taactcccag 540
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcaa caccctgacg 600
ctgagcaaa cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 660
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttaa 705

```

<210> 32

<211> 234

<212> PRT

<213> Artificial Sequence

<220>

<223> D1B5-hG1 Light chain (human ck)

<400> 32

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
Val His Ser Arg Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser
20 25 30
Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn
35 40 45
Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
50 55 60
Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp
65 70 75 80
Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95
Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp
100 105 110
Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
115 120 125
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
130 135 140
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145 150 155 160
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
165 170 175
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
180 185 190
Tyr Ser Leu Ser Asn Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195 200 205
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
210 215 220
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230

```

<210> 33

<211> 696

<212> DNA

<213> Artificial Sequence

<220>

<223> G2G4 63L1D Light chain

<400> 33

```

atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcttcc 60
tatgtgctga ctacgccacc ctcgaggtca gtggccccag gacagacggc caggatttcc 120
tgtgggggga gcaacattgg aagttacggt gtgcactggg accagcagaa ggcaggacag 180
gccccgtgct tggctgtcca tgatgatgcc gaccggccct cagggattcc tgagcgattc 240
tctggctcca attctgggaa cacggccacc ctgacctca gcagtgtcga agccggcgat 300
gaggccgact attactgtca ggtgtgggat aatagtgtct tgatattcgg cggaggagac 360
aaactaacgc tcctaagtca gcccaaggct gccccctcgg tcactctgtt cccgccctcc 420
tctgaggagc ttcaagccaa caaggccaca ctggtgtgtc tcataagtga cttctaccgc 480
ggagctgtga cagtggcttg gaaagcagat agcagccccg tcaaggcggg agtggagacc 540
accacacctt ccaaacaaag caacaacaag tacgcggcca gcagctatct gagcctgacg 600
cctgagcagt ggaagtcca cagaagctac agctgccagg tcacgcatag agggagcacc 660
gtggagaaga cagtggcccc tacagaatgt tcataa 696

```

<210> 34

<211> 231

<212> PRT

<213> Artificial sequence

<220>

<223> G2G4 63L1D Light chain (human CL)

<400> 34

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

```

```

1      5      10      15
Val His Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Glu Ser Val Ala
20      35      40      45      50      55      60      65      70      75      80
Pro Gly Gln Thr Ala Arg Ile Ser Cys Gly Gly Ser Asn Ile Gly Ser
35      40      45      50      55      60      65      70      75      80
Tyr Gly Val His Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Val Leu
50      55      60      65      70      75      80      85      90      95      100
Val Val His Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe
65      70      75      80      85      90      95      100      105      110      115
Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Val
85      90      95      100      105      110      115      120      125      130      135
Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Ser
100      105      110      115      120      125      130      135      140      145      150
Ala Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Gln Pro
115      120      125      130      135      140      145      150      155      160      165
Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
130      135      140      145      150      155      160      165      170      175      180
Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro
145      150      155      160      165      170      175      180      185      190      195
Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
165      170      175      180      185      190      195      200      205      210      215
Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
180      185      190      195      200      205      210      215      220      225      230
Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
195      200      205      210      215      220      225      230      235      240      245
Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
210      215      220      225      230      235      240      245      250      255      260
Val Ala Pro Thr Glu Cys Ser
225      230      235      240      245      250      255      260      265      270      275

```

<210> 35

<211> 31

<212> DNA

<213> Artificial sequence

<220>

<223> forward primer

<400> 35

gacaagcttg caaggatgga gaggtgggtg a 31

<210> 36

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer

<400> 36

gacggatccg ccccttttcc tctgtcttt ctc 33

<210> 37

<211> 2160

<212> DNA

<213> Artificial Sequence

<220>

<223> chC2aB7-hG1 Heavy chain

<400> 37

```

gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt 60
ctgcagtcac cgtccttgac acgaggcgcg ccgccaccat gggatggagc tgtatcatcc 120
tcttcttggt agcaacagct acaggtgtcc actccctcga ggtccagctg caacagctctg 180
gacctgagct ggtgaagcct ggggcttcac tgaagatgtc ctgcaaggct tctggttatt 240
cattcactga ctacatcata ctctgggtga agcagaacca tggaaagagc cttgagtggg 300
ttggacatat tgatccttac tatggtagtt ctaactacaa tctgaaattc aagggcaagg 360

```

```

ccacattgac tgtagacaaa tcttcagca cagcctacat gcagctcaac agtctgacat 420
ctgaggactc tgcagtctat tactgtggaa gatctaagag ggactacttt gactactggg 480
gccaaaggac cactctcaca gtttcttcag cctccaccaaa gggcccatcg gtcttcccc 540
tggcaccctc ctccaagagc acctctggcg gcacagcggc cctgggctgc ctggtaacagg 600
actacttccc cgaaccgggtg acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc 660
acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc gtggtgaccg 720
tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac aagcccagca 780
acaccaaggt ggacaagaga gttggtgaga ggccagcaca gggaggaggg gtgtctgctg 840
gaagccaggc tcagcgtctc tgccctggacg catcccggct atgcagtccc agtcagggc 900
agcaaggcag gccccgtctg cctcttcacc cggaggcctc tgcccgcccc actcatgctc 960
agggagaggg tcttctggct ttttccccag gctctgggca ggcacaggct aggtgcccc 1020
aaccagggtc ctgcacacaa aggggcagggt gctgggctca gacctgcaa gagccatc 1080
cgggagagacc ctgccccgta cctaagccca ccccaaaggc caaactctcc actccctcag 1140
ctcggacacc ttctctcttc ccagattcca gtaactccca atcttctctc tgcagagccc 1200
aaatcttgtg acaaaactca cacatgccca ccgtgccag gtaagccagc ccaggcctcg 1260
ccctccagct caaggcgagg accgtgccct agagttagct gcattccagg acaggcccca 1320
gccgggtgct gacacgtcca cctccatctc ttctcagca cctgaactcc tggggggacc 1380
gtcagttctt ctcttcccc caaaacccaa ggacacctc atgattccc ggaacctga 1440
ggtcacatgc gtggtgtgtg acgtgagcca cgaagacct gaggtcaagt tcaactgcta 1500
cgtggcaggc gtggaggtgc ataagccaa gacaaagccg cgggaggagc agtaacacag 1560
cagctaccgt gtggtcagcg tctcaccgt cctgcaccag gactggctga atggcaagga 1620
gtacaagtgc aaggtctcca acaaagcct cccagcccc atcgagaaaa ccattcccaa 1680
agccaaaggt gggaccgtg ggggtcgagg gccacatgga cagaggccgg ctcggcccat 1740
cctctgcccc gatagtgacc gctgtaccaa cctctgtccc tacaggcgag ccccgagaa 1800
cacagggtga caccctgccc ccattccggg aggagatgac caagaaccag gtcagcctga 1860
cctgccttgt caaaggcttc tatcccgagc acatcgccgt ggagtgggag agcaatgggc 1920
agccggagaa caactacaag accacgctc ccgtgctgga ctccgacggc tccttcttcc 1980
tctatagcaa gctaccgtg gacaagagca ggtggcagca ggggaacgtc ttctcatgct 2040
ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc ctgtccccgg 2100
gtaaatgagt gcgacggcca gaattcatt atcataatca gccataccac attttagtag 2160

```

<210> 38

<211> 720

<212> DNA

<213> Artificial Sequence

<220>

<223> chc2aB7-hG1 Light chain

<400> 38

```

aagcttgccg ccaccatggg atggagctgt atcatcctct tcttggtagc aacagctaca 60
gggtccagct ctgagagact ccagatgaca cagtctccat ctctcatgta tgcattctca 120
ggagagagag tcactatcac ttgcaaggcg agtcaggaca ttaatagcta tttaagctgg 180
ttccagcaga aaccagggaa atctcttaag acctgtatct atcgtgcaaa cagatttgta 240
gatgggggtt ctacaagggt cagtggcagt ggtatctggg aagattatct tctcaccatc 300
agcagctcgg agtatgaaga tatgggaatt tattattgtc tacagtatga tgaatttccg 360
tacacgttgc gaggggggac caagctggaa ataaaaagca ctgtggctgc accattctgc 420
ttcatcttcc cgcatctgta tgagcagttg aaatctggaa ctgcctctgt tgtgtgctcg 480
ctgaataact tctatccag agaggccaaa gtacagtgga aggtggataa cgccctccaa 540
tcgggttaact cccaggagag tgctacagag caggacagca aggcagcac ctacagctc 600
agcagcacc tgacgtctgag caaagcagac tacgagaaac acaagtcta cgcttgcgaa 660
gtcaccatc agggcctgag ctgcgccgtc acaagagct tcaacagggg agagtgttaa 720

```

<210> 39

<211> 1402

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7v4v1-hG1 Heavy chain

<400> 39

```

catgggatgg agctggatct ttctctttct cctgtcagta actgcagggtg tgttctctga 60
gggtccagct gtggagtcag gacctgaggt gaagaagcct ggggcttcag tgaagggtgc 120
ctgcaaggct tctggttatt cattcactga ctacatcata ctctggatca ggcagcatag 180
cggaaagggc cttgagtgga ttggacatat tgatccttac tatggtagtt ctaactacaa 240

```

```

tctgaaattc aagggcaggg tcacaatcac tgcagacaaa tctaccagga caacctacat 300
ggagctcacc agtctgacat ctgaggacac tgcagtctat tactgtggaa gatctaagag 360
ggactacttt gactacttgg gccaaaggac cactctcaca gtttcttcag cctccacca 420
gggcccacatg gtcttccgc tagcaccctc ctccaagagc acctctgggg gcacagcggc 480
cctgggctgc ctggtaagg actacttccc cgaaccgggt acggtgtcgt ggaactcagg 540
cgccctgacc agcggcgtgc acaccttccc ggctgttcta cagtctcag gactctactc 600
cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa 660
cgtgaatcac aagcccagca acaccaaggt ggacaagaga gttgagccca aatcttgtga 720
caaaaactcac acatgcccac cgtgccagc acctgaactc ctgggggggac cgtcagttct 780
cctcttcccc ccaaaaccca aggcacacct catgatctcc cggaccctgt aggtcacatg 840
cgtgtgtgtg gacgtgagcc acgaagacc tgaggtcaag ttcaacttgt acgtggacgg 900
cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcactaccg 960
tgtgtcagc gtctcaccg tcttgacca ggaactggct aatggcaagg agtaacagt 1020
caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg 1080
gcagccccga gaaccacagg tgtacacct gccccatcc cgggaggaga tgaccaagaa 1140
ccaggtcagc ctgacttgc ttgtcaaagg ctcttatccc agcagcatcg ccgtggagt 1200
ggagagcaat gggcagccgg agaacaacta caagaccag cctccggtgc tggactccga 1260
cggctcttcc ttctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa 1320
cgtcttctca tgctcgtgga tgcagaggc tctgcacaa cactacacgc agaagagcct 1380
ctccctgtct ccgggttaaa ga 1402

```

<210> 40
 <211> 765
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> hB7v4V1-hG1 and hB7v3v1-hG1 Light chains

<400> 40
 tttccatggg tcttttctgc agtcaccgtc cttgacacga agcttgccgc caccatggac 60
 atgaggggtct ctgctcagct cctggggctc ctgctgctct ggctctcagg agccagatgt 120
 gacatccaga tgacacagtc tccatcttcc ctgtctgcat ctataggaga cagagtcact 180
 atcacttgca aggcgagtca ggacattaat agctatttaa gctggtagca gcagaaacca 240
 gggaaagctc ctaagtccct gatctatcgt gcaaacagat tggtagatgg ggttccatca 300
 aggttcagtg gcagtggaac tgggacagat tatactctca ccatcagcag cctgcagcct 360
 gaagatttctg cagtttatta ttgtctacag tatgatgagt ttccgtacac gttcggaggg 420
 gggaccaagc tggaaataaa acgtacggtg gctgcaccaa ctgtcttcat ctcccgcga 480
 tctgatgagc agttgaaatc tggaaactgcc tctgttgtgt gcctgctgaa taacttctat 540
 cccagagagg ccaaagtaca gtggaagggtg gataacgccc tccaatcggg taactcccag 600
 gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 660
 ctgagcaaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 720
 ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 765

<210> 41
 <211> 1402
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> hB7V3v1-hG1 and hB7v3v2-hG1 Heavy chains

<400> 41
 catgggatgg agccgatct tctcttctct cctgtcaata attgcagggtg tccattgcca 60
 ggtccagctg caacagctctg gatctgagct gaagaagcct ggggcttcag tgaagatctc 120
 ctgcaaggct tctgggttatt cattcactga ctacatcata ctctgggtga ggcagaaccc 180
 tggaaagggtc cttgagtggg ttggacatat tgatccttac tatggtagtt ctaactacaa 240
 tctgaaattc aagggcagag tgacaatcac cggcgaccag tctaccacca cagcctacat 300
 ggagctctcc agtctgagat ctgaggacac tgcagtctat tactgtggaa gatctaagag 360
 ggactacttt gactactggg gccaaaggac cactctcaca gtttctcag cctccaccaa 420
 gggcccatcg gtcttcccg tagcaccttc ctccaagagc acctctgggg gcacagcggc 480
 cctgggctgc ctggtcaagg actactctcc cgaacccgtg acggtgtctg ggaactcagg 540
 cgccctgacc agcggcggtg acaccttccc ggctgtccta cagtcctcag gacttactc 600
 ctctacagcag gtggtgaccg tgccctccag cagcttgggg acccagacct acatctgcaa 660
 cgtgaatcac aagccacga acaccaaggt ggacaagaga gttgagccca aatcttgtga 720
 caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagttct 780
 cctcttcccc ccaaaacca aggacacct catgatctcc cggactcctg aggtcacatg 840
 cgtggtggtg gacgtgagcc acgaagacct tgaggtcaag ttcaactggg acgtggacgg 900
 --
 cgtggaggtg cataatgcc agacaaagcc gcgggaggag cagtacaaca gcacgtaccg 960
 tgtggtcagc gtcttcccg tctgcacca ggaactggctg aatggcaagg agtacaagtg 1020
 caagggtctc acaaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg 1080
 ccagccccga gaaccacagg tgtacacctc gcccccactc cgggaggaga tgaccaagaa 1140
 ccaggtcagc ctgacctgct tggcacaagg cttctatccc agcgacatcg ccgtggagtg 1200
 ggagagcaat gggcagcctg agaacaacta caagaccacg cctcccgctg tggactccga 1260
 cggctccttc ttctcttaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa 1320
 cgtcttctca tgctcctgta tgcagaggc tctgcacaac cactacacgc agaagagcct 1380
 ctccctgtct ccggttaaat ga 1402

<210> 42
 <211> 765
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> hB7v3v2-hG1 and hB7v3v2-hG2G4 Light chains

<400> 42
 tttccatggg tcttttctgc agtcaccgtc cttgacacga agcttgccgc caccatggac 60
 atgaggggtct ctgctcagct cctggggctc ctgctgctct ggctctcagg ggccaggtgt 120
 gacatccaga tgacacagtc tccatcttcc ctgtctgcat ctataggaga cagagtcact 180
 atcacttgca aggcgagtca ggacattaat agctatttaa gctgggtcca gcagaaacca 240
 gggaaagctc ctaagtctct gatctatcgt gcaaacagat tggtagatgg ggttccatca 300
 aggttcagtg gcagtggaac tgggacagat tatactctca ccatcagcag cctgcagcct 360
 gaagatttctg cagtttatta ttgtctacag tatgatgagt ttccgtacac gttcggaggg 420
 gggaccaagc tggaaataaa acgtacggtg gctgcaccaa ctgtcttcat ctcccgcga 480
 tctgatgagc agttgaaatc tggaaactgcc tctgttgtgt gcctgctgaa taacttctat 540
 cccagagagg ccaaagtaca gtggaagggtg gataacgccc tccaatcggg taactcccag 600
 gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 660
 ctgagcaaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 720
 ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 765

<210> 43

<211> 2159

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7v3v2-hG2G4 Heavy chain

<400> 43

```

ccaccagaca taatagctga cagactaaca gactgttctt ttccatgggt cttttctgca 60
gtcaccgtcc ttgacacgaa gcttgccgcc accatgggat ggagccggat ctttctcttc 120
ctcctgtcaa taattgcagg tgtccattgc caggtccagc tgcaacagtc tggatctgag 180
ctgaagaagc ctggggcttc agtgaagatc tcctgcaagg cttctgggta ttcatctact 240
gactacatca tactctgggt gaggcagaac cctggaaaagg gccttgagtg gattggacat 300
attgatcctt actatggtag ttctaactac aatctgaaat tcaaggcgag agtgacaatc 360
accgccgacc agtctaccac cacagcctac atggagctct ccagictgag atctgaggac 420
actgcagtct attactgtgg aagatctaag agggactact ttgactactg gggccaaggc 480
accactctca cagtttcttc agcctccacc aagggcccat ccgtcttccc cctggcgccc 540
tgctccagga gcactctcga gagcacagcc gccctgggct gcctgggtcaa ggactacttc 600
cccgaaccgg tgacgggtgc gtggaactca ggcgccttga ccagcggcgt gcacaccttc 660
ccggtgtctc tacagtcttc aggactctac tccctcagca gcgtggtgac cgtgcccttc 720
agcaactctg gcaccagac ctacacctgc aacgtagatc acaagcccag caacaccaag 780
gtggacaaga cagttgggtg gaggccagct cagggaggga ggggtgtctg tgggaagccag 840
gctcagccct cctgcctgga cgcaccccg cgtgtcagcc ccagcccagg gcagcaaggc 900
aggccctc cctgtctctc cccggaggcc tctgcccgc ccactcatgc tcaggagag 960
gggtcttctg cttttctcac caggctccag gcaggcacag gctgggtgcc cctaccccag 1020
gcccttcaca cacaggggca ggtgcttggc tcagacctgc caaaagccat atccgggagg 1080
accctgcccc tgacttaagc cgaccccaaa ggcctaaact tccactccct cagctcgagc 1140
accctctctc ctccagatc cgagtaactc ccaatcttct ctctgcagag cgcaaatggt 1200
gtgtcgagtg cccacctgct ccagtaagc cagcccaggc ctgcctcttc agctcaaggc 1260
gggacaggtg ccttagatga gcttgcattc agggacaggg ccgctgggt gctgacacgt 1320
ccactctcat ctcttctcga gcaccactg tggcaggacc gtcagtcttc ctcttcccc 1380
caaaacccaa ggacacccct atgatctccc ggacccttga ggtcacgtgc gtgtgtgtgg 1440
acgtgagcca cgtgagcccc aggttccagt tcaactggta cgtggatggc gtggaggtgc 1500
ataatgcca gacaaagccg cgggaggagc agttcaacag cacgtaccgt gtgtcagcg 1560

```

```

tcctcacctg cctgcaccag gactggctga acgccaagga gfacaagtgc aaggctctca 1620
acaaaggcct ccgtctcttc atcgagaaaa ccactctcaa agccaaagggt gggaccacg 1680
gggtgagagg gccacatgga cagaggtcag ctgcccac cctctgccc gggagtgacc 1740
gctgtgcaa cctctgtccc tacaggagag ccccgagagc cacaggtgta caccctgccc 1800
ccatccagg aggagatgac caagaaccag gtcagcctga cctgctgggt caaaggcttc 1860
tacccagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag 1920
accacgctc ccgtgctgga ctccgacggc tcttcttctc tctacagcag gctaaccgtg 1980
gacaagagca ggtggcagga ggggaatgtc ttctcatgct ccgtgatgca tgaggctctg 2040
cacaaccact acacacagaa gagcctctcc ctgtctctgg gtaaatgatg agaattcatt 2100
gatcataatc agccatacca cattgtaga ggttttactt gctttaaaaa acctccac 2159

```

<210> 44

<211> 1600

<212> DNA

<213> Artificial Sequence

<220>

<223> chC2aB7-hG2G4 Heavy chain

<400> 44

```

gctgacagac taacagactg ttcttttcca tgggtctttt ctgcagtcac cgtccttgac 60
acgaggcgcg ccgcccacat gggatggagc tgtatcatcc tcttcttggg agcaacagct 120
acagggtgct actccctcga ggtccagctg caacagtcgt gacctgagct ggtgaagcct 180
ggggcttcac tgaagatgct ctgcaaggct tctggttatt cattcactga ctacatcata 240
ctctgggtga agcagaacca tggaaagagc cttgagtggg ttggacatat tgatccttac 300
tatggtagtt ctaactacaa tctgaaattc aagggcaagg ccacattgac tgtagacaaa 360
tcttcagca cagcctacat gcagctcaac agtctgacat ctgaggactc tgcagtctat 420
tactgtggaa gatctaagag ggaactactt gactactggg gccaaaggc cactctcaca 480
gtttctctag ctccaccaa gggcccatcc gtcttcccc tggcgccctg ctccaggagc 540
accctcgaga gcacagcgcg cctgggtgct ctggtcaagg actacttccc cgaaccgggt 600
acgggtgtct ggaactcagg cgccctgacc agcggcgctg acaccttccc ggcgtgtccta 660
cagtcctcag gacttactc ctccagcagc gtggtgaccg tgccctccag caacttcggc 720
accagacct acactgcga cgtagatcac aagcccagca acaccaaggt ggacaagaca 780
gttgggtgaga ggccagctca gggaggagg gtgtctgctg gaagccaggc tcagcccttc 840
tgcttgagc caccctggct gtgcagccc agcccaggc agcaaggcag gccctactg 900
tctctcacc cggaggtctc tgcccgcctc actcatgctc agggagaggg tcttctggct 960
ttttccacca ggctccaggc aggcacaggg tgggtgcccc taccccaggc ctttcacaca 1020
caggggagc gtcttggtc agacctgcga aaagccatat ccgggaggac cctgcccctg 1080
acctaaagcg accccaaagg ccaaatgtct cactccctca gctcggacac cttctctct 1140
cccagatccg agtaactccc aatcttctct ctgcagagcg caaatgttgt gtcgagtgcc 1200
caccgtgccc aggtaaagcca gccagggcct cgccctccag ctcaaggcgg gacaggtgcc 1260
ctagagtgc ctgcatccag ggacaggccc cagctgggtg ctgacagctc caccctcatc 1320
tcttctcag caccactgt ggcaggacgg tcagtcttcc tcttcccccc aaaacccaag 1380
gacacctca tgatctccc gaccctgag gtcacgtgcg tgggtgtgga cgtgagccag 1440
gaagaccgg aggtccagtt caactggatc gtggatggcg tggaggtgca taatgccag 1500
acaaagccg gggaggagca gttcaacagc acgtaccctg tggtcagcgt cctcacgcgc 1560
ctgcaccagg actggctgaa cggcaaggag tacaagtcca

```

<210> 45

<211> 337

<212> PRT

<213> Artificial Sequence

<220>

<223> chC2aB7-hG2G4 Heavy chain

<400> 45

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 1      5      10      15
Val His Ser Leu Glu Val Gln Leu Gln Ser Gly Pro Glu Leu Val
 20     25     30
Lys Pro Gly Ala Ser Leu Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser
 35     40     45
Phe Thr Asp Tyr Ile Ile Leu Trp Val Lys Gln Asn His Gly Lys Ser
 50     55     60
Leu Glu Trp Ile Gly His Ile Asp Pro Tyr Tyr Gly Ser Ser Asn Tyr
 65     70     75     80
Asn Leu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
 85

```

```

      85      90      95
Ser Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
100     105     110
Val Tyr Tyr Cys Gly Arg Ser Lys Arg Asp Tyr Phe Asp Tyr Trp Gly
115     120     125
Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
130     135     140
Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala
145     150     155     160
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
165     170     175
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
180     185     190
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
195     200     205
Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His
210     215     220
Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys
225     230     235     240
Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val
245     250     255
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
260     265     270
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
275     280     285
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
290     295     300
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
305     310     315     320
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
325     330     335
cys

```

<210> 46

<211> 735

<212> DNA

<213> Artificial Sequence

<220>

<223> chC2aB7-hG2G4 Light chain

<400> 46

```

aagcttgccg ccaccatggg atggagctgt atcatcctct tcttggtagc aacagctaca 60
ggtgtccact cttagagacat ccagatgaca cagtctccat cttccatgta tgcattcagg 120
agagagagtc actatcactt gcaaggcgag tcaggacatt aatagctatt aagctgggtc 180
cagcagaaac caaggaaatc tcctaagacc ctgatctatc gtgcaaacag attggtagat 240
gggggttccat caagggttcag tggcagtggg tctgggcaag attattctct caccatcagc 300
agcctggagt atgaagatat gggaaattat tattgtctac agtatgatga gtttccgtac 360
acgttcggag ggggggaccaa gctggaaata aaacggactg tggctgcacc atctgtcttc 420
atcttcccgc catctgatga gcagttgaaa tctggaaactg cctctgttgt gtgcttgcgtg 480
aataacttct atcccagaga ggccaaagta cagtggaaagg tggataacgc cctccaatcg 540
ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600
agcaccctga gcctgagcaa agcagactac gagaacaca aagtctacgc ctgccaagtc 660
accatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttcagcg 720
gccgaattc attga
735

```

<210> 47

<211> 240

<212> PRT

<213> Artificial Sequence

<220>

<223> chC2aB7-hG2G4 Light chain

<400> 47

```

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 1

```

```

1      5      10      15
val His Ser Arg Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Met Tyr
20      25      30
Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp
35      40      45
Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro
50      55      60
Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser
65      70      75      80
Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser
85      90      95
Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp
100     105     110
Glu Phe Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
115     120     125
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
130     135     140
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145     150     155     160
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
165     170     175
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
180     185     190
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195     200     205
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
210     215     220
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser Ala Ala Ala Ile His
225     230     235     240

```

<210> 48

<211> 1560

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7v3v2-cG2G4 Heavy chain

<400> 48

```

ccaccagaca taatagctga cagactaaca gactgttcct ttccatgggt cttttctgca 60
gtcaccgtcc ttgacacgaa gcttgccgcc accatgggat ggagccggat ctttctcttc 120
ctcctgtcaa taattgcagg tgtccattgc cagggtccagc tgcaacagtc tggatctgag 180
ctgaagaagc ctggggcttc agtgaagatc tctgtcaagg cttctggtta ttcatctact 240
gactacatca tactctgggt gaggcagaac cctggaaagg gccttgagtg gattggacat 300
attgatcctt actatgttag ttctaactac aatctgaaat tcaaggcgag agtgacaatc 360
accgccgacc agtctaccac cacagcctac atggagctct ccagictgag atctgaggac 420
actgcagtct attactgttg aagatctaag agggactact ttgactactg gggccaaggg 480
accactctca cagtttcttc agcctccacc aagggcccat ccgtctctcc cctggcgccc 540
tgtccaggga gcacctccga gagcacagcc gccctgggct gcctgggtcaa ggactacttc 600
cccgaaccgg tgacgggtgc gtggaactca ggcgccttga ccagcgcgct gcacaccttc 660
cggcgtgttc tacagtcctc aggactctac tccctcagca gcgtgggtgac cgtgcccttc 720
agcaacttcg gcaccacagc ctacacctgc aacgtagatc acaagcccgag caacaccaag 780
gtggacaaga cagttgagcg caaatgttgt gtcgagtgcc caccgtgccc agcaccacct 840
gtggcaggac cgctcagctt cctcttcccc ccaaaaccca aggacacctt catgatctcc 900
cggaccctgt aggtcacgtg cgtggtgggt gacgtgagcc aggaagaccc cgaggtccag 960
ttcaactggt acgtggatgg cgtggaagtg cataatgcca agacaaagcc gcgggaggag 1020
cagttcaaca gcacgtaccg tgtgtcagc gtcttcaccg tctgtcacca ggactggctg 1080
aacggcgaag agtacaagtg caaggtctcc aacaaaggcc tcccgctctc catcgagaaa 1140
accatctcca aagccaaagg gcagccccga gagccacagg tgtagacctt gcccccattc 1200
caggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtaaaagg cttctacccc 1260
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1320
ctcccgctgc tggactccga cggctctctt ttctcttaca gcaggctaac cgtggacaag 1380
agcaggtggc aggaaggcca tgtcttctca tgtccgtgta tgcatgaggg cctgacacac 1440
cactacacac agaagagcct ctccctgtct ctgggtaaat gatgagaatt cattgatcat 1500
aatcagccat accacatttg tagaggtttt acttgcttta aaaaacctcc cacacctccc 1560

```

<210> 49

<211> 772

<212> DNA

<213> Artificial Sequence

<220>

<223> hB7v3v2-cG2G4 Light chain

<400> 49

```

ctgttccttt ccatgggtct tttctgcagt caccgtcctt gacacgaagc ttgccgccac 60
catggacatg agggctctct ctacagctcct ggggctcctg ctgctctggc tctcaggggc 120
cagggtgtgac atccagatga cacagtctcc atcttccctg tctgcatcta taggagacag 180
agtcactatc acttgcaagg cgagtcagga catataatgc tatttaagct ggtttcagca 240
gaaaccaggg aaagctccct agctctgat ctatcgtgca aacagattgg tagatgggg 300
tccatcaagg ttcatgggca gtggatctgg gacagattat actctcacca tcagcagcct 360
gcagcctgaa gatttcgcag ttattatttg tctacagtat gatgagtttc cgtacacggt 420
cggagggggg accaagctgg aaataaaacg tacggtggct gcacctctg tcttcatctt 480
cccgccatct gatgagcagt tgaatcttgg aactgcctct gttgtgtgct tgcgtaataa 540
cttctatccc agagaggcca aagtacagtg gaaggtggat aacgcctctc aatcgggtaa 600
ctcccgaggg agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac 660
cttgacgctg agcaaaagcag actacagaga acacaaagtc tacgcctgag aagtcaccca 720
tcagggcctg agctgcctcg tcacaaagag cttcaacagg ggagagtgtt ag 772

```

<210> 50
 <211> 2158
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> DIB5-hG1 Heavy chain

<400> 50
 gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt 60
 ctgcagtcac cgtccttgac acgaggcgcg ccgccaccat gggatggagc tgtatcatcc 120
 tcttcttggt agcaacagct acaggtgtcc actccctcga ggtccaaactg cagcagcctg 180
 gggcagaagct tgtgaggcca ggggcctcag tcaagttgtc ctgcaaaactg tctggcttca 240
 acattaaaga ctactatata cactgggtga agcagaggcc tgaacagggc ctggagtggg 300
 ttggatggat tgatcttgag attggtgcta ctaaatatgt cccgaagttc cagggcaagg 360
 ccactatgac tacagacaca tcttccaaca cagcctacct gcagctcagc agcctgacat 420
 ctgaggacac tgccgtctat tactgtaatg cctcttatgg taactacgac cgttactatg 480
 ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctacgctcc accaagggcc 540
 catcggtctt ccccttgcca cctcctcca agagcacctc tggcggcaca gcggcctgg 600
 gctgcctggt caaggactac tccccgaac cggtgacggt gtcgtggaac tcaggcgccc 660
 tgaccagcgg cgtgcacacc tccccggctg tcctacagtc ctacaggactc tactccctca 720
 gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga 780
 atcacaaagg cagcaacacc aaggtggaca agagagtgg tgagaggcca gcacagggag 840
 ggagggtgtc tgtctggaag caggctcagc gctcctgctt ggagcagctc cggctatgca 900
 gtcccaagtc agggcagcaa ggcaggcccc gtctgcctct tcaccggag gcctctgccc 960
 gccccactca tgtctaggga gagggtcttc tggctttttc cccaggctct gggcaggcac 1020
 aggctaggtg cccctaacc aggccttgca cacaaaggg cagggtgctg gctcagacct 1080
 gccaaagacc atatccggga ggacctgccc cctgacctaa gccacccca aaggccaaac 1140
 tctccactcc ctacagctcg acaccttctc tcttcccaga ttccagtaac tcccaatctt 1200
 ctctctgcag agcccaaatc ttgtgacaaa actcacacat gccacccgtg cccaggtaag 1260
 ccagccaggg cctcgccttc cagctcaagg cgggacaggt gccctagagt agcctgcatc 1320
 cagggacagg ccccagccgg gtgctgacac gtccacctcc atctcttctt cagcacctga 1380
 actcctgggg ggaacgtcag tcttctcttt cccccaaaa cccaaggaca cctcatgat 1440
 ctcccgacc cctgaggtca catgctggtt ggtggacgtg agccacgaag accctgaggt 1500
 caagttcaac tggtagctgg acggcgtgga ggtgcataat gccaaagcaa agcccgagg 1560
 ggagcagtag aacagcagc acgtgtggt cagcgtcttc accgtctgc accaggactg 1620
 gctgaattgg aaggagtaca agtgcaaggt ctccaacaaa gccctccag ccccatcga 1680
 gaaaaccatc tccaaagcca aaggtgggac cgtgggggt cgagggccac atggacagag 1740
 gccggctcgg cccacctctc gccctgagag tgaccgtgt accaacctct gtccctacag 1800
 ggcagcccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag atgaccaaga 1860
 accaggtcag cctgacttgc ctggtcaaa gcttctatcc cagcgacatc gccgtggagt 1920
 gggagagcaa tgggcagccg gagaacaact acaagaccac gccctccgtg ctggactccg 1980
 acggctctct tctctctat agcaagctca ccgtggacaa gagcaggtgg cagcagggga 2040
 acgtctcttc atgtccctg atgcattgag ctctgcacaa ccactacag cagaagagcc 2100
 tctccctgtc cccgggtaaa tgagtgcgac ggccagaatt cattgatcat aatcagcc 2158

<210> 51
 <211> 720
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> DIB5-hG1 Light chain

<400> 51
 aagcttgccg ccaccatggg atggagctgt atcatctct tcttgtagc aacagctaca 60
 ggtgtccact ctagagacat tgtgatgacc cagtctcaaa aattcatgtc cacatcagta 120
 ggagacaggg tcagcatcac ctgcaaggcc agtcagaatg ttcgtactgc ttagcctgg 180
 tatcaacaga aaccagggca gtctcctaaa gcactgattt acttggcatc caaccggcac 240
 actggagtcc ctgatcgctt cacaggcagt ggaatctggga cagatttcac tctcaccatt 300
 agcaatgtgc aatctgaaga cctggcagat tatttctgtc tgcaacattg gaattatcct 360
 ctacggttcg gtgctgggac caagctggag ctgaaacgga ctgtggctgc accatctgtc 420
 ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgctg 480
 ctgaataact tctatcccag agaggccaaa gtacagtggg aggtggataa cgccctccaa 540
 tcgggtaact cccaggagag tgtcacagag caggacagca aggcagcac ctacagcctc 600
 agcaacaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcttgcgaa 660
 gtcacccatc agggcctgag ctgcccgtc acaagagct tcaacagggg agagtgttaa 720

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US75842606P [0001]
- US60759085P [0001]
- US60801991P [0001]
- US2005129690A1 [0006]
- US2002168364A1 [0009]
- US6908432B [0040]
- US5225539A [0050]
- US4376110A [0056] [0143]
- WO9708320A [0056]
- US5427908A [0056]
- US5508717A [0056]
- US5403484A [0056]
- US5223409A [0056]
- WO8806630A [0056]
- WO9215679A [0056]
- US5780279A [0056]
- US5571698A [0056]
- US6040136A [0056]
- US4816567A [0063]
- US6794132B [0066]
- US6680209B [0066]
- US4634666A [0066]
- US5939598A [0067]
- US6673986B [0067]
- US6114598A [0067]
- US6075181A [0067]
- US6162963A [0067]
- US6150584A [0067]
- US6713610B [0067]
- US6657103B [0067]
- US10421011B [0067]
- US20030229905A1 [0067]
- WO10455013A [0067]
- US20040010810A1 [0067]
- WO10627250A [0067]
- US20040093622A1 [0067]
- WO10656623A [0067]
- US20060040363A1 [0067]
- WO10658521A [0067]
- US20050054055A1 [0067]
- WO10917703A [0067]
- US20050076395A1 [0067]
- WO10978297A [0067]
- US20050287630A1 [0067]
- US9306926W [0067]
- EP0463151B1 [0067]
- WO9402602A [0067]
- WO9634096A [0067]
- WO9824893A [0067]
- US5545807A [0068]
- US5545806A [0068]
- US5625825A [0068]
- US5625126A [0068]
- US5633425A [0068]
- US5661016A [0068]
- US5770429A [0068]
- US5789650A [0068]
- US5814318A [0068]

- [US5591669A \[0068\]](#)
- [US5612205A \[0068\]](#)
- [US5721367A \[0068\]](#)
- [US5789215A \[0068\]](#)
- [US5643763A \[0068\]](#)
- [US5569825A \[0068\]](#)
- [US5877397A \[0068\]](#)
- [US6300129B \[0068\]](#)
- [US5874299A \[0068\]](#)
- [US6255458B \[0068\]](#)
- [US7941871B \[0068\]](#)
- [EP0546073B1 \[0068\]](#)
- [WO9203918A \[0068\]](#)
- [WO9222645A \[0068\]](#)
- [WO9222647A \[0068\]](#)
- [WO9222670A \[0068\]](#)
- [WO9312227A \[0068\]](#)
- [WO9400569A \[0068\]](#)
- [WO9425585A \[0068\]](#)
- [WO9614436A \[0068\]](#)
- [WO9713852A \[0068\]](#)
- [WO9824884A \[0068\]](#)
- [WO04108158A \[0069\]](#)
- [WO0034317A \[0069\]](#)
- [WO02069232A \[0069\]](#)
- [WO9429351A \[0089\] \[0099\]](#)
- [US5648260A \[0089\] \[0099\]](#)
- [US5624821A \[0089\] \[0099\]](#)
- [WO9428027A \[0097\]](#)
- [WO9847531A \[0097\]](#)
- [US6194551B \[0099\]](#)
- [WO9951642A \[0099\]](#)
- [WO2005011735A \[0103\]](#)
- [US5092885A \[0128\]](#)
- [US5112946A \[0128\]](#)
- [US5192744A \[0128\]](#)
- [US5202352A \[0128\]](#)
- [US6573256B \[0128\]](#)
- [US6395718B \[0128\]](#)
- [US6462075B \[0128\]](#)
- [US6465431B \[0128\]](#)
- [US6475794B \[0128\]](#)
- [US6482802B \[0128\]](#)
- [US6482810B \[0128\]](#)
- [US6500431B \[0128\]](#)
- [US6500924B \[0128\]](#)
- [US6518298B \[0128\]](#)
- [US6521438B \[0128\]](#)
- [US6525019B \[0128\]](#)
- [US6538103B \[0128\]](#)
- [US6544758B \[0128\]](#)
- [US6544947B \[0128\]](#)
- [US6548477B \[0128\]](#)
- [US6559126B \[0128\]](#)
- [US6569845B \[0128\]](#)
- [WO8403508A \[0132\]](#)
- [WO8503508A \[0132\]](#)

- [US3940475A \[0143\]](#)
- [US4289747A \[0143\]](#)
- [WO9627011A \[0147\]](#)
- [US4676980A \[0147\]](#)
- [US20050129690A \[0159\]](#)
- [US6075842B \[0204\]](#)
- [US6075908B \[0204\]](#)
- [US6080199B \[0204\]](#)

Non-patent literature cited in the description

- KIANI et al. Haematologica, 2003, vol. 88, 754-761 [0003]
- MAGGIO et al. Ann Oncol, 2002, vol. 13, 152-56 [0003]
- ITO et al. Cancer, 1999, vol. 85, 2359-2367 [0003]
- PODHORECKA et al. Leuk Res, 2002, vol. 26, 657-660 [0003]
- TATSUMI et al. J Exp Med, 2002, vol. 196, 619-628 [0003]
- AGARWAL et al. Immunol Invest, 2003, vol. 32, 17-30 [0003]
- SMYTH et al. Ann Surg Oncol, 2003, vol. 10, 455-462 [0003]
- CONTASTA et al. Cancer Biother Radiopharm, 2003, vol. 18, 549-557 [0003]
- LAUEROVA et al. Neoplasma, 2002, vol. 49, 159-166 [0003]
- WINTER et al. Immunology, 2003, vol. 108, 409-419 [0003]
- INAGAWA et al. Anticancer Res, 1998, vol. 18, 3957-3964 [0003]
- GORCZYNSKI et al. Transplantation, 1998, vol. 65, 1106-1114 [0004]
- EXLEY A. R. et al. Lancet, 1990, vol. 335, 1275-1277 [0006]
- MIRICK et al. Q J Nucl Med Mol Imaging, 2004, vol. 48, 251-7 [0006]
- LOBUGLIO et al. P.N.A.S., 1989, vol. 86, 4220-4224 [0006]
- KRETZ-ROMMEL et al. Journal of Immunotherapy, 2004, vol. 27, 6S46- [0007]
- BARCLAY et al. TRENDS Immunol., 2002, 23- [0042]
- WRIGHT et al. J. Immunol., 2003, 3034-3046 [0042]
- WRIGHT et al. Immunity, 2000, 233-242 [0042]
- ROSENBLUM et al. Blood, 2004, 2691-2698 [0042]
- Computational Molecular Biology Oxford University Press 1988 0000 [0046]
- Biocomputing: Informatics and Genome Projects Academic Press 1993 0000 [0046]
- Computer Analysis of Sequence Data Humana Press 1994 0000 [0046]
- HEINJE, G. Sequence Analysis in Molecular Biology Academic Press 1987 0000 [0046]
- Sequence Analysis Primer M Stockton Press 1991 0000 [0046]
- CARILLO, H. LIPMAN, D. SIAM J. Applied Math., 1988, vol. 48, 1073- [0046]
- DEVEREUX, J. et al. Nucleic Acids Research, 1984, vol. 12, 1387- [0046]
- ALTSCHUL, S. F. et al. J. Molec. Biol., 1990, vol. 215, 403-410 [0046]
- ALTSCHUL et al. Nuc. Acids Res, 1997, vol. 25, 3389-3402 [0046]
- ALTSCHUL, S. et al. BLAST Manual NCBI NLM NIH Bethesda [0046]
- ALTSCHUL, S. et al. J. Mol. Biol., 1990, vol. 215, 403-410 [0046]
- KOHLER MILSTEIN Nature, 1975, vol. 256, 495-497 [0056]
- HARLOW LANE Antibodies: a Laboratory Manual Cold Spring Harbor 1988 0000 [0056]
- SMITH Science, 1985, vol. 225, 1315-1317 [0056]
- PARMLEY SMITH Gene, 1988, vol. 73, 305-318 [0056]
- DE LA CRUZ et al. Journal of Biological Chemistry, 1988, vol. 263, 4318-4322 [0056]
- DAVIS et al. Cancer Metastasis Rev., 1999, vol. 18, 4421-5 [0056]
- TAYLOR et al. Nucleic Acids Research, 1992, vol. 20, 6287-6295 [0056]
- TOMIZUKA et al. Proc. Natl. Academy of Sciences USA, 2000, vol. 97, 2722-727 [0056]
- JONES et al. Nature, 1986, vol. 321, 522-525 [0064]
- REICHMANN et al. Nature, 1988, vol. 332, 323-327 [0064]
- VERHEOEYEN et al. Science, 1988, vol. 239, 1534-1536 [0064]
- STAELENS et al. Mol Immunol, 2006, vol. 43, 1243-1257 [0064]

- JAKOBOVITS et al.PNAS, 1993, vol. 90, 2551- [0065]
- JAKOBOVITS et al.Nature, 1993, vol. 362, 255-258 [0065]
- BRUGGERMANN et al.Year in Immuno., 1993, vol. 7, 33- [0065]
- DUCHOSAL et al.Nature, 1992, vol. 355, 258- [0065]
- HOOGENBOOM et al.J. Mol. Biol., 1991, vol. 227, 381- [0066]
- MARKS et al.J. Mol. Biol., 1991, vol. 222, 581-597 [0066]
- VAUGHAN et al.Nature Biotech, 1996, vol. 14, 309- [0066]
- OSTBERG et al.Hybridoma, 1983, vol. 2, 361-367 [0066]
- MENDEZ et al.Nature Genetics, 1997, vol. 15, 146-156 [0067]
- GREENJAKOBOVITSJ. Exp. Med., 1998, vol. 188, 483-495 [0067]
- TAYLOR et al.Nuc. Acids. Res., 1992, vol. 20, 6287- [0068]
- CHEN et al.Int. Immunol., 1993, vol. 5, 647- [0068]
- TUAILLON et al.PNAS USA., 1993, vol. 90, 3720-4 [0068]
- CHOI et al.Nature Genetics, 1993, vol. 4, 117- [0068]
- LONBERG et al.Nature, 1994, vol. 368, 856-859 [0068]
- TAYLOR et al.International Immunology, 1994, vol. 6, 579-591 [0068]
- TUAILLON et al.J Immunol., 1995, vol. 154, 6453-65 [0068]
- FISHWILD et al.Nature Biotechnology, 1996, vol. 14, 845- [0068]
- TUAILLON et al.Eur J Immunol., 2000, vol. 10, 2998-3005 [0068]
- MULLIGAN, R. C.BERG, P.Proc. Natl. Acad. Sci., USA, 1981, vol. 78, 2072- [0077]
- SOUTHERN, P. J.BERG, P., J.Mol. Appl. Genet., 1982, vol. 1, 327- [0077]
- WIGLER, M. et al.Cell, 1979, vol. 16, 77- [0077]
- SARVER, N. et al.Proc. Natl. Acad. Sci., USA, 1982, vol. 79, 7147- [0077]
- DEANS, R. J. et al.Proc. Natl. Acad. Sci., USA, 1984, vol. 81, 1292- [0077]
- LUSKY, M.BOTCHAN, M.Nature, 1981, vol. 293, 79- [0077]
- OKAYAMA, H.BERG, P.Mol. Cell Biol., 1983, vol. 3, 280- [0078]
- CEPKO, C. L. et al.Cell, 1984, vol. 37, 1053- [0078]
- KAUFMAN, R. J.Proc. Natl. Acad. Sci., USA, 1985, vol. 82, 689- [0078]
- DAERONAnnu. Rev. Immunol, 1997, vol. 15, 203-234 [0081]
- WARDGHETITherapeutic Immunol, 1995, vol. 2, 77-94 [0081]
- RAVETCHKINETAnnu. Rev. Immunol., 1991, vol. 9, 457-492 [0081] [0083]
- KABAT et al.Sequences of Proteins of Immunological InterestNational Institutes of Health19910000 [0085]
- WOOF et al.Molec. Immunol., 1986, vol. 23, 319-330 [0085]
- DUNCAN et al.Nature, 1988, vol. 332, 563- [0085]
- CANFIELDMORRISONJ. Exp. Med., 1991, vol. 173, 1483-1491 [0085]
- CHAPPEL et al.Proc. Natl. Acad. Sci USA, 1991, vol. 88, 9036-9040 [0085]
- WOOF et al.Molec Immunol., 1986, vol. 23, 319-330 [0086]
- SARMAY et al.Molec. Immunol., 1984, vol. 21, 43-51 [0086]
- GERGELY et al.Biochem. Soc. Trans., 1984, vol. 12, 739-743 [0086]
- LUND et al.Molec. Immunol., 1992, vol. 29, 53-59 [0086]
- BURTONWOOFAdvances in Immunol., 1992, vol. 51, 1-84 [0088]
- WARDGHETITherapeutic Immunology, 1995, vol. 2, 77-94 [0088] [0089]
- GAZZANO-SANTORO et al.J. Immunol. Methods, 1996, vol. 202, 163- [0089]
- XU et al.J. Immunol., 1993, vol. 150, 152A- [0089]
- TAO et al.J. Exp. Med., 1993, vol. 178, 661-667 [0089]
- BREKKE et al.Eur. J. Immunol, 1994, vol. 24, 2542-47 [0089]
- BURTON et al.Nature, 1980, vol. 288, 338-344 [0089]
- DUNCANWINTERNature, 1988, vol. 332, 738-40 [0089]
- XU et al.Cell Immunol, 2000, vol. 200, 16-26 [0097]
- HEZAREH et al.J Virol., 2001, vol. 75, 12161-8 [0097]
- KLEIN et al.PNAS USA, 1981, vol. 78, 524-528 [0098]
- CARON et al.J. Exp Med., 1992, vol. 176, 1191-1195 [0099]
- SHOPES, B.J. Immunol., 1992, vol. 148, 2918-2922 [0099]
- DUNCANWINTERNature, 1988, vol. 322, 738-40 [0099]
- WOLFF et al.Cancer Research, 1993, vol. 53, 2560-2565 [0099]
- STEVENSON et al.Anti-Cancer Drug Design, 1989, vol. 3, 219-230 [0099]
- RAJU, TS.BioProcess International, 2003, 44-53 [0100] [0100]
- WRIGHT A.MORRISON SL.TIBTECH, 1997, vol. 15, 26-32 [0100]

- **ISRAEL et al.**Immunology, 1996, vol. 89, 4573-578 [0100]
- **NEWKIRK et al.**P. Clin. Exp., 1996, vol. 106, 2259-64 [0100]
- **SHIELDS et al.**J Biol Chem, 2001, vol. 276, 96591-604 [0100]
- **SHIELDS et al.**J Biol Chem., 2002, vol. 277, 3026733-40 [0100]
- **SHINKAWA et al.**J Biol Chem., 2003, vol. 278, 53466-73 [0101]
- **UMANA et al.**Nat Biotechnol., 1999, vol. 17, 2176-80 [0102]
- J Exp Med, 1994, vol. 180, 1087-1096 [0102]
- **MARZOCCHI-MACHADO et al.**Immunol Invest, 1999, vol. 28, 89-101 [0104]
- **HOEK et al.**Science, 2000, [0106]
- **BLOOD et al.**Biochim. Biophys. Acta, 1990, vol. 1032, 89-118 [0128]
- **MOSES et al.**Science, 1990, vol. 248, 1408-1410 [0128]
- **INGBER et al.**Lab. Invest., 1988, vol. 59, 44-51 [0128]
- Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy**S. E. ORDER et al.**Monoclonal Antibodies for Cancer Detection and TherapyAcademic Press19850000303-316 [0134]
- **WENSELMEARES**Radioimmunoimaging and RadioimmunotherapyElsevier19830000 [0140]
- **D. COLCHER et al.**Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic MiceMeth. Enzymol, 1986, vol. 121, 802-816 [0140]
- Developments in Antibody Imaging**A. R. BRADWELL et al.**Monoclonal Antibodies for Cancer Detection and TherapyAcademic Press1985000065-85 [0142]
- **STRYER**Science, 1968, vol. 162, 526- [0143]
- **BRAND, L. et al.**Annual Review of Biochemistry, 1972, vol. 41, 843-868 [0143]
- **MILSTEINCUELLO**Nature, 1983, vol. 305, 537-539 [0147]
- **SURESH et al.**Methods in Enzymology, 1986, vol. 121, 210- [0147]
- **BRENNAN et al.**Science, 1985, vol. 229, 81- [0147]
- **SHALABY et al.**J. Exp. Med., 1992, vol. 175, 217-225 [0147]
- **KOSTELNY et al.**J. Immunol., 1992, vol. 148, 51547-1553 [0147] [0148]
- **HOLLINGER et al.**Proc. Natl. Acad. Sci. USA, 1993, vol. 90, 6444-6448 [0147] [0148]
- **GRUBER et al.**J. Immunol., 1994, vol. 152, 5368- [0147] [0148]
- **TUTT et al.**J. Immunol., 1991, vol. 147, 60- [0147]
- **ZAPATA et al.**Protein Eng, 1995, vol. 8, 101057-1062 [0148]
- Remington's Pharmaceutical SciencesMack Publishing Co. [0150]
- **WEI SKRYCZEK IZOU LDANIEL BCHENG PMOTTRAM PCURIEL TLANGE AZOU W**Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.Cancer Res., 2005, vol. 65, 125020-6 [0197]
- **AGARWAL et al.**Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinomaImmunol Invest, 2003, vol. 32, 17-30 [0203]
- **ALMASRI, NM et al.**Am J Hemato, 1992, vol. 140, 259-263 [0203]
- **CONTASTA et al.**Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functionsCancer Biother Radiopharm, 2003, vol. 18, 549-557 [0203]
- **GORCZYNSKI et al.**Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survivalTransplantation, 1998, vol. 65, 1106-1114 [0203]
- **GORCZYNSKI et al.**Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice.Clin Exp Immunol, 2001, vol. 126, 220-229 [0203]
- **HAINSWORTH, JD**Oncologist, 2000, vol. 5, 5376-84 [0203]
- **INAGAWA et al.**Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesionsAnticancer Res, 1998, vol. 18, 3957-3964 [0203]
- **ITO et al.**Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometryCancer, 1999, vol. 85, 2359-2367 [0203]
- **KIANI et al.**Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.Haematologica, 2003, vol. 88, 754-761 [0203]
- **LAUEROVA et al.**Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy responseNeoplasia, 2002, vol. 49, 159-166 [0203]
- **MAGGIO et al.**Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.Ann Oncol, 2002, vol. 13, 152-56 [0203]
- **NILSSON, KB**um Cell, 1992, vol. 5, 125-41 [0203]
- **PODHORECKA et al.**T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia-the three-color flow cytometry analysisLeuk Res, 2002, vol. 26, 657-660 [0203]

- **PU, QQBEZWODA, W**Anticancer Res., 2000, vol. 20, 42569-78 [0203]
- **SMYTH et al.**Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cellsAnn Surg Oncol, 2003, vol. 10, 455-462 [0203]
- **TATSUMI et al.**Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaJ Exp Med, 2002, vol. 196, 619-628 [0203]
- **WALLS A VET**Int. J Cancer, 1989, vol. 44, 846-853 [0203]
- **WINTER et al.**Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.Immunology, 2003, vol. 108, 409-419 [0203]
- **CAMERON, C. M. J. W. BARRETT L. LIA. R. LUCASG. MCFADDEN**Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivoJ Virol, 2005, vol. 79, 6052- [0203]
- **FOSTER-CUEVAS, M. G. J. WRIGHT M. J. PUKLAVECM. H. BROWNA. N. BARCLAY**Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptorJ Virol, 2004, vol. 78, 7667- [0203]
- **NICHOLAS, J.**Human herpesvirus-8-encoded signalling ligands and receptorsJ Biomed Sci, 2003, vol. 10, 475- [0203]
- **SHIRATORI, I. M. YAMAGUCHI M. SUZUKAWAK. YAMAMOTO L. L. LANIERT. SAITO H. ARASE.**Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200J Immunol, 2005, vol. 175, 4441- [0203]
- **VOIGT, S. G. R. SANDFORD G. S. HAYWARD W. H. BURNS**The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV Maastricht.J Gen Virol, 2005, vol. 86, 263- [0203]
- **ZHANG, J. J. WANG C. WOODD. XUL. ZHANG**Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elementsJ Virol, 2005, vol. 79, 5640- [0203]

Patentkrav

1. Farmaceutisk sammensætning, der omfatter et farmaceutisk acceptabelt bæremiddel og en effektiv mængde af et anti-CD200-antistof, hvor anti-CD200-antistoffet:
- (i) hæmmer interaktionen mellem CD200 og CD200R; og
 - (ii) omfatter en variant Fc-konstant region, som:
 - (a) er en variant Fc-konstant region, hvor CH1- og hængselregionen stammer fra human IgG2, og CH2- og CH3-regionerne stammer fra human IgG4;
 - (b) omfatter den ene eller begge af: (A) en phenylalanin-til-alanin-substitution i position 234 og (B) en leucin-til-alanin-substitution i position 235 ifølge EU-indekset;
 - (c) omfatter en K322A-mutation i CH2-domænet ifølge EU-indekset;
 - eller
 - (d) mangler en hængselregion.
2. Farmaceutisk sammensætning ifølge krav 1, hvor anti-CD200-antistoffet er et murint antistof, et kimærisk antistof, et humaniseret antistof, et deimmuniseret antistof eller et humant antistof.
3. Farmaceutisk sammensætning ifølge krav 1, hvor anti-CD200-antistoffet omfatter:
- I.
 - (a) et let kæde-polypeptid, der omfatter:
 - (i) aminosyreresterne 21 til 127 af SEQ ID NO: 24; eller
 - (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 24; og
 - (b) et tung kæde-polypeptid, der omfatter:
 - (iii) aminosyreresterne 21 til 137 af SEQ ID NO: 15; eller
 - (iv) aminosyreresterne 21 til 463 af SEQ ID NO: 15;
 - II.
 - (a) et let kæde-polypeptid, der omfatter:
 - (i) aminosyreresterne 21 til 127 af SEQ ID NO: 32; eller
 - (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 32; og
 - (b) et tung kæde-polypeptid, der omfatter:
 - (iii) aminosyreresterne 21 til 142 af SEQ ID NO: 20;

III.

(a) et let kæde-polypeptid, der omfatter:

(i) aminosyreresterne 23 til 129 af SEQ ID NO: 28; eller

(ii) aminosyreresterne 23 til 236 af SEQ ID NO: 28; og

5 (b) et tung kæde-polypeptid, der omfatter:

(iii) aminosyreresterne 20 til 136 af SEQ ID NO: 13; eller

(iv) aminosyreresterne 20 til 462 af SEQ ID NO: 13; eller

IV.

(a) et tung kæde-polypeptid, der omfatter:

10 (i) aminosyreresterne 20 til 136 af SEQ ID NO: 11; eller

(ii) aminosyreresterne 20 til 136 af SEQ ID NO: 9; og

(b) et let kæde-polypeptid, der omfatter aminosyreresterne 23 til 129 af SEQ ID NO: 26.

15 4. Farmaceutisk sammensætning ifølge krav 1, hvor den variante Fc-konstante region har nul ADCC- eller CDC-aktivitet.

5. Farmaceutisk sammensætning ifølge et hvilket som helst af
20 kravene 1-4 til anvendelse til behandling af cancer.

6. Farmaceutisk sammensætning til anvendelse ifølge krav 5, hvor canceren omfatter cancerceller, der udtrykker CD200.

25 7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor cancercellerne overudtrykker CD200 i forhold til normale celler af samme histologiske type som de celler, hvorfra cancercellerne er afledt.

30 8. Farmaceutisk sammensætning til anvendelse ifølge krav 7, hvor canceren er udvalgt fra gruppen, der består af crista neuralis-cellecancer, plasmacellecancer, lymfom, leukæmi, ovariecancer, hudcancer, lungecancer, nyrecancer, brystcancer, prostatacancer, neuroblastom og myelom.

35

9. Anti-CD200-antistof til anvendelse til behandling af cancer, hvor anti-CD200-antistoffet:

(i) hæmmer interaktionen mellem CD200 og CD200R; og

(ii) omfatter en variant Fc-konstant region, som:

(a) er en variant Fc-konstant region, hvor CH1- og hængselregionen stammer fra human IgG2, og CH2- og CH3-regionerne stammer fra human IgG4;

5 (b) omfatter den ene eller begge af: (A) en phenylalanin-til-alanin-substitution i position 234 og (B) en leucin-til-alanin-substitution i position 235 ifølge EU-indekset;

(c) omfatter en K322A-mutation i CH2-domænet ifølge EU-indekset;

10 eller

(d) mangler en hængselregion.

10. Anti-CD200-antistof ifølge krav 9 til anvendelse ifølge krav 9, hvor anti-CD200-antistoffet er et murint antistof, et
15 kimærisk antistof, et humaniseret antistof, et deimmuniseret antistof eller et humant antistof.

11. Anti-CD200-antistof ifølge krav 9 til anvendelse ifølge krav 9, hvor anti-CD200-antistoffet omfatter:

20 I.

(a) et let kæde-polypeptid, der omfatter:

(i) aminosyreresterne 21 til 127 af SEQ ID NO: 24; eller

(ii) aminosyreresterne 21 til 234 af SEQ ID NO: 24; og

(b) et tung kæde-polypeptid, der omfatter:

25 (iii) aminosyreresterne 21 til 137 af SEQ ID NO: 15; eller

(iv) aminosyreresterne 21 til 463 af SEQ ID NO: 15;

II.

(a) et let kæde-polypeptid, der omfatter:

(i) aminosyreresterne 21 til 127 af SEQ ID NO: 32; eller

30 (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 32; og

(b) et tung kæde-polypeptid, der omfatter:

(iii) aminosyreresterne 21 til 142 af SEQ ID NO: 20;

III.

(a) et let kæde-polypeptid, der omfatter:

35 (i) aminosyreresterne 23 til 129 af SEQ ID NO: 28; eller

(ii) aminosyreresterne 23 til 236 af SEQ ID NO: 28; og

(b) et tung kæde-polypeptid, der omfatter:

(iii) aminosyreresterne 20 til 136 af SEQ ID NO: 13; eller

(iv) aminosyreresterne 20 til 462 af SEQ ID NO: 13; eller
IV.

(a) et tung kæde-polypeptid, der omfatter:

(i) aminosyreresterne 20 til 136 af SEQ I D NO: 11; eller

5 (ii) aminosyreresterne 20 til 136 af SEQ ID NO: 9; og

(b) et let kæde-polypeptid, der omfatter aminosyreresterne 23
til 129 af SEQ ID NO: 26.

12. Anti-CD200-antistof ifølge krav 9 til anvendelse ifølge
10 krav 9, hvor den variante Fc-konstante region har nul ADCC-
eller CDC-aktivitet.

13. Anti-CD200-antistof ifølge et hvilket som helst af
kravene 9-12 til anvendelse ifølge et hvilket som helst af
15 kravene 9-12, hvor canceren omfatter cancerceller, der
udtrykker CD200.

14. Anti-CD200-antistof ifølge krav 13 til anvendelse ifølge
krav 13, hvor cancercellerne overudtrykker CD200 i forhold til
20 normale celler af samme histologiske type som de celler,
hvorfra cancercellerne er afledt.

15. Anti-CD200-antistof ifølge et hvilket som helst af
kravene 9-14 til anvendelse ifølge et hvilket som helst af
25 kravene 9-14, hvor canceren er udvalgt fra gruppen, der består
af crista neuralis-cellecancer, plasmacellecancer, lymfom,
leukæmi, ovariecancer, hudcancer, lungecancer, nyrecancer,
brystcancer, prostatacancer, neuroblastom og myelom.

30 16. Anti-CD200-antistof ifølge et hvilket som helst af
kravene 9-15 til anvendelse ifølge et hvilket som helst af
kravene 9-15, hvor patienten skal have administreret et andet
middel eller en terapi.

35 17. Anti-CD200-antistof ifølge krav 16 til anvendelse ifølge
krav 16, hvor det andet middel er et kemoterapeutisk middel.

18. Anti-CD200-antistof ifølge krav 16 til anvendelse ifølge

krav 16, hvor terapien er strålebehandling.

DRAWINGS

FIGURE 1

Primer C7mhHF (SEQ ID NO: 1)
TCCTCAGCCTCCACCAAGGGCC

FIGURE 2

Primer Rev Age Pri (SEQ ID NO: 2)
GGGCGCCTGAGTTCCACGAC

FIGURE 3

Primer C2aB7 rev (SEQ ID NO: 3)
GGCCCTTGGTGGAGGCTGAGGAACTGTGAGAGTGGTGC

FIGURE 4

lacpri (SEQ ID NO: 4)
GCTCCCGGCTCGTATGTTGTGT

FIGURE 5

LeadVHpAX (SEQ ID NO: 5)
ATATGAAATATCTGCTGCCGACCG

FIGURE 6A Note: Figs. 6-15, leader sequences (AA) are underlined and constant regions are in bold.

chC2aB7-hG1

Heavy chain (introns in hG1) (SEQ ID NO. 7)

MGWSCHLFLVATATGVHSLEVQLQQSGPELVKPGASLKMCKASGYSFT
 DYHLWVKQNHGKSLEWIGHIDPYYGSSNYNLKFKGKATLTVDKSSSTAY
 MQLNSLTSEDSAVYYCGRSKRDYFDYWGQGTLTVSSASTKGPSVFPLA
 PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKYDKRVEPKSCDKTHT
 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEV
 KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
 YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT
 CLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDK
 SRWQQGNVVFCSVMHEALHNHYTQKSLSLSPGK

FIGURE 6B**(SEQ ID NO. 6) (genomic sequence hG1)**

ATGGGATGGAGCTGTATCATCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
 GTCCAGCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCACTGAAGATGTCTGC
 AAGGCTTCTGGTTATTTCATTCACTGACTACATCATACTCTGGGTGAAGCAGAAACCATGGAAAG
 AGCCTTGAGTGGATTGGACATATTGATCCTTACTATGGTAGTCTAACTACAATCTGAAATTCA
 AGGGCAAGGCCACATTGACTGTAGACAAATCTTCCAGCACAGCCTACATGCACTCAACAGT
 CTGACATCTGAGGACTCTGCAGTCTATTACTGTGGAAGATCTAAGAGGGACTACTTTGACTAC
 TGGGGCCAAGGCACCACTCTCACAGTTTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCOC
 CTGGCACCCCTCTCCAAGAGCACCTCTGGCGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGAC
 TACTTCCCGAACCCTGTGACGGTGTCTGTGAACTCAGGCGCCTGACCAGCGCGTGACACCC
 TTCCCGCTGTCTACAGTCTCAGGACTCTACTCCTCAGCAGCGTGGTGACCGTGCCCTCCA
 GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCAGCAACACCAAGGTG
 GACAAAGAGAGTTGGTGAGAGGCCAGCACAGGGAGGGAGGGTGTCTGTGGAAGCCAGGCTC
 AGCGCTCCTGCTGGACGCATCCCGCTATGCACTCCAGTCCAGGGCAGCAAGGCAGGCC
 CGTCTGCTCTTCAACCCGGAGGCCCTCTGCCCGCCCACTCATGCTCAGGGAGAGGGTCTTCTG
 GCTTTTTCCCGAGGCTCTGGGCAGGCACAGGCTAGGTGCCCTAACCCAGGCCCTGCACACAA
 AGGGGCAGGTGCTGGGCTCAGACCTGCCAAGAGCCATATCCGGGAGGACCTGCCCTGACC
 TAAGCCCAACCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGACACCTTCTCTCTCCAGA
 TTCCAGTAATCCCAATCTTCTCTGTCAGAGCCCAATCTTGTGACAAAACCTCACACATGCC
 ACCGTGCCAGGTAAAGCCAGCCAGGCCCTCGCCCTCCAGCTCAAGGCCGGGACAGGTGCCCTA
 GAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACAGTCCACCTCCATCTCTTCC
 TCAGCACCTGAATCTCTGGGGGACCGTCAGTCTTCTCTTCCCGCAAAACCCAAAGGACACC
 CTATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCT
 GAGGTCAAGTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG
 GGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCGTCTGCAACAGGACT
 GGTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCATCGAG
 AAAACCATCTCCAAGGCCAAAGGTGGGACCCGTGGGGTGGGAGGGCCACATGGACAGAGGCC
 GGCTCGGCCACCCCTCTGCCCTGAGAGTGACCGGTGTACCAACCTCTGTCCCTACAGGGCAGC
 CCGGAGAACCAAGGTGTACACCTGCCCCATCCCGGAGGAGATGACCAAGAACCAAGGT
 AGCCTGACCTGCTGCTCAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGGAGAGCAAT
 GGGCAGCCGGAGAACAACTACAAGACCGCCTCCCGTGGTGGACTCGACGGCTCCTTCTTC
 CTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCC
 GTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCGGGTAAA
 TGA




FIGURE 6D


Light Chain (human Ck) (SEQ ID NO. 24)

MGWSCILFLVATATGVHSRDIQMTQSPSSMYASLGERVTITCKASQDINSYL
 SWFQKPKGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTSSLEYEDMGY
 YCLQYDEFPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
 FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTLSSTLTLSKADYE
 KHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 6E

(SEQ ID NO. 23)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGT
 CCACTCTAGAGACATCCAGATGACACAGTCTCCATCTTCCATGTATGCATC
 TCTAGGAGAGAGAGTCACTATCACTTGCAAGGCGAGTCAGGACATTAATA
 GCTATTTAAGCTGGTTCCAGCAGAAACCAGGGAAATCTCCTAAGACCTG
 ATCTATCGTGCAAAACAGATTGGTAGATGGGGTTCCATCAAGGTTCAAGTGG
 CAGTGGATCTGGGCAAGATTATTCTCTCACCATCAGCAGCCTGGAGTATG
 AAGATATGGGAATTTATTATTGTCTACAGTATGATGAGTTTCCGTACACGT
 TCGGAGGGGGGACCAAGCTGGAAATAAAACGGACTGTGGCTGCACCATC
 TGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTC
 TGTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGT
 GGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTAC
 AGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCTGACG
 CTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCA
 CCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGA
 GTGTAA



hB7V4V1-hG1
Heavy chain (SEQ ID NO:9)

MGWSWIFLFLLSVTAGVFSEVQLVESGPEVKKPGASVKVSCKASGYSTFD
YIILWIRQHSKGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADKSTRITTYME
LTSLTSEDTA VYYCGRSKRDYFDYWGQGTTLTVSSASTKGPSVFPLAPSS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDRVEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

FIGURE 7A

FIGURE 7B

(SEQ ID NO. 8) (cDNA hG1)

ATGGGATGGAGCTGGATCTTTCTCTTCTCCTGTCACTAACTGCAGGTG
 TGTCTCTGAGGTCCAGCTGGTGGAGTCCGGACCTGAGGTGAAGAAGC
 CTGGGGCTTCAGTGAAGGTGTCCTGCAAGGCTTCTGGTTATTCATTAC
 TGAATACATCATACTCTGGATCAGGCAGCATAGCGGAAAGGGCCTTGA
 GTGGATTGGACATATTGATCCTTACTATGGTAGTTCTAACTACAATCTG
 AAATTCAAGGGCAGGGTCACAATCACTGCAGACAAATCTACCAAGGAC
 AACCTACATGGAGCTCACCAGTCTGACATCTGAGGACACTGCAGTCTA
 TTAATGTGGAAGATCTAAGAGGGACTACTTTGACTACTGGGGCCAAGG
 CACCACTCTCACAGTTTCTCAGCCTCCACCAAGGGCCCATCGGTCTTC
 CCGCTAGCACCTCTCCTCAAGAGCACCTCTGGGGGCACAGCGCCCTG
 GGTGCTGTGGTCAAGGACTACTTCCCGAACCAGGTGACGGTGTCTGTG
 AACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGTGTCTTA
 CAGTCCTCAGGACTCTACTCCTCAGCAGCGTGGTGACCGTGCCCTCC
 AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCC
 AGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAA
 AACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACC
 GTGAGTCTTCTCTTCCCGCCAAAACCCAAGGACACCTCATGATCTCC
 CGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGA
 CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
 TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG
 TGGTCAGCGTCTCACCCTCTGCACCAGGACTGGCTGAATGGCAAGG
 AGTACAAGTGCAAGGTCTCCAACAAGCCCTCCAGCCCCCATCGAG
 AAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTA
 CACCCTGCCCCCATCCCGGAGGAGATGACCAAGAACCAGGTACGCC
 TGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGT
 GGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCAGCCTCCC
 GTGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTG
 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT
 GCATGAGGCTCTGCACAACCACTACACGCAGAAAGACCTCTCCCTGTC
 TCCGGGTAATGA

FIGURE 7C (part1)




FIGURE 7D


Light chain (human Ck) (SEQ ID NO. 26)

MDMRVSAQLLGLLLWLSGARCDIQMTQSPSSLSASIGDRVITTKASQD
 INSYLSWYQQKPGKAPKSLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQ
 PEDFAVYYCLQYDEFPYTFGGGTGLEIKRTVAAPSVFIFPPSDEQLKSGT
 ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLS
 STLTLISKADYEKKHVVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 7E

(SEQ ID NO. 25)

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGG
 CTCTCAGGAGCCAGATGTGACATCCAGATGACACAGTCTCCATCTTCC
 CTGTCTGCATCTATAGGAGACAGAGTCACTATCACTTGCAAGGCGAGT
 CAGGACATTAATAGCTATTTAAGCTGGTACCAGCAGAAACCAGGGAA
 AGCTCCTAAGTCCCTGATCTATCGTGCAAAACAGATTGGTAGATGGGGT
 TCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTATACTCTCAC
 CATCAGCAGCCTGCAGCCTGAAGATTTGCGAGTTTATTATTGTCTACA
 GTATGATGAGTTTCCGTACACGTTCCGAGGGGGGACCAAGCTGGAAAT
 AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
 GAGCAGTTGAAATCTGGAACCTGCTCTGTGTGTGCTGCTGAATAAC
 TTCTATCCCAGAGAGGCCAAAGTACAGTGAAGGTGGATAACGCCCTC
 CAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
 CAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACT
 ACGAGAAAACAAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
 AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG



hB7V3V1-hG1 (SEQ ID NO.11)
Heavy chain

MGWSRIFELLSIIAGVHCQVQLQQSGSELKKPGASVKISCKASGYSTFDY
IILWVRQNPQGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYME
LSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSSASTKGPSVFPLAPSS
KSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVTVTPSSSLGTQTYICNVNHHKPSNTKVDRKRVPEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSR
WQQGNVVFSCVMHEALHNHYTQKSLSLSPGK

FIGURE 8A

FIGURE 8B

(SEQ ID NO. 10) (cDNA hGI)

ATGGGATGGAGCCGGATCTTTCTCTCTCTCTGTCAATAATTGCAGGTG
 TCCATTGCCAGGTCCAGCTGCAACAGTCTGGATCTGAGCTGAAGAAGC
 CTGGGGCTTCAGTGAAGATCTCTGCAAGGCTTCTGGTTATTATTAC
 TGAATACATCATACTCTGGGTGAGGCAGAACCTGGAAAGGGCCTTGA
 GTGGATTGGACATATTGATCCTTACTATGGTAGTTCTAACTACAATCTG
 AAATTCAAGGGCAGAGTGACAATCACCGCCGACCACTTACCACCAC
 AGCCTACATGGAGCTCTCCAGTCTGAGATCTGAGGACACTGCAGTCTA
 TTAATGTGGAAGATCTAAGAGGGACTACTTTGACTACTGGGGCCAGG
 CACCACCTCTCAGATTTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTC
 CCGCTAGCACCTCTCTCAAGAGCACCTCTGGGGGCACAGCGGCCCTG
 GGCTGCCTGGTCAAGGACTACTTCCCGAACCAGGTGACGGTGTCTGTG
 AACTCAGGCGCCCTGACCAGCGCGTGCACACCTTCCCGGTGTCTTA
 CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
 AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCC
 AGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAATCTGTGACAA
 AACTCACACATGCCACCGTGCCAGCACCTGAACCTCTGGGGGACC
 GTCACTCTCTCTTCCCCCAAAACCAAGGACACCTCATGATCTCC
 CGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGA
 CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
 TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG
 TGGTCAGCGTCTCACCGTCTGCACCAAGGACTGGCTGAATGGCAAGG
 AGTACAAGTGCAAGGTCTCAACAAAGCCCTCCAGCCCCATCGAG
 AAAACCATCTCCAAGGCAAAGGGCAGCCCCGAGAACCACAGGTGTA
 CACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTGAGCC
 TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT
 GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAGCCTCCC
 GTGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTG
 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT
 GCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTC
 TCCGGGTAAATGA

[illegible]

FIGURE 8C

Light chain (human Ck) (SEQ ID NO.26)


MDMRVSAQLGLGLLLWLSGARCQMTQSPSSLSASIGDRVTITCKASQD
INSYLSWYQQKPGKAPKSLIYRANRLVDGVPSRFGSGGSDYTLTISSLQ
PEDFAVYYCLQYDEFPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCCLINNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC

FIGURE 8D

FIGURE 8E

(SEQ ID NO. 25)

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGG
CTCTCAGGAGCCAGATGTGACATCCAGATGACACAGTCTCCATCTTCC
CTGTCTGCATCTATAGGAGACAGAGTCACTATCACTTGCAAGGCGAGT
CAGGACATTAATAGCTATTTAAGCTGGTACCAGCAGAAACCAGGGAA
AGCTCCTAAGTCCCTGATCTATCGTGCAAACAGATTGGTAGATGGGGT
TCCATCAAGGTTTCACTGGCAGTGGATCTGGGACAGATTATACTCTCAC
CATCAGCAGCCTGCAGCCTGAAGATTTCGCAGTTTATTATTGTCTACA
GTATGATGAGTTTCCGTACACGTTCCGAGGGGGGACCAAGCTGGAAAT
AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
GAGCAGTTGAAATCTGGAACGCTCTGTGTGTGCCTGCTGAATAAC
TTCTATCCCAGAGAGGCCAAAGTACAGTGAAGGTGGATAACGCCCTC
CAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
CAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACT
ACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG.



hB7V3V2-hG1
Heavy chain (SEQ ID NO.11)

MGWSRIFLFLLSIIAGVHCQVQLQQSGSELKPGASVKISCKASGYSTFDY
IILWVRQNP^{KG}GLEWIGHID^{PYY}GSSNYN^{LKFK}GRVTITADQSTTTAYME
LSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSSAST^{KG}PSVFFLAPSS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSV^{TV}TPSSSLGTQTYICNVNHHKPSNTKVDKRV^{EP}KSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFELYSKLTVDKSR
WQQGNV^{VF}SCSV^{MM}HEALHNHYTQKSLSLSPGK

FIGURE 9A

FIGURE 9B

(SEQ ID NO. 10) (cDNA hG1)

ATGGGATGGAGCCGGATCTTTCTCTTCTCCTGTCAATAATTGCAGGTG
 TCCATTGCCAGGTCCAGCTGCAACAGTCTGGATCTGAGCTGAAGAAGC
 CTGGGGCTTCAGTGAAGATCTCCTGCAAGGCTTCTGGTTATTCAATCAC
 TGA CTACATCATACTCTGGGTGAGGCAGAACCCCTGGAAAGGGCCTTGA
 GTGGATTGGACATATTGATCCTTACTATGGTAGTTCTAACTACAATCTG
 AAATTCAAGGGCAGAGTGACAATCACCGCCGACCACTCTACCACCAC
 AGCCTACATGGAGCTCTCCAGTCTGAGATCTGAGGACACTGCAGTCTA
 TTA CTGTGGAAGATCTAAGAGGGACTACTTTGACTACTGGGGCCAAGG
 CACCACTCTCACAGTTTCTCAGCCTCCACCAAGGGCCCATCGGTCTTC
 CCGTAGCACCCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTG
 GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGG
 AACTCAGGCGCCCTGACCAGCGCGGTGCACACCTTCCCGGCTGTCTTA
 CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
 AGCAGCTTGGGCAACCAGACCTACATCTGCAACGTGAATCACAAGCCC
 AGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAATCTTGTGACAA
 AACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACC
 GTCAGTCTTCTCTTCCCCCAAACCCAAGGACACCTCATGATCTCC
 CGGACCCCTGAGGTACATGCGTGGTGGTGACGTGAGCCACGAAGA
 CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
 TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG
 TGGTCAGCGTCTCACCCTCCTGCACCAGGACTGGCTGAATGGCAAGG
 AGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAG
 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTA
 CACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTACGCC
 TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGT
 GGGAGAGCAATGGGCAGCCGGAGAACAATAACAAGACCACGCCCTCCC
 GTGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTG
 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGAT
 GCATGAGGCTCTGCAACAACCACTACACGCAAGAAGGCCTCTCCCTGTC
 TCCGGGTAAATGA

FIGURE 9C

Light chain (human Ck) (SEQ ID NO. 28)

MDMRVSAQLLGLLLWLSGARCDIQMTQSPSSLSASIGDRVTITCKASQD
INSYLSWFFQKPGKAPKLLIYRANRLVDGVPFRFSGSGTDYTLTISSLQ
PEDFAVYYCLQYDEFPYTFGGGKLEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCILNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLS
STLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 9D

FIGURE 9E

(SEQ ID NO. 27)

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGG
CTCTCAGGGGCCAGGTGTGACATCCAGATGACACAGTCTCCATCTTCC
CTGTCTGCATCTATAGGAGACAGAGTCACTATCACTTGCAAGGCGAGT
CAGGACATTAATAGCTATTTAAGCTGGTTCAGCAGAAACCAGGGAA
AGCTCCTAAGCTGCTGATCTATCGTGCAAACAGATTGGTAGATGGGGT
TCCATCAAGGTTCACTGGCAGTGGATCTGGGACAGATTATACTCTCAC
CATCAGCAGCCTGCAGCCTGAAGATTTTCGCAGTTTATTATTGTCTACA
GTATGATGAGTTTCCGTACACGTTCCGAGGGGGACCAAGCTGGAAAT
AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
GAGCAGTTGAAATCTGGAACCTGCCTCTGTGTGTGCTGCTGAATAAC
TTCTATCCCAGAGAGGCCAAAGTACAGTGAAGGTGGATAACGCCCTC
CAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
CAGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACT
ACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG

FIGURE 9F

hB7V3V2-hG24
Heavy chain (SEQ ID NO.13)

MGWSRIELFLLSIIAGVHCQVQLQQSGSELKPKGASVKISCKASGYSTDY
IILWVRQNPQKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYME
LSSLRSEDTAVYYCGRSKRDYFDYWGGQTLLTVSSASTKGPSVFPLAPC
SRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVTVTPSSNFGTQTYTCNVDHKPSNTKVDKTKVERKCCVECPPCP
APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYV
DGEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KGLPSSIEKTIISKAKGQPREPQVYITLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSYMHEALHNHYTQKSLSLGLGK

FIGURE 10A

FIGURE 10B

(SEQ ID NO. 12) (genomic sequence hG2G4)

ATGGGATGGAGCTGTATCATCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
 GTCCAGCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCACTGAAGATGTCTGTC
 AAGGCTTCTGGTTATTCACTGACTACATCATCTCTGGGTGAAGCAGAACCATGGAAAG
 AGCCTTGAGTGGATTTGACATATTGATCTTACTATGGTAGTTCTAACTACAATCTGAAATTCA
 AGGGCAAGGCCACATTGACTGTAGACAAATCTTCCAGCACAGCCTACATGCAGCTCAACAGT
 CTGACATCTGAGGACTCTGCAGTCTATTACTGTGAAGATCTAAGAGGGACTACTTTGACTAC
 TGGGGCCAAGGCACCACTCTCACAGTTTCTCAGCCTCAOCAAAGGGCCATCCGTCTTCCCC
 CTGGCGCCCTGTCCAAGGACACCTCCGAGAGCACAGCCGCCCTGGGCTGCCGTGTCAAOGA
 CTACTTCCCGAACCAGGTGACGGTGTCTGTGAACCTCAGGCGCCCTGACCAAGCGGCGTGACAC
 CTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
 AGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCAGCAACACCAAGGT
 GGCAAGACAGTTGGTGAGAGGCCAGCTCAGGGAGGGAGGGTGTCTGTGGAAGCCAGGCTC
 AGCCCTCTCTGCTGGACGCAACCCCGGCTGTGCAAGCCAGCCAGGGCAGCAAGGCAGGCC
 CATCTGTCTCTCACCCGGAGGCTCTGCCGCCCACTCATGCTCAGGAGAGGGTCTTCTG
 GCTTTTCCACCAAGGCTCCAGGCAGGCACAGGCTGGGTGCCCTACCCAGGCCCTTACACA
 CAGGGGCAGGTGCTTGGCTCAGACCTGCCAAAAGCCATATCCGGGAGGACCTGCCCTGAC
 CTAAGCCGACCCCAAAGGCCAACTGTCCACTCCCTCAGCTCGGACACCTTCTCTCTCCAG
 ATCCGAGTAACCTCCAATCTTCTCTCTGACAGCGCAATGTTGTGTCGAGTGCCCAACCGTGC
 CCAGGTAAGCCAGCCAGGCTCGCCCTCCAGCTCAAGGGGGACAGGTGCTAGAGTAGC
 CTGCATCCAGGGACAGGCCAGCTGGGTGCTGACACGTCCACCTCCATCTCTCTCAGCAC
 CACCTGTGGCAGGACCGTCAGTCTTCTCTTCCCCCAAAACCCAAAGGACACCTCATGATCT
 CCCGGACCCCTGAGGTCAAGTGGTGGTGGTGGACGTGAGCCAGGAAGACCCGAGGTCCAG
 TTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCA
 GTTCAACAGCACGTACCGTGTGGTCAAGCTCTCACCCTCTGCAACCAGGACTGGCTGAAOGG
 CAAGGAGTACAAAGTGAAGGTCTCCAAACAAAGGCTCCCGTCTCCATCGAGAAAACCATCT
 CCAAAGCCAAAGGTGGGACCCACGGGGTGGAGGGCCACATGGACAGAGGTGAGCTCGGCC
 ACCCTCTGCCCTGGGAGTGACCGCTGTGCCAACCTCTGTCCCTACAGGGCAGCCCGAGAGCC
 ACAAGTGTACACCTGCCCCCATCCAGGAGGAGATGACCAAGAACCAAGGTGAGCCTGACCT
 GCCTGGTCAAAGGCTTCTAOCACAGGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG
 GAGAACAACATAAGACCGCTCCCGTGTGGACTCCGAAGGCTCTTCTCTCTACAGC
 AGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTCTCATGCTCCGTGATGCA
 TGAGGCTCTGCACAACCACTACACACAGAAAGAGCCTCTCCCTGTCTCTGGGTAATGATGA

FIGURE 10C (part1)



FIGURE 10D

Light Chain (human Ck) (SEQ ID NO. 28)

MDMRVSAQLLGLLLWLSGARCDIQMTQSPSSLSASIGDRVITTCASQD
 INSYLSWFQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQ
 PEDFAVYYCLQYDEFYTFGGGTTKLEKRTVAAPSVFIFPPSDEQLKSGT
 ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSITYSL
 STLTLISKADYEKHKVYACEVTHQGLSPVTKSFNRGEC

FIGURE 10E

(SEQ ID NO. 27)

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGG
 CTCTCAGGGGCCAGGTGTGACATCCAGATGACACAGTCTCCATCTTCC
 CTGTCTGCATCTATAGGAGACAGAGTCACTATCACTTGCAAGGCGAGT
 CAGGACATTAATAGCTATTTAAGCTGGTTCCAGCAGAAACCAGGGAA
 AGCTCCTAAGCTGCTGATCTATCGTGCAAACAGATTGGTAGATGGGGT
 TCCATCAAGGTTCAAGTGGCAGTGGATCTGGGACAGATTATACTCTCAC
 CATCAGCAGCCTGCAGCCTGAAGATTTCGCAGTTTATTATTGTCTACA
 GTATGATGAGTTTCCGTACACGTTTCGGAGGGGGGACCAAGCTGGAAAT
 AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
 GAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAAC
 TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTC
 CAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
 CAGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACT
 ACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
 AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG

FIGURE 10F

chC2aB7-hG2G4
Heavy chain (SEQ ID NO.15)

MGWSCILFLVATATGVHSLEVLQQSGPELVKPGASLKMCKASGYSFT
DYIILWVKQNHGKSLEWIGHIDPYCGSSNYNLKFKGKATLTVDKSSSTAY
MQLNSLTSEDSAVYYCGRSKRDYFDYWGQGTTLTVSSASTKGPSVFPLA
PCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVTVTPSSNFGTQTYTCNVVDHKPSNTKVDKTVERRKCCVECP
PCPAPPVAGPSVFLPPPKDITLMISRTPEVTCVVVDVSDQEDPEVQFN
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNNKGLPSSIEKTIKAKGQPREPQVYITLPPSQEEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSR
WQEGNVFSCSVMEALHNHYTQKSLSLGLGK

FIGURE 11A

FIGURE 11B

(SEQ ID NO. 14) (genomic sequence hG2G4)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
 GTCCAGCTGCAACAGTCTGGACCTGAGCTGTTGAAGCCTGGGGCTTCACTGAAGATGTCCTGC
 AAGGCTTCTGGTTATTCACTCACTGACTACATCATCTCTGGGTGAAGCAGAACCATGGAAAG
 AGCCTTGAGTGGATTGGACATATTGATCCITACTATGGTAGTTCTAACTACAATCTGAAAITCA
 AGGGCAAGGCCACATTGACTGTAGACAAATTTCCAGCACAGCCTACATGCAGCTCAACAGT
 CTGACATCTGAGGACTCTGCACTCTATTACTGTGGAAGATCTAAGAGGGACTACTTTGACTAC
 TGGGGCCAAGGCACCACTCTCACAGTTTCTCAGCCTCCACCAAGGGCCATCCGTCTTCCCC
 CTGGCGCCTGTCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGTGCTGCTCAAGGA
 CTACTCCCCGAACCGGTGACGGTGTGTGGAAGTCAAGGGCCCTGACCAGGGGTGCACAC
 CTTCGGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
 AGCAACTTGGGACCCAGACCTACACCTGCAACGTAGATCAAGCCAGCAACACCAAGGT
 GGACAAGACAGTTGGTGAGAGGCCAGCTCAGGGAGGGAGGTGTCTGCTGGAAGCCAGGCTC
 AGCCCTCTGCTGGACGCAACCCGCTGTGTCAGCCCAAGCCAGGGCAGCAAGGCAGGGCC
 CATCTGTCTCTCACCCGGAGGCCTCTGCCGCCCCACTCATGCTCAGGGAGAGGGTCTTCTG
 GCTTTTCCACAGGCTCCAGGCAGGCACAGGCTGGGTGCCCTACCCAGGCCCTTCACACA
 CAGGGGCAAGTGTCTGGCTCAGACCTGCCAAAGCCATATCCGGGAGGACCTGCCCCTGAC
 CTAAGCCGACCCCAAGGCCAACTGTCCACTCCCTCAGCTCGGACACCTTCTCTCTCCAG
 ATCCGAGTAACCTCCCAATCTTCTCTGCAAGCGCAAATGTTGTGCGAGTGCCCAACGTGC
 CCAGGTAAGCCAGCCAGGCCTGCCCTCCAGCTCAAGGGGGACAGGTGCCCTAGAGTAGC
 CTGCATCCAGGGACAGGCCCCAGCTGGGTGTGACAGTCCACCTCATCTTCTCTCAGCAC
 CACCTGTGGCAGGACCGTCACTTCTCTTCCCCOAAAACCAAGGACACCTCATGATCT
 CCCGGACCCCTGAGGTCAAGTGCCTGGTGGTGGACGTGAGCCAGGAAGACCCGAGGTCCAG
 TTCAACTGGTACCTGGATGGGTGGAGGTGCATAATGCCAAGACAAAGCCGGGGAGGAGCA
 GTTCAACAGCACGTACCGTGTGTGTCAGCGTCTCAACGTCTGCAACAGGACTGGTGAACGG
 CAAGGAGTACAAATGCAAGGTCTCCAAACAAAGGCCCTCCCGTCTCCATCGAGAAAACCATCT
 CCAAAGCCAAAGGTGGGACCCACGGGGTGGAGGGCCACATGGACAGAGGTCAAGCTCGGCC
 ACCCTCTGCCCTGGGAGTGACCGCTGTGCCAACCTCTGTCCCTACAGGGCAGCCCCGAGAGCC
 ACAGGTGTACACCTGCCCCATCCAGGAGGAGATGACCAAGAACAGGTCAAGCTGACCT
 GCCTGGTCAAAAGGCTTCTACCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG
 GAGAACACTACAAGACACGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCTACAGC
 AGGCTAACCGTGGACAAAGCAAGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCA
 TGAGGCTCTGCACAACCACTACACACAGAAAGGCCTCTCCCTGTCTCTGGGTAATGA

A schematic representation of the heavy chain of antibody chC2aB7-hG2G4 (amino acids 1-337) (part 1).




FIGURE 11C (part1)

FIGURE 11C (part2)

FIGURE 11D

Light Chain (human Ck) (SEQ ID NO. 24)

MGWSCILFLVATATGVHSRDIQMTQSPSSMYASLGERVTITCKASQDINS
 YLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSEYED
 MGIYYCLQYDEFPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV
 VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTL
 TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 11E

(SEQ ID NO. 23)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGT
 GTCCACTCTAGAGACATCCAGATGACACAGTCTCCATCTTCCATGTAT
 GCATCTCTAGGAGAGAGAGTCACTATCACTTGCAAGGCGAGTCAGGA
 CATTAATAGCTATTTAAGCTGGTTCCAGCAGAAACCAGGGAAATCTCC
 TAAGACCCGTGATCTATCGTGCAAACAGATTGGTAGATGGGGTTCCATC
 AAGGTTCACTGGCAGTGGATCTGGGCAAGATTATTCTCTACCATCAG
 CAGCCTGGAGTATGAAGATATGGGAATTTATTATTGTCTACAGTATGA
 TGAGTTTCCGTACACGTTCCGAGGGGGGACCAAGCTGGAAATAAAAC
 GGACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCA
 GTTGAAATCTGGAACTGCCTCTGTTGTGTGCTGCTGAATAACTTCTAT
 CCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATC
 GGGTAACTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCA
 CCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAG
 AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTC
 GCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAA

A schematic representation of the light chain of antibody chC2aB7-hG2G4.




FIGURE 11F

FIGURE 12A**hB7V3V2-cG2G4****Heavy Chain (SEQ ID NO. 13)**

MGWSRIFLFLSLIAGVHCQVQLQSGSELKKPGASVKISCKASGYSFTDY
ILWVRQNPQKGLWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYME
LSSLRSEDVAVYYCGRSKRDYFDYWGQGTTLTVSSASTKGPSVFPLAPC
SRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVVDKTVKCCVECPPCP
APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV
DQVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHREALHNHYTQKSLSLSLGK

FIGURE 12B

(SEQ ID NO. 16) (cDNA G2G4)

ATGGGATGGAGCCGGATCTTTCTCTCCTCCTGTCAATAATTGCAGGTG
 TCCATTGCCAGGTCCAGCTGCAACAGTCTGGATCTGAGCTGAAGAAGC
 CTGGGGCTTCAGTGAAGATCTCCTGCAAGGCTTCTGGTTATTCAATCAC
 TGA CTACATCACTCTGGGTGAGGCAGAACCCCTGGAAAGGGCCTTGA
 GTGGATTGGACATATTGATCCTTACTATGGTAGTTCTAACTACAATCTG
 AAATTCAAGGGCAGAGTGACAATCACCGCCGACCACTTACCACCAC
 AGCCTACATGGAGCTCTCCAGTCTGAGATCTGAGGACACTGCAGTCTA
 TTACTGTGGAAGATCTAAGAGGGACTACTTTGACTACTGGGGCCAAGG
 CACCCTCTCACAGTTTCCTCAGCCTCCACCAAGGGCCCATCCGTCTTC
 CCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTG
 GGCTGCCTGGTCAAGGACTACTTCCCGAACCAGGTGACGGTGTCTGG
 AACTCAGGCGCCCTGACCAGCGCGTGACACCTTCCCGCTGTCTTA
 CAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
 AGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCAAAAGCCC
 AGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCGA
 GTGCCCACCGTGCCAGCACCACTGTGGCAGGACCGTCAGTCTTCTCT
 CTTCCTCCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGA
 GGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCC
 AGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACA
 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGT
 CCTCACCGTCTCTGCACCAAGGACTGGCTGAACGGCAAGGAGTACAAGT
 GCAAGGTCTCCAACAAAGGCCTCCCGTCTCCATCGAGAAAACCATCT
 CCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCTGCCCT
 CCATCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCT
 GGTCAAAGGCTTCTACCCAGCGACATCGCCGTGGAGTGGGAGAGCA
 ATGGGCAGCCGGAGAACAACTACAAGACCAAGCCTCCCGTGTGGAC
 TCCGACGGCTCCTTCTCTCTACAGCAGGCTAACCGTGGACAAGAGC
 AGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCT
 CTGCACAACCACTACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA
 TGATG

[illegible]

FIGURE 12C

FIGURE 12D

Light Chain (human Ck) (SEQ ID NO. 28)

MDMRVSAQLLGLLLWLSGARCDIQMTQSPSSLSASIGDRVITTCASQD
 INSYLSWFQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQ
 PEDFAVYYCLQYDEFPYTFGGGKLEIKRTVAAPSVEFFPPSDEQLKSGT
 ASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYSL
 STLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 12E

(SEQ ID NO. 27)

ATGGACATGAGGGTCTCTGCTCAGCTCCTGGGGCTCCTGCTGCTCTGG
 CTCTCAGGGGCCAGGTGTGACATCCAGATGACACAGTCTCCATCTTCC
 CTGCTGTCATCTATAGGAGACAGAGTCACTATCACTTGCAAGGCGAGT
 CAGGACATTAATAGCTATTTAAGCTGGTTCAGCAGAAACCAGGGAA
 AGCTOCTAAGCTGCTGATCTATCGTGCAAAACAGATTGGTAGATGGGGT
 TCCATCAAGGTTCACTGGCAGTGGATCTGGGACAGATTATACTCTCAC
 CATCAGCAGCCTGCAGCCTGAAGATTCGCAGTTTATTATTGTCTACA
 GTATGATGAGTTTCCGTACACGTTCCGAGGGGGGACCAAGCTGGAAAT
 AAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGAT
 GAGCAGTTGAAATCTGGAACGCTCTGTGTGTGCTGCTGAATAAC
 TTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTC
 CAATCGGGTAACTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGA
 CAGCACTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACT
 ACGAGAAAACAAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG
 AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG

FIGURE 12F

ChC7-hG2G4
Heavy chain (genomic sequence hG2G4) (SEQ ID NO. 18)

MGWSCILFLVATATGVHSLEVLQQSGPELEKPGASVKISCKASGYSTFIG
YNMNVVKQSSGKSLEWIGNFDPPYYGVITYNQKFKGKATLTVDKSSSTAY
MQLKSLTSEDSAVYYCARTATALTMDYWGQGSTVTVSSASTKGPSVF
PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSVVTVPSNFGTQYTCNVVDHKPSNTKYVDKTVKRCCKVE
CPPCPGKPAAPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDP
EVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKGLPSSIEKTTISKAKGQPREPQVYITLPPSQEEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFFLYSRLTV
DKSRWQEGNVFSCVMHEALHNHYTQKSLSLGLK

FIGURE 13A

FIGURE 13B**(SEQ ID NO. 17)**

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
 GTCCAACTGCAGCAGTCTGGACCTGAGCTGGAGAAAGCTGGCGCTTCAGTGAAGATATCCTGC
 AAGGCTTCTGGTTACTCATTCACTGGCTACAACATGAACCTGGGTGAAGCAGAGCAGTGGAAA
 GAGCCTTGAGTGGATTGGAAATTTTGATCCTTACTATGGTGTATTACCTACAACCAAGATTTC
 AAGGGCAAGGCCACATTGACTGTAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAAGAG
 CCTGCATCTGAGGACTCTGCAGTCTATTACTGTGCAAGAACGGCTACGGCTCTCTATACTAT
 GGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCCGT
 CTTCCCTCTGGCGCCTGCTCCAGGAGCACCTCGAGAGCACAGCCGCCCTGGGCTGCCTGGT
 CAAGGACTACTTCCCGAACCCTGACGGTGTCTGGAACTCAGGCGCCTGACCAAGCGCG
 TGCACACCTTCCCGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGT
 GCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGGCCAGCAACA
 CCAAGGTGGACAAGACAGTTGGTGAGAGGCCAGCTCAGGGAGGGAGGGTGTCTGTGGAAGC
 CAGGCTCAGCCCTCTGCTGGAAGCACCCCGGCTGTGCAGCCCCAGCCAGGGCAGCAAGG
 CAGGCCCATCTGTCTCTCACCCTGAGGGCTCTGCCCGCCCCACTCATGCTCAGGGAGAGGG
 TCTTCTGGCTTTTCCACCAAGCTCCAGGCAGGCACAGGCTGGGTGCCCTACCCAGGCCCTT
 CACACACAGGGGCAGGTGCTTGGCTCAGACCTGCCAAAAGCCATATCCGGGAGGACCTGCC
 CCTGACCTAAGCCGACCCCAAAGGCCAACTGTCCACTCCCTCAGCTCGGACACCTTCTCTCC
 TCCAGATCCGAGTAACCTCCCAATCTTCTCTCTGCAAGCGCAAAATGTTGTGTGAGTGCCCA
 CCGTGCCCAAGTAAGCCAGCCAGGCCCTCGCCCTCCAGCTCAAAGCGGGACAGGTGCCCTAG
 AGTAGCCTGCATCCAGGGACAGGCCCCAGCTGGGTGCTGACAGTCCACCTCCATCTCTTCT
 CAGCACCACTGTGGCAGGACCGTCACTCTTCTTCCCCCAAAAACCAAGGACACCCCTCA
 TGATCTCCCGACCCCTGAGGTCAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT
 GTCCAGTTCAACTGGTACGTGGATGGCTGGAGGTGCATAATGCCAAGACAAGCCGCGGGA
 GGAGCAGTTCAACAGCACGTACCGTGTGGTCAAGCTCTCAACCGTCTGCACCCAGGACTGGCT
 GAACGGCAAGGAGTACAAGTGCAGGTCTCAACAAAGGCCTCCGTCCTCCATCGAGAAAA
 CCATCTCCAAAGCCAAAGGTGGGACCCACGGGGTGGAGGGCCACATGGACAGAGGTCAAGT
 CGGCCACCTCTGCTGGGAGTGACCGCTGTGCGAACCTCTGTCCCTACAGGGCAGCCCCG
 AGAGCCACAGGTGTACACCTGCCCCATCCCAAGGAGGAGATGACCAAGAAACAGGTCAAGC
 TGACCTGCCTGGTCAAAGGCTTCTACCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
 CAGCCGGAGAAACACTACAAGACCAAGCCTCCCGTGTGACTCCGACGGCTCTTCTTCTCT
 TACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGT
 GATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAATG

A

FIGURE 13C

Light Chain (human Ck) (SEQ ID NO. 30)

MGWSCILFLVATATGVHSREIVLTQSPAIMASPGKEVTMTCRASSSVSS
 SYLHWYQQKSGASPKLWYSTSNLASGVPARFSGSGSGTSYSLTISSEAE
 DAATYYCQYSGYPLTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTAS
 VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSST
 LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 13D

(SEQ ID NO. 29)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGT
 GTCCACTCTAGAGAAATTGTGCTCACCCAGTCTCCAGCAATCATGTCT
 GCATCTCCAGGGGAAAAGGTCACCATGACCTGCAGGGCCAGCTCAAG
 TGTAAGTTCAGTTACTTGCACTGGTACCAGCAGAAGTCAGGTGCTC
 CCCCAACTCTGGATTATAGCACATCCAACCTTGGCTTCTGGAGTCCCT
 GCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATCA
 GCAGTGTGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTACA
 GTGGTTACCCACTCACGTTCCGGCTCGGGGACAAAGTTGAAATAAAAC
 GGACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCCGATGAGC
 AGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCTGCTGAATAACTTCTA
 TCCAGAGAGGCCAAAAGTACAGTGAAGGTGGATAACGCCCTCCAAT
 CGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC
 ACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGA
 GAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCT
 CGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAA

FIGURE 14A

D1B5-hG1

Heavy Chain (SEQ ID NO. 20)

MGWSCILFLVATATGVHSLEVQLQQPGAELVRSGASVKLSCKASGFNIK
DYYIHWVKQRPEQGLEWIGWIDPEIGATKYVPKFQGKATMTTDTSSNTA
YLQLSSLTSEDIAVYYCNALYGNIDRYAMDYWGQGTSTVTVSSASTKG
PSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTISWNSGALTSGVHTF
PAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKRVPEPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNQKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKITPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

FIGURE 14B

(SEQ ID NO. 19) (genomic sequence hG1 constant region)

ATGGGATGGAGCTGTATCATCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCTCGAG
 GTCCAACTGCAGCAGCCTGGGGCAGAGCTTGTGAGGTCAAGGGGCTCAGTCAAGTTGTCTGC
 AAAGCTTCTGGCTTCAACATTAAGACTACTATATACACTGGGTGAAGCAGAGGCCTGAACA
 GGGCCTGGAGTGGATTGGATGGATTGATCCTGAGATTGGTGTACTAAATATGTCCCGAAGTT
 CCAGGGCAAGGCCACTATGACTACAGACATCTCCAAACACAGCCTACCTGCAGCTCAGCA
 GCCTGACATCTGAGGACACTGCGGTCTATTACTGTAATGCCCTCTATGGTAACGACCGTT
 ACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCTCCACCAAGG
 GCCCCATCGTCTTCCCCCTGGCACCTCTCTCCAAGACACCTCTGGCGGCACAGCGCCCTGG
 GCTGCCCTGGTCAAGGACTACTTCCCCGAAACCGGTGACGGTGTCTGTGGAACTCAGGCGCCCTGA
 CCAGGGCGGTGCACACCTTCCCGGTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCG
 TGGTGACCGTGGCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAACAAG
 CCAAGCAACCAAGGTGGACAAGAGATTGGTGAGAGGCCAGCACAGGGAGGGAGGGTGTCT
 TGCTGGAAGCCAGGCTCAGCGCTCTGCTGGACGCATCCCGGCTATGCAGTCCCAGTCCAGG
 GCAGCAAGGCAGGCCCCCTGCTCTCTCAACCGGAGGCCCTCTGCCCGCCCACTCATGCTCA
 GGGAGAGGGTCTTCTGGCTTTTTCCCCAGGCTCTGGGCAGGCACAGGCTAGGTGCCCTAAC
 CAGGCCCTGCACACAAAAGGGCAGGTGCTGGGCTCAGACCTGCCAAGAGCCATATCCGGGAG
 GACCTGCCCCGACCTAAGCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGACAC
 CTTCTCTCTCCAGATTCCAGTAACCTCCAACTCTCTCTCTGCAGAGCCAAATCTTGTGACA
 AAATCAGACATGCCACCGTGCCAGGTAAGCCAGGCCAGGCTCGCCCTCCAAGCTCAAGGC
 GGGACAGGTGCCCTAGAGTAGCTGCATCCAGGGACAGGCCCGCAGCGGCTGCTGACAGCTC
 CACCTCCATCTCTTCTCAGCACCTGAACCTCTGGGGGACCGTCAGTCTTCTCTTCCCCCA
 AAACCCAAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACATGCTGGTGGTGGACGTG
 AGCCACGAAGACCTGAGGTCAAATTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGC
 CAAGACAAGGCCGGGAGGAGCAGTACAACAGCAGTACCGTGTGGTACGCGTCTCACC
 TCTGACCCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC
 CCAGCCCCATCGAGAAAAACCATCTCCAAAGCCAAAGGTGGGACCGTGGGGTGGCAGGGCC
 ACATGGACAGAGGCCGGCTGGGCCACCTCTGCCCTGAGAGTGACCGCTGTACCAACCTCTG
 TCCCTACAGGGCAGCCCCGAGAACCACAGGTGTACACCTGCCCCCATCCCGGAGGAGATG
 ACCAAGAACCAGGTGACGCTGACCTGCTGTGTAAGGCTTCTATCCAGCGACATCCCGTG
 GAGTGGGAGAGCAATGGGCAGCGGAGAACAACTACAAGACCGCCTCCCGTGTGACTC
 CGACGGCTCTTCTTCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA
 ACGTCTTCTATGCTCCGTGATGATGAGGCTCTGCACAACCACTACAGCAGAGAGCCTCT
 CCCTGTCCCGGTAATGA

GGAGCGATGACACAGCAGTACGGTGTGGTCAGGGCTCTCACGGCTCTGCACAGAGTGGCTGATGCGACAGGAGTACAGATGCGACAGGCTCTCCACAGGCGCTCCACGCCGCCCATCGA 4560
E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y K C K V S N K A L P A P I E
hgl CH3
KATAACCATCTCCAAACGACAGGTGGGACCGCTGGGGTGGGAGGGGCGCAATATGGACAGAGCGCGGCTCGGCGCCACACCTCTGCGCTGTCTGTCTCTACAG 4680
G A A T T A A C K A K
hglCH2
GGCAGCCCGCCGACACCAAGGTGTACCACTGCTCCCGGAGGAGATGACACAGACCAAGCTCAGCGTCTGACTGCTGGTCAAGGCTCTTATCCACAGGACATCGCGGTGGGT 4800
G Q P R E P Q V Y T L P P S R E E M T K N Q V S L T C L V K G F Y P S D I A V E
hgl CH3
GGAGAGCAGTGGGCGCGGAGACCACTACAGACCCACTCCGCTCCGGCTCCGACGGCTCTCTTCTCTATAGCAAGCTCAGCTGGACAGGACAGGTGGCAGGAGGGA 4920
W W S E S C N G Q P E N N Y K T T P P V L T D S G D G C T F F T T C K S L T V D K S R W Q Q G
hgl CH3
AGCTCTTCTACCTGCTCGGTGATGATGAGGCTCTGCACAAACCACTACACAGCAGAGGCTCTCTCCCTGCTCCGGGTAAATCATGTCGACGCCAGAGATTCATTGATCATATATACGCC 5038
N V F S C S V M H E A L H N H Y T Q K K S L S L S P G K
hgl CH3

FIGURE 14C (part 2)

Light chain (human Ck) (SEQ ID NO. 32)

MGWSCIILFLVATATGVHSDIVMTQSQKFMSTSVGDRVSTCKASQNV
TAVAWYQQKPGQSPKALIYLAASN^RH^TGV^PDRFTGSGSGTDFTLTISNVQS
EDLADYFCLQHWNYPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS^TYSLS
NTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC

FIGURE 14D

FIGURE 14E

(SEQ ID NO. 31)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGT
GTCCACTCTAGAGACATTGTGATGACCCAGTCTCAAAAATTCATGTCC
ACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGAA
TGTTTCGTAAGTGTAGCCTGGTATCAACAGAAACCAGGGCAGTCTCC
TAAAGCACTGATTACTTGGCATCCAACCGGCACACTGGAGTCCCTGA
TCGCITCACAGGCAGTGGATCTGGGACAGATTTCACCTCTCACCATTAG
CAATGTGCAATCTGAAGACCTGGCAGATTATTTCTGTCTGCAACATTG
GAATTATCCTCTCACGTTCCGGTGTGGGACCAAGCTGGAGCTGAAACG
GACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
CCAGAGAGGCCAAAGTACAGTGGGAGGTGGATAACGCCCTCCAATCG
GGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCAC
CTACAGCCTCAGCAACACCCCTGACGCTGAGCAAAGCAGACTACGAGA
AACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
CCGTACAAAGAGCTTCAACAGGGGAGAGTGTTAA

FIGURE 14F

FIGURE 15A**G2G4 63L1D****Heavy chain (SEQ ID NO. 22)**

MGWSCILFLVATATGVHSQMLVQSGAEVKKPGSSVKVSCKASGGTFS
NYATSWVRQAPGQGLEWLGGINPVFGTANYAQKFQGRVTITADESTSTAY
MELNSLTFFDDTA VYYCARGGGGWGGRNYYYYYMDVWGKGITTVTVSS
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVTVPSNFGTQTYTCNVDHKPSNTKVDK
TVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYITLPPSQEEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPFVLDSGDSFLL
YSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK

FIGURE 15B

(SEQ ID NO. 21) (genomic sequence hG2G4)

ATGGGATGGAGCTGTATCATCTCTCTTGGTAGCAACAGCTACAGGTGTCCACTCCAGATG
 CAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAAGCCTGGTCTCGGTGAAGGTCTCTGCAA
 GGCTCTGGAGGCACCTTCAGCAACTATGCTACCAAGTTGGGTGCGACAGGCCCTGGACAA
 GTCTTGAGTGGCTGGGAGGGATCATCCCCGTCTTCGGTACTGCAAACTACGCACAGAAGTTTC
 AGGGCAGAGTCAACATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGTTGAATAGT
 CTGACATTTGACGACACGGCCGTCTATTACTGTGCGAGAGGGGGTGGGGGATGGGAGGCCG
 GAACTACTACTACTACTACTACATGGAAGTCTGGGGCAAAGGGACCACTGTCAACGCTCTCTC
 AGCCTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCTGCTCCAGGAGCACCTCCGAGAG
 CACAGCGCCCTGGGTGCTGTGTCAGGACTACTTCCCGAACCGGTGACGGTGTCTGGAA
 CTCAGGGGGCCCTGACCAAGGGCGTGCACACCTTCCGGCTGTCTACAGTCTCAGGACTCTA
 CTCCTCAGCAGCGTGTGAACGTGCTCCAGCAACTTCGGCAACCCAGACCTACACCTGCAA
 CGTAGATCAACAAGCCGCAACACCAAGGTGGACAAGACAGTTGGTGAAGGCGAGCTCAGG
 GAGGGAGGGTGTCTGTGGAAGCCAGGCTCAGCCCTCTGCTGGAACGCAACCCGGCTGTGC
 AGCCCCAGCCAGGGCAGCAAGGCAGGCCCATCTGTCTCTCAACCCGAGGCCCTGTGCCGC
 CCCACTCATGCTCAGGGAGAGGGTCTTCTGGCTTTTCCACAGGCTCCAGGCAGGCACAGGC
 TGGGTGCCCTACCCAGGCCCTTCACACACAGGGGCAGGTGCTTGGCTCAGACCTGCCAAA
 GCCATATCCGGGAGGACCTGCCCTGACCTAAGCGACCCAAAGGCCAACTGTCCACTCC
 CTAGCTCGGACACCTTCTCTCTCCAGATCCGAGTAACTCCCAATCTTCTCTCTGACAGCG
 CAAATGTTGTGTGAGTGCACCGTGCCAGGTAAAGCCAGCCAGGCCCTGCCCTCCAGCTC
 AAGGCGGGACAGGTGCCCTAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCTGGGTGCTGAC
 ACGTCCACCTCCATCTCTCTCAGCACCACTGTGGCAGGACCGTCAGTCTCTCTCTCCCCC
 CAAAAACCAAGGACACCTCATGATCTCCCGACCCCTGAGGTACCGTGCCTGGTGGTGAC
 GTGAGCCAGGAAGACCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAA
 TGCCAAAGACAAAGCCGCGGAGGAGCAATTCAACAGCACGTACCGTGTGGTCAGGTCCTCA
 CCGTCTGCAACGAGACTGGCTGAACGGCAAGGAGTACAAAGTGCAAGGTCTCCAAACAAAGGC
 CTCCTGCTCCATCGAGAAAACATCTCCAAAGCCAAAGGTGGGACCCAGGGGTGCGAGG
 GCCACATGGACAGAGGTGAGCTCGGCCACCCCTCTGCCCTGGGAGTGACCGCTGTGCCAACCT
 CTGTCCCTACAGGGCAGCCCGAGAGCCACAGGTGTACACCTGCCCCATCCAGGAGGAG
 ATGACCAAGAACCAGGTACGCTGACCTGCTGGTCAAAGGCTTCTACCCAGCGACATCGGC
 GTGGAGTGGGAGGCAATGGGCAGCCGAGAACTACAAGACACGCTCCCGTGTGGA
 CTCGACGGCTCTCTCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGG
 GGAATGTCTTCTCATGCTCCGTGATGATGAGGCTTGCAACCACTACACACAGAAAGGCC
 TCTCCCTGTCTCTGGGTAAATGA

FIGURE 15C

Light chain (human CL) (SEQ ID NO. 34)

MGWSCILFLVATATGVHSSVLTQPPSESVAPGQTARJSCGGSNIGSYGV
 HWYQQKAGQAPVLVVHDDSDRPSGIPERFSGSNSGNTATLTISSVEAGDE
 ADYYCQVWDNSAVIFGGGKLTVLSPKAAPSVTLFPPSSEELQANKA
 TLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYL
 SLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

FIGURE 15D

(SEQ ID NO. 33)

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGT
 GTCCACTCTTCCTATGTGCTGACTCAGCCACCTCGGAGTCAGTGGCC
 CCAGGACAGACGGCCAGGATTTCTGTGGGGGAGCAACATTGGAAG
 TTACGGTGTGCACTGGTACCAGCAGAAGGCAGGACAGGCCCTGTGCT
 GGTCTGTCATGATGATTCCGACCGGCCCTCAGGGATTCTTGAGCGATT
 CTCTGGCTCCAATTCTGGGAACACGGCCACCCTGACCATCAGCAGTGT
 CGAAGCCGGCGATGAGGCCGACTATTACTGTCAGGTGTGGGATAATA
 GTGCTGTGATATTCGGCGGAGGGACCAAACTAACCGTCCTAAGTCAGC
 CCAAGGCTGCCCTCGGTCACTCTGTTCGCGCCCTCCTCTGAGGAGCT
 TCAAGCCAACAAGGCCCACTGGTGTGTCTCATAAGTGACTTCTACCC
 GGGAGCTGTGACAGTGGCTTGGAAAGCAGATAGCAGCCCCGTCAAGG
 CGGGAGTGGAGACCACCAACCCTCCAAACAAAGCAACAACAAGTAC
 GCGGCCAGCAGCTATCTGAGCCTGACGCTGAGCAGTGGAAAGTCCCA
 CAGAAGCTACAGTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGA
 AGACAGTGGCCCTACAGAATGTTTCATAA

FIGURE 16

5'-GACAAGCTTGCAAGGATGGAGAGGCTGGTGA-3' (SEQ ID NO: 35)

FIGURE 17

5'-GACGGATCCGCCCCCTTTCCTCCTGCCTTCTC-3' (SEQ ID NO: 36)

FIGURE 18

Efficacy of humanized anti CD200 antibodies (C2aB7) in the RAJI_CD200/PBL model.




FIGURE 19

Comparison of mean tumor volumes in C2aB7-G1 versus C2aB7-G2G4 treated animals in the Namalwa_CD200 model.




FIGURE 20

FACS analysis of CD200 expression on B-CLL cells in comparison to normal B cells.

CLL sample		Healthy donor		
Donor ID	B-CLL CD200 (GMFI)	Normal B (GMFI)	CD200	Ratio(CLL/normal B)
RC011731	93	58		1.6
RF020934	659	185		3.6
JA073031	334	64		5.2
GR011846	156	64		2.4
BB101735	420	95		4.4
DM6988172	290	97		2.9
MR8074020	403	97		4.2
CB8267677	300	97		3.1
GB1325248	178	77(7)		2.3
VN7029373	154	77(7)		2.0
DG8942820	146	77(7)		1.9
MM8451869	237	77(7)		3.1
JR4539931	215	77(7)		2.8
HS6787771	305	77(7)		4.0
VB040439	123	41		3.0
				MEAN= 3.1
				STDEV= 1.0

FIGURE 21

Tumor type	Cell line	CD200 staining
Melanoma	SK-MEL2	-
	SK-MEL28	++
	SK-MEL1	+
	SK-MEL5	+/-
	SK-MEL24	+++
Ovarian	OVCAR3	++
	SKOV3	+/-
Renal	CAKI-1	+
	ACHN	-
	SN12C	+
Neuroblastoma	IMR-32	+++
	SK-N-SH	++
Breast cancer	MDA-MB-435	+/-
	MCF7	-
	MDA-MB-231	-

RTQ-PCR OF PRIMARY OVARIAN CANCER SAMPLES

RT-QPCR: CD200 ON OVARIAN CANCER SAMPLES			
NUMBER	SAMPLE	norm/#51	sd/#51
51	PBL	1.00	0.03
124	normal ovary	5.82	0.16
125	normal ovary	19.45	1.33
127	ov. adenocarc, serous	10.93	0.47
128	ov. adenocarc, serous met	10.08	0.60
134	ov. adenocarc, serous met	21.24	0.69
129	ov. adenocarc, papill. serous	13.33	1.26
130	ov. adenocarc, papill. serous	8.71	0.42
126	ov. adenocarc, endometroid	11.02	0.54
131	ov. adenocarc, endometroid	1.38	0.20
135	ov. adenocarc, endometroid	2.42	0.02
132	ov. adenocarc, mucinous	1.61	0.00
133	ov. adenocarc, mucinous	2.46	0.23
136	ov. adenocarc, clear cell	6.51	1.14
137	ov. adenocarc, clear cell	0.70	0.04

FIGURE 22 (part 1)




FIGURE 22 (part 2)

RT-QPCR: CD200 on melanoma samples

Number	Sample	norm/#51	sd/#51
51	PBL	1.00	0.28
139	norm jejunum -1	2.60	0.15
138	jejunum met -1	8.39	0.24
147	norm jejunum -2	1.37	0.81
146	jejunum met -2	14.46	3.38
143	norm small intestine -1	3.57	1.21
142	small intestine met -1	4.61	0.55
141	norm lymph node -1	8.52	1.00
140	lymph node met -1	6.22	0.53
151	norm lymph node -2	4.80	1.40
150	lymph node met -2	12.94	0.51
155	lymph node met -3	0.69	0.21
156	lymph node met -4	2.72	1.72
145	norm lung -1	14.87	1.14
144	lung met -1	8.93	0.83
149	norm lung -2	4.25	0.64
148	lung met -2	3.65	1.04
111	norm skin -1	1.55	0.25
152	melanoma metastatic, skin -2	0.05	0.06
158	melanoma metastatic, skin -3	2.22	0.61
159	norm brain -1	10.49	1.68
159	malign. melanoma, brain met -2	22.92	3.20
153	malign. melanoma, lung met	18S low	
154	malign. melanoma, LN met	18S low	
157	malign. melanoma, LN met	18S low	
160	malign. melanoma, skin	18S low	
160-No RT	malign. melanoma, skin	0.00	0.00

FIGURE 23 (part 1)




FIGURE 23 (part 2)

IMMUNOHISTOCHEMISTRY STAINING OF MELANOMA PATIENT SAMPLES.

FROZEN SKIN, MELANOMA - POSITIVE CONTROL

SAMPLE 1: THIS SAMPLE OF MELANOMA WAS OBTAINED FROM AN 83-YEAR-OLD FEMALE





FIGURE 24

FIGURE 25

IL-2 production in MLR with cancer cell lines.

A. In the absence of antibody



B. In the presence of antibody





FIGURE 26

Tumor volumes in the Namalwa/PBL model (no CD200 expression) comparing anti-CD200 G1 or G2G4 construct treated groups.



Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3




FIGURE 27 (part 1)

Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3




FIGURE 27 (part 2)

Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3




FIGURE 27 (part 3)

Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3




FIGURE 27 (part 4)

Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3




FIGURE 27 (part 5)

Cell surface expression of CD200 on human CD3+ cells following activation with mOKT3

CD8 PerCPCy5.5/CD4 APC




FIGURE 27 (part 6)

HUMAN T CELLS ACTIVATED THROUGH T CELL RECEPTOR SIGNALING SERVE
AS SENSITIVE TARGETS FOR ANTI-CD200 MEDIATED ADCC




FIGURE 28A

HUMAN T CELLS ACTIVATED THROUGH T CELL RECEPTOR SIGNALING SERVE AS SENSITIVE TARGETS FOR ANTI-CD200 MEDIATED ADCC




FIGURE 28B

CD200 EXPRESSION ON CD38+ BRIGHT CELLS (PLASMA CELLS)					CURRENT CLINICAL TREATMENT
SAMPLE	STATUS	LIGHT CHAIN ISOTOPE	THRESHOLD SET THROUGH ISOTOPE CONTROL (EXPRESSED AS %)	THRESHOLD SET THROUGH ISOTOPE CONTROL (EXPRESSED AS GEOMETRIC MEAN INTENSITY)	
1	NORMAL	POLYCLONAL	48	6575	NA
2	NORMAL	POLYCLONAL	48	19411	NA
3	NORMAL	POLYCLONAL	33	87084	NA
4	M MYELOMA	KAPPA	12	4056	MELPHALAN, VELCADE
5	M MYELOMA	KAPPA	12	3091	ATO, VELCADE, ARANESP, ZOMETA
6	M MYELOMA	NEGATIVE	14	2162	COUMADIN, ARANESP, DVD (DOX, VIN, DEX)
7	M MYELOMA	POLYCLONAL	37	3419	NONE
8	M MYELOMA	KAPPA	71	4024	ZOMETA, PREDNISONE
9	M MYELOMA	KAPPA	76	1506	ARANESP, ZOMETA
10	M MYELOMA	KAPPA	82	9056	HTN, PCTA
11	M MYELOMA	KAPPA	85	5388	PREDNISONE, ZOMETA
12	M MYELOMA	KAPPA	89	23269	ZOMETA, COUMADIN
13	M MYELOMA	LAMBDA	95	1535	ZOMETA, IVIG, BIAVIN, MEDROL

FIGURE 29